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Synopsis
This thesis describes an investigation into the growth characteristics of a human pre-B cell 
acute lymphocytic leukaemia cell line, SMS-SB. Most lymphocytic tumours are difficult to 
adapt to tissue culture and enter a crisis after a few rounds of cell division where the 
majority of cells die. To sustain proliferation of the remaining cells, addition of exogenous 
mitogens is usually required. SMS-SB was an unusual leukaemia because the cells did not 
go through a crisis phase and grew indefinitely, in the absence of exogenous mitogens. 
This sustained proliferation in tissue culture appears to reflect the synthesis and secretion 
of an autocrine growth factor (s); the cells are density-dependent for growth, and 
proliferation can occur in media completely devoid of protein.
The original aim of this work was to identify and characterise the autocrine growth factor, 
termed SB-AF. During investigations to identify cytokines with the ability to substitute for 
the autocrine growth factor activity, platelet-derived growth factor (PDGF) was shown to 
stimulate the growth of SMS-SB cells under low cell density conditions; SMS-SB cells 
are known to secrete PDGF and express PDGF receptors. However, antibody inhibition 
experiments suggest that PDGF cannot account for all the autocrine activity of SB-AF, 
thus other cytokine components of SB-AF were sought.
CD23 is a 45kDa type-II transmembrane glycoprotein and a member of the C-type lectin 
superfamily. There is a soluble form of CD23 (sCD23) which is released by cleavage from 
the surface of cells into the extracellular fluid, and this form has been attributed multiple 
cytokine activities. It was discovered that sCD23 dramatically promotes thymidine 
incorporation by SMS-SB cells.
The work of this thesis has shown that SMS-SB cells undergo apoptosis when cultured at 
low cell der^ity; sCD23 is the only cytokine tested with the ability to prevent SMS-SB 
cell apoptosis. Apoptotic SMS-SB cells have low levels of the proto-oncogene bcl-2 but 
sCD23 can sustain bcl-2 levels in the cells.
The investigations have shown that SMS-SB cells do not express CD23, negating the 
hypothesis that CD 23 is acting in an autocrine fashion. The most interesting discovery 
made during these investigations was that SMS-SB cells bind CD23-containing liposomes
__
specifically but they do not express the known receptors for CD23, namely CD21, C D lla 
and CD llb; SMS-SB cells express a novel CD23 receptor.
Thus, SMS-SB cells express a novel receptor for CD23 and signalling via this receptor 
prevent apoptosis of the cells. Preliminary data is presented from CD23 affinity columns 
used to isolate and characterise the novel CD23 receptor. A protein of 85kDa has been 
identified as a candidate receptor, but further characterisation is required.
SMS-SB cells will provide a good model to examine the role of autocrine growth factors 
in early B cell development, moreover, the discovery of a novel CD 23 receptor on pre-B 
cells, implies a role for sCD23 in early B cell development. Since sCD23 has previously 
been shown to promote the growth and maturation of early T cells and myeloid 
progenitors, it will be interesting to investigate the role of CD23, and the novel receptor, 
in all aspects of haematopoiesis.
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Chapter 1
Introduction
Chapter 1 
Introduction
Of the many cell types involved in mediating specific immune responses, T cells are 
recognised by many as being the most important since they can play both a cytotoxic and 
a helper role in destruction of pathogen-infected cells. However, the B lymphocyte may 
have a more important role in development of an immune response than many wish to 
believe. B lymphocytes express membrane immunoglobulin (Ig) on their surface and are 
activated when the Ig binds its speciBc antigen. However, to develop into plasma cells 
which secrete antibody, the B cells usually require T cell help, m the form of secreted 
interleukins and ceU-cell surface interactions.
Antibodies are mediators of the humoral immune response since they bind to specific 
antigens and aid in their eiirmnation. The protective biologic effects of antibodies are 
numerous and include: neutrahsation of soluble antigen (viruses and bacteria); activation 
of the classical complement pathway; opsonization of particulate matter to allow enhanced 
phagocytosis; and antibody-dependent cell-mediated cytotoxicity (ADCC). However, the 
B cell itself can play another important role in an immune response - that of an antigen- 
presenting cell which acts to activate T-helper cells. Antigen-specific B cells are highly 
efficient at presenting their cognate antigen because membrane Ig molecules function as
1
1.1 The Immune System
The homeostatic basis of every biological system is the absolute necessity for tightly 
regulated cell growth, differentiation and death. For organs, tissues and systems it is 
implicit that the growth of individual cells is tightly controlled and balanced by levels of 
cell death. If the control becomes deregulated, or an individual cell escapes from the 
regulation, there may be abnormal growth leading to the formation of a tumour.
The immune system is a highly complex, integrated network of cells and soluble factors 
which cooperate to protect the body against invasion by pathogens. Aquired immunity is
induced or stimulated by exposure to foreign antigen; it is highly specific, and is able to 
discrirninate between self and non-self. Since intercellular communication and growth 
regulation in the immune system are so complex, the results of inappropriate cell
■ ■activation or proliferation can be disasterous, leading to the development of allergy, 
autoimmunity or mahgnancies such as lymphomas and leukaemias. Studying the 
mechanisms of malignant transformation in vitro may provide insight into the processes 
which regulate noimal cell proliferation and differentiation, and possibly lead to rationale 
for cancer therapy.
high-affinity receptors which effectively internalise and present antigen, even at very low 
concentrations. This interaction, as well as activating a T cell response, ensures that the 
antigen-specific B ceU is the preferential recipient of T cell-derived cytokines and the 
dii'ect cell-ceU contacts which provide additional signals to the B cell allowing a humoral 
response to develop.
Thus, the B lymphocyte plays a centr al role in the immune system, and its development is 
a subject of extensive investigation since there are numerous pathological conditions 
known to occur if this development becomes uncontrolled.
1.2 B CeU Development
Lymphoid, as well as erythroid and myeloid, lineages of haematopoietic cells are 
descendants of pluripotential, self-renewable CD34+ haematopoietic stem cells (HSC) in 
the bone marrow (Sutherland et a i, 1993). From the HSC it appears that the next stage of 
B cell development is generation of a common, bipotcntial, lymphoid-committed 
precursor which can give rise to T and B lymphocytes (Ikuta et al., 1992). The exact 
point at which commitment to the lymphoid lineage occurs is, at present, unknown, 
however, discovery of genes, for example, Ikaros, wliich can prevent lymphoid 
development if inactivated, will allow clarification of this early developmental stage 
(Georgopoulos et aL, 1994),
Later stages of development have been resolved based on phenotypic analyses, 
demonstrating that B lymphocyte growth and differentiation is a multi-stage process 
which involves the collaboration of numerous cell types and cytokines. B cell 
differentiation can be divided into two main phases: the antigen-independent and the 
antigen-dependent phase (figure 1.1). The first phase involves development of the 
haematopoietic stem ceU into an immature surface IgM-positive B ceU - it is independent 
of antigen involvement and occurs in the bone marrow. The second phase involves 
negative selection of B cells which express a receptor with specificity for self antigen and 
maturation of cells which are speciric for non-self (Taidinton, 1994). In the periphery and 
secondary lymphoid tissue, such as lymph node, the cells mature to become surface 
IgM+/IgD+ and, if they contact specific antigen, may become activated to Ab-producing 
plasma cells or memory B cells (reviewed by RoHnk & Melchers, 1991). This antigen- 
dependent phase of development is also regulated by T ceU-derived cytokines, for 
example, IL-2, IL-4, IL-6 , IL-10, UL-13, IL-15 etc.
The focus of this thesis wUl be the antigen-independent phase of B ceU differentiation.
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1.3.1 Antigen - independent B cell differentiation
The initial phase of B cell development occurs in the bone marrow - an environment 
which consists of various types of stromal cells including fibroblasts, macrophages, |
adipocytes, reticulocytes, adventitial and endothelial cells (Dorshkind & Landreth., 1992).
The influence of stromal cells is mandatory for B cell development both via production of 
cytokines and through cell-ceU contacts. The stages of early B cell differentiation are 
carefully ordered and can be defined by phenotypic changes, including the status of Ig 
gene rearrangement.
1.3.2 Phenotypic changes in B cell development.
Hai’dy and colleagues, 1991, developed a scheme to compartmentalise murine B cell
precursors into five distinct fractions based on their expression of vaiious surface
molecules; these categories are also used to describe human B cell precursors (Hardy et
aL, 1991; Tarhnton, 1994). The first committed B cell precursors are referred to as pro-B
cells. They express ceU surface CD45RA (B220) and leukosialin (CD43) but have no
other B ceU specific markers and have not yet begun immunoglobuUn (Ig) gene I
rearrangement. Pre-B cells express cytoplasmic ji chains and also B ceU specific markers
such as CDIO, CD24, CD19, CD20, CD45, CD72 (Schwarting et aL, 1992; Duperray et
aL, 1990), BP-1 and Heat stable antigen (HSA) but have lost expression of CD43 (Hardy,
1991). They also begin to express major histocompatibUity complex (MHC) class II (la)
antigens (Tarlinton, 1994). Both pro-B and large pre-B ceUs are highly proliferative and,
.by definition, lack surface immunoglobulin. Expression of CD20 at the smaU pre-B stage 'Li'coincides with cessation of ceU division, exit from the bone marrow, and maturation 
towards a mature B-ceU phenotype (Salvaris et aL, 1992), with a concomitant decrease in 
expression of surface antigens such as CDIO and CD24 (Duperray et al., 1990).
i
1.3.3 Ig gene rearrangement determines the stage of B cell differentiation
The early stages of B ceU development involve production of Ig heavy and tight chains 
which can be assembled as the B cell antigen receptor - surface Ig.
The Ig heavy and tight chains are composed of multiple gene segments which undergo a 
precise sequence of somatic recombination to create the variable and constant regions of 
the molecule. The loci which compose heavy chains include a variable (V^) region as weU 
as diversity (D^) and joining (Jy) regions, all of which encode the antigen binding site, and 
constant (C) regions. Light chains are encoded by a combination of Vl, and Cl loci and 
so have less variability than heavy chains. The first recombination events occur in the 
heavy chain genes by joining of a Dy to a Jy locus. At this stage the precursors express the 
nuclear enzyme terminal deoxynucleotidyl transferase (TdT) which is involved in N-region 
addition and hence generation of additional diversity during gene rearrangement. 
Subsequently, one of the many Vy region genes is juxtaposed to the rearranged DyJy, the
rean'anged heavy chain gene is ti’anscribed and the remaining non-coding sequences
between the VDJy and the Cp exons removed by post-tianscriptional processing. The
.result is formation of a Vy-Dpj-Jy-Cji transcript which is translated into heavy chain 
protein (Rolink & Melchers, 1993).
B cells appear to be able to detect if the Ig gene locus is productively reaixanged by 
displaying the Ig heavy chain on the ceU surface. If productive, the heavy chain is
7postulated to bind to a Ligand in the stromal cell environment and signal the ceU to
proceed to the next stage of reaixangement. At first, this explanation appeared unlikely
since heavy chains were known to require assembly with light chains before they could be
expressed on the cell surface (McCubrey et aL, 1985). The problem was solved after the
discovery of two genes, ^preB ^5 . These encode proteins able to associate non-
'covalently to form, what is now known as, a surrogate light chain (Sakaguchi & Melchers,
1986; Kudo & Melchers, 1987). These genes appear to be expressed exclusively in B 
cells, from the pro-B ceU stage through to immature mlg+ B cells in the bone marrow 
(Melchers et aL, 1993), with the À.5 protein able to bmd covalently to DjjJjjCp proteins 
and to fuUy rearranged heavy chains, allowing their expression on the cell surface 
(Karasuyama et aL, 1990). It is still not cleai' exactly what the complex binds
to in the bone mairow, but it functions in the selection and amplification of pre-B cells 
with functionally rearranged Ig heavy chain genes and its expression is obligatory for 
conventional (B-2) B cell differentiation to occur (Ehlich et aL, 1993). After successful 
heavy chain rearrangement, cytoplasmic p chains are found in the cell and it is said to have 
differentiated to the pre-B cell stage. Successful expression of heavy chain protein with 
^preB " ^ 5  prevents further heavy chain rearrangement (allelic exclusion) and is thought to 
signal the initiation of light chain gene rearrangements (Tsubata, 1992). However, Ehlich 
et aL, 1993, have evidence that light chain rearrangment can occur at the pre-B cell stage 
and without prior rearrangement of heavy chain genes. There are also data to suggest that 
light chain rearrangement can occur before that of heavy chains in human EBV- 
bansformed pre-B cells (Kubagawa et aL, 1989).
The kappa light chain is the most common light chain found in humans, with 
rearrangement at the X locus occuring only if k  reaixangements fail to generate a 
functional light chain (Tarlinton, 1994). After foimation of a Vl-Jl-Ck/à transcript and its 
translation to light chain protein, rearrangement of the remaining alleles is halted and the 
IgM molecule is assembled on the cell surface marking the transition from a non-dividing 
small pre-B ceU to an immature B lymphocyte. The immature B lymphocyte, with its 
clonotypic receptor (Burnet, 1959), then leaves the bone marrow for the periphery where, 
as a mIgM+/IgD+ B cell, antigen is essential for further differentiation.
_
1.3 A  CDS-positive B cells
CD5 is a 67kD glycoprotein whose murine homologue, Ly-1 , was originally discovered 
on T cells and thought to be expressed exclusively by CD4‘+‘ T helper cells (Cantor & 
Boy se, 1977). However, later studies in humans reported CD5 expression on all normal T 
ceils (Ledbetter et a i, 1981), on some B cell tumoui's (especially chronic lymphocytic 
leukaemia (B-CLL) (Martin et aL, 1981) and, as in the mouse, on a small proportion of 
normal B cells (Calligaris-Cappio et aL, 1982). It has now been established that CD5 is 
expressed by a sub-population of B cells, termed B-la cells, that express normal B cell 
markers such as CD 19, CD20, CD21 and class II MHC, but are CD23-, have high levels 
of mIgM and dull to moderate levels of mIgD (Herzenberg et aL, 1986; Gadol & Ault, 
1986). These cells may represent the normal cellular counterparts of B-CLL cells 
(Calligaris-Cappio et aL, 1982). In the mouse, Ly-1 cells can be divided into two sister 
populations - B-la (CD5+) and B-lb (CD5“) compaied to conventional (or B-2) B cells 
(Kantor, 1991), and a similar CD5" population, which has aU the functional characteristics 
of CD5+ cells, has been described in human peripheral blood B cells (Kasaian et aL,
1992).
B-1 cells can be distinguished from conventional B cells by patterns of gene expression, 
anatomical localisation and functional chaiacteristics. The phenotype of these cells has 
already been mentioned but, in addition, B-1 cells tend to use a restricted set of Vjj genes 
(Pennell et aL, 1988). Several of these Vg families, including V^5, appear to be 
overexpressed in B-CLL (Humphiies et al, 1988). Another distinguisliing characteristic of 
B-1 cells is their ability to self-replenish, unlike conventional B cells (Kantor, 1991). 
CD5+ cells are responsive to numerous cytokines including IL-2 and especially EL-5, and 
may themselves produce IL-10 (Calligaris-Cappio et aL, 1989; Tominaga et aL, 1991; 
O'Garra & Howard, 1992). IL-10 has been implicated in the development of CD5+ B cells 
and is thought to have an autocrine growth factor function. In mice, administi'ation of 
anti-IL-10 antibody depletes the CD5+ B cell population but not the conventional B cell 
population (Ishida et aL, 1992).
Early experiments showed that CD5+ B ceEs produce auto- and polyreactive antibodies 
(Broker et aL, 1988; Sthoeger et aL, 1989). Indeed, this population in man appears to be 
responsible for production of the majority of anti-Fcy and anti-Fcp antibodies, (Hardy et 
aL, 1987) and for production of IgM which reacts with low avidity with a variety of self- 
and non-self antigens (MacKenzie et at., 1991).
The CD5+ population is prominent early in ontogeny and this is thought to mimic 
phylogeny since CD5+ cells produce these 'natural antibodies' - polyreactive, and often 
autoreactive, antibodies of the IgM isotype (Bofill et al., 1985).
' '
L o c A l is A t io n : B-1 cells represent approximately 1% of the total B cell population in 
mice and they are mainly localised in the peritoneal cavity with some in the marginal 
zones of the spleen (Herzenberg et al,, 1986). In humans, the first B cells to appear in the 
developing lymph nodes are virtually 100% CD5+ (BofiU et al,, 1985) but the numbers 
decrease with age until, in the adult, only 5-30% of the circulating B cells are Less
than 30% of lymph node B cells are CD5+ and these are largely found at the periphery of 
germinal centres (Lydyard et al., 1993). i :
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There are contrasting views as to whether B-1 cells actually represent a distinct lineage of 
B cells or whether CD5 is in fact an activation marker. That the B-1 cells represent a
V-..'separate lineage of cells is supported by the finding that hematopoetic stem cells (HSC) 
fiom foetal or neonatal liver wUl repopulate the B-1 and conventional B-2 cell 
compartments of irradiated SCID mice, but HSC transfeiTed from adult bone marrow will 
only repopulate the B-2 compartment (Hardy et al., 1986). Thus, progenitors of B-1 cells 
are abundant m foetal liver but are rare in adult bone marrow. Also, if mice are irradiated, 
only those repopulated with peritoneal cells in addition to bone marrow have B-1 cells 
(Herzenberg et al., 1986). Further evidence for a separate B-1 lineage comes from the À5 
knockout mouse which has pertui'bation of B-2 cell development but apparently normal 
B-1 cell development (Kitamura et al., 1992), and from PAX-5 knockout mice which lack 
CD5+ B cells (Urbanek et al., 1994). It is possible that this observation can be explained 
by the abüity of 'surviving' B-1 cells to self-replenish but it may also be argued that SCID 
and knockout mice provide an alien environment for B cell development.
The ai'gument that CD5+ B cells represent an activated subpopulation is supported by 
reports that human CD5" B cells can be induced to become CD5+ in vitro by activation 
with phorbol esters, and several cytokines modulate expression of the molecule (Paavonen 
et al., 1990). In the mouse, stimulation of splenic B cells with anti-IgM and IL- 6  induces 
expression of CD5 and down-regulates CD23 (Kantor, 1991; Ying-zi et al., 1991). 
Activation of human B cells by EBV has the opposite effect and causes down-reguiation 
of surface CD5 (Van de Velde et al., 1991). IL-4 also reduces the expression of CD5 on 
normal and malignant B cells (Freedman et al., 1989) which suggests that CD23 and CD5 
undergo reciprocal regulation. However, co-expression of CD5 and CD23 can occur in 
humans and, indeed, is used to diagnose B-CLL cells (Delespesse, 1992). This is of 
interest since the work of Van de Velde and colleagues, 1991 demonstrated that CD72, a 
member of the same superfamily as CD23, is the receptor for CD5. The CD5/CD72 
interaction is thought to aid B/T cell interaction although CD5+ B cells may also interact 
with other B cells. It is important to note that CD5+ B cells themselves express very high 
levels of CD72 (Lydyard et al., 1993).
13A-2 CD72 structure and proposed functions
CD72 is a B cell marker found to be expressed at the very earliest (pro-B) stages of B cell 
development and lost after terminal differentiation to plasma cells (Gordon, 1994). It is 
highly B cell restiicted but there ai*e reports of expression on some macrophages, FDCs 
and some epithelial ceUs. In germinal centres and the follicular mantle, B cells are strongly 
positive for CD72. CD72 is a type II integral membrane protein and, in common with 
CD23, is a member of the C-type lectin family (described in section - CD23). Like CD23, 
it has a leucine zipper motif between the membrane and lectin-hke domains which cause 
an a-helical coUed-coil structure and thus there is oligomerisation of CD72 to create a 
stable homodimer of 8 6 kD (Gould et al, 1991). Unlike CD23, there is no evidence that 
CD72 has a soluble form. Transformation with EBV upregulates expression of CD23 but 
appears to downregulate CD72 expression, as well as that of CD5 (Gordon, 1994).
The function of CD72 remains elusive but, as mentioned above, its interaction with CD5 
has been implicated in B-T cell contacts since T cells express CD5. This may be the case 
in murine B cells where antibody to murine CD72 blocks the in vitro response to T- 
dependent antigens (Yakura et al., 1981), but it has not been demonstrated for human 
CD72. In resting human B cells, anti-CD72 mAbs deliver a co-mitogenic signal with 
immobilised anti-IgM (rnimics T cell-independent antigens) to stimulate DNA synthesis. 
However, soluble anti-jX, which rnimics T cell-dependent antigen, was unable to interact 
with the CD72 signal (Kamal et al., 1991). Therefore, it has been suggested that CD72 
may play a role during T-cell-independent B cell responses, possibly by interaction with 
CD5+ B-1 cells. As previously noted, human CD6 + B cells have a tendency to express 
low-affinity polyspecific antigen receptors and it has been suggested that these cells could 
serve as antigen-presenting cells (APC) for conventional B (B-2) ceUs which express more 
specific receptors. It is proposed that CD5 on the B-l-APC would interact with CD72 on 
the B-2 cell to augment the Ag-delivered signal and activate the ceU. This hypothesis may 
be supported by studies which show that CD5 deficient mice are unable to mount 
responses to certain T-independent antigens (Gordon, 1994).
It has been shown that CD5 can exist as a soluble molecule, extending the possiblity that 
CD72 may also be tiiggered on the B ceU surface by a soluble ligand (Jamin et al., 1991). 
However, the role of CD72 remains obscure and the real function of CD5+ cells in the 
immune system is not yet clear. It is possible that CD5+ cells develop early in life due to 
selection by endogenous antigens, including anti-idiotypic B cells, which are present in the 
foetus and not in the adult. In this role they may parallel the yÔ T cells, progenitors of 
which are only present in foetal HSC (Kantor, 1991), and so represent the primitive layer 
of the immune system, with B-2 cells and ap  T cells making up the most developed layer. 
B-1 cells may have evolved to continually produce autoantibodies with a regulatory role 
and possibly 'natural' antibodies which offer a first line of defence against pathogens. They
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do not seem to become permanently committed to antibody production and appear to 
retain their self-renewal capacity (Herzenberg et al., 1986).
The ability of CD5+ cells to produce IL-10 may also be important in immune regulation 
since IL-10 can inhibit cytokine synthesis by macrophages and inhibit THj cell function, 
but favour the function of TH2  ceUs. IL-10 is also produced by macrophages and T cells, 
so its regulation and effects wül be complex. However, in diseases, for example CLL, 
elevated levels of CD5+ B cells, leading to overproduction of IL-10, may explain the 
dysregulation of immune function (O'Garra & Howard, 1992).
It is not yet cleai’ which, if any, of these roles of B-1 cells is most important in 
maintenance of an effective normal immune system. Both B-1 and conventional, B-2, B 
cells must derive from a common progenitor but the exact point in B cell development at 
which the two lineages branch is unknown.
1.4 Regulation ofB cell development by stromal cells
Progenitor B cells proliferate and differentiate in close contact with bone marrow stromal 
cells, within the interstices of a network of cytoplasmic processes (Jacobsen & Osmond, 
1990). CeU-cell contacts and the cytokines that stromal cells secrete are both essential for 
B lymphopoiesis, but relatively little is known about the exact interactions which occur. 
The bone marrow is a difficult environment to study in vivo so most infoimation has come 
from in vitro long-term bone manow culture techniques (Whitlock & Witte, 1982). 
Several stromal cell lines have been developed and appear to exhibit heterogeneity of 
function with respect to the stage of B ceU development they can support (Dorshkind & 
Landreth, 1992). Some cell lines support the maturation of pro-B cells to pre-B cells but 
others wül support only proliferation, not maturation, of these cells (Nishikawa et al., 
1988). It is not clear whether these cell Hnes represent distinct populations of stromal cells 
or that, as cell .lines, they are deficient in certain functions and so unable to provide 
complete support for B lymphopoiesis. However, the discovery of these cell Hnes has 
demonstrated the existence of multiple signals which act at defined points in B ceU 
development.
1.4.2 Cell-cell contacts
As mentioned previously, developing human and murine lymphoid cells can be observed 
in direct, intimate contact with stromal cells in bone marrow cultures (Dorshkind & 
Landreth, 1992) and in vivo they have been shown to make extensive contact with stromal 
reticulai' cell processes (Jacobsen & Osmond, 1990). This contact appears to be essential 
for the long-term survival of B220" cells (Kearney et al., 1987) and understanding how B 
cells modulate and are affected by this adhesion has relevance to both normal B cell 
differentiation and to the spread of leukaemic ceUs outside the bone marrow environment.
Several adhesion molecules have been implicated in these cell to cell contacts. Developing 
B lymphocytes express VLA-4 integrin which may bind to VCAM-1 found on stromal 
cells; during murine B lymphopoiesis, the interaction between VLA-4 on progenitor B 
ceils and the murine homologue of VCAM-1, has been shown to be essential for 
maturation (Miyake et al., 1991). The adhesion molecules VLA-4 and VLA-5 are also 
expressed by progenitor B cells, and are able to bind to fibronectin. Antibodies to CD9, a 
member of the newly defined tetrahelical family of proteins which ai’e proposed to 
modulate adhesive processes, have been shown to induce pre-B cell adhesion to bone 
marrow stromal cells by promoting reognition of fibronectin by VLA-4 and VLA-5 
(Maselhs-Smith & Shaw, 1994). Since CD9 is present on pre-B cells but not on 
cii'culating B ceUs, it could serve to retain B cell progenitors within the bone marrow 
microenvironment.
A stromal cell surface molecule termed BST-1, which has 33% homology with CD38, 
also facilitates pre-B ceil growth but the Hgand for BST-1 is, at present, unknown. 
Stromal ceU Hnes from rheumatoid arthritis patients have enhanced BST-1 expression and 
were previously shown to have an enhanced ability to support the growth of a pre-B cell 
line when compared to stromal cell lines from healthy donors (Kaisho et al., 1994).
In addition to facilitating B cell development, there is another role for cell-ceU contact in 
the bone marrow. In the rnouse, many B Hneage cells are observed in such close contact 
with macrophages that their ceU membranes are indistinguishable. Apoptotic cells are 
phagocytosed after recognition and binding by macrophages and, during B cell 
development, apoptosis probably occurs after a cell has undergone non-functional Ig gene 
rearrangement to 'abort' theh development (Jacobsen & Osmond, 1990).
The exact role of cell-ceH contact in B lymphopoiesis is not clearly understood but the 
existence of progenitors whose survival is absolutely dependent upon contact with stromal 
cells suggests that it plays a crucial role. It is possible that a function of adhesion is to 
expose B cell progenitors to regulatory cytokines produced by stromal cells, however, 
there is evidence that the maturation (as opposed to growth) of pro-B cells, although 
dependent upon stromal cells, does not require direct contact but can be potentiated by 
soluble mediators (Landreth & Dorshkind, 1988).
1.4.3 Cytokines
Normal stromal cells, from pihnary cultures, have been shown to produce numerous 
cytokines including IL-3, IL-7 and IL-11, macrophage (M)-colony-stimulating factor 
(CSF), stem cell growth factor (SCGF) and occasionally InsuHn-Hke growth factor 1 
(IGF-1) (Witte et al., 1993). However, in contrast to some observations with stromal cell
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lines and clones, there was no evidence for constitutive expression of IL-4, IL-6 or GM- 
CSF. Witte et al., 1993 suggest that this discrepancy may have been caused, in the case of 
IL-6, by the cells becoming more fibroblast-hke after extended culture. Most of the 
stromal cells examined were shown to produce IL-7 but about 20% had no detectable IL- 
7 protein. Thus, primary stromal cells may include functional subsets and these, at least in 
regard to IL-7 production, mirror the differences in cytokine profiles seen in stromal cell 
lines. However, it is possible that IL-7 is produced by aU stromal cells but constitutive 
levels are maintaind by highly localised inductive signals. Indeed, Sudo and colleagues 
(Sudo et al., 1989), showed that transcription of IL-7 was actually induced in a cloned 
stromal cell line after contact with pre-B cells, although other reports dispute this 
observation (Witte et al., 1993). It has been suggested that, in addition to cytokines, 
stromal cells may secrete extracellular matrix proteins which act to stabilise and provide a 
high local concentration of the secreted growth factors .
There are numerous cytokines, for example IL-1, IL-3 and IL-11, which have a general 
involvement in haematopoiesis, including stimulation of stem cells. IL-11 appeal's to act in 
synergy with IL-3, stem cell factor and also G-CSF to expand and sustain long-term 
culture-initiating cells (Brandt et al., 1993). However, there are cytokines which act more 
specifically on lymphopoiesis; those involved in B cell development wül be described 
below.
P ro -B  CELLS: The stromal ceU cytokines involved in maturation and proliferation of pro- 
B cells are poorly defined. Long-term survival of these cells apparently requires direct 
stromal cell contact (Nagasawa, 1994) and this makes it difficult to examine which soluble 
factors are actually involved. Maturation of B220" cells to pre-B cells is not affected by 
IL-7 or /rfr-Mgand but conditioned medium from stromal cells can mediate this effect 
(Landreth & Dorshkind, 1988), suggesting that cytokines are involved. As yet, these 
additional cytokines have not been identified, however, the stromal ceU line PA6, which 
can maintain pro-B ceU growth, has been shown to produce a novel cytokine called pre-B 
cell growth stimulating factor (PBSF) which is a member of the interciine a  famüy. 
Although the observed effects of PBSF were to promote the growth of pre-B ceUs, the 
authors suggest that it may also act to increase the numbers of pro-B cells able to mature 
to pre-B ceils (Nagasawa, 1994).
PRE-B CELLS: Most infoimation about cytokine effects on early B lymphopoiesis relates to 
the pre-B ceü stage. IL-7 is known to play a key role in B lymphopoiesis but, although 
necessary, it is clearly not sufficient for pre-B ceü development and most of its effects are 
observed in synergy with other stromal ceü derived cytokines. The primary action of IL-7 
is to promote prohferation, with this responsivness only developing after B cells have 
begun to express B220 (Lee et al., 1989). Administi'ation of IL-7 to normal mice
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increases the number of B220+/sIgM“ pre-B cells, which subsequently matui’c to 
slgM'^/sIgD'*’ B cells (Morrissey et a i, 1991), and administration of monoclonal 
antibodies to IL-7 virtually eliminates the pre-B cell population in mice (Grabstein et aL,
1993).
Another cytokine involved in B lymphopoiesis is kit~]igmd (KL), the gene product of the 
Steel locus and also known as stem cell factor (SCF), whose effects appear only in 
synergy with IL-7 (McNeice et al., 1991). Most stromal cells secrete KL and this may 
explain the synergy observed between IL-7 and stromal cell supernatants (BHlips et al.,
1992). However, injection of anti-SCF mAb does not significantly affect murine B 
lymphopoiesis (Ogawa et al., 1991) so other molecules may be able to compensate for KL 
functions. As mentioned previously, pre-B cell growth stimulating factor (PBSF) can 
stimulate proliferation of a pre-B cell line by itself and, furthermore, synergistically 
augment the growth of bone marrow B cell progenitors in the presence of IL-7. Samal and 
colleagues, 1994, cloned a 52kDa human pre-B cell colony enhancing factor produced by 
stromal cells and showed that it acts in synergy with IL-7 and SCF to enhance murine pre- 
B colony formation (Samal et al, 1994). Insulin-like growth factor-1 (IGF-1) is also able 
to promote proliferation of IL-7-dependent pre-B cells (Landreth et al, 1992).
As well as its abüity to promote pre-B ceü prohferation, IL-7 has been imphcated in the 
maturation of pre-B cells to immature B ceüs, with responsiveness to IL-7 lost once the 
cells have surface Ig (Dorshkind & Landreth, 1992). A study involving a human acute 
lymphocytic leukaemia (ALL) showed limited maturation of the pre-B cells to CD20 
expressing B cells which were sig-negative, on addition of IL-7 (Ohyashüd et al., 1993). 
However, another report demonstrated that c-kit, the receptor for kit-hgmd, and the IL- 
7R are no longer expressed once cells have undergone kappa rearrangements and thus, 
they suggest a rninimal role for IL-7 and KL in mediating the pre-B to B ceü transition 
(Henderson et al., 1992). Another cytokine involved in this hansition is an IL-4-like 
molecule produced by the stromal ceü line SCL 160 (Dorshkind & Landreth, 1992), IL-4 
itself has been shown to inhibit growth of stromal cell-dependent pre-B ceü lines 
(Rennick, 1987; Ohyashiki et al., 1993) consistent with it acting to induce pre-B ceü 
differentiation. Another group faÜed to see an effect of IL-4 on the differentiation of 
leukaemic pre-B cells but it is possible that these cells had a differentiation block and so 
were unable to respond (Consolini et al., 1993).
A second model of pre-B ceü maturation is proposed by Rolink et al., 1991, who suggest 
that, in the mouse, it is removal of IL-7 from cultures which releases cells to differentiate 
to surface Ig-positive ceÜs. Tlieir hypothesis is that proliferation of precursors pushes 
them away from the centre of the bone marrow and thus away from stromal ceü contacts 
and the appropriate cytokine supply, forcing or allowing the cells to differentiate.
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N e g A t iv e  r e g u l A t io n : There is emerging evidence that B cell development is sensitive 
to negative regulation in culture and in vivo. Various cytokines, including transforming 
growth factor-|3 (TGF-p), IL-1, IL-4 and granulocyte-macrophage colony-stimulating 
factor (GM-CSF) appear to inhibit early B lymphopoiesis. This inhibition may be ehcited 
through action on the stromal cells since treatment of stromal cells with GM-CSF 
abrogates their ability to support pre-B cell differentiation (Lee et al., 1993; Dorshkind & 
Landieth, 1992). In addition, pre-incubation of stromal cells with either XL-la or IL-4 
completely abrogates their ability to support pre-B cell generation in subsequent culture 
with freshly isolated bone marrow cells, apparently via induction of an inhibitory cytokine 
(Bülips et al., 1990).
Thus, the regulation of B lymphopoiesis appears to be highly complex, involving positive 
and negative acting cytokines and direct B cell-stromal cell contact. It is likely that other, 
as yet unidentified, ceU surface antigens and cytokines ai'e also involved in early B ceU 
development.
The cytokines mentioned previously are all produced by bone marrow cells other than B 
cells themselves. There is, however, evidence that B cells produce cytokines to control 
their own growth and this autocrine conti'ol may have a role in B lymphopoiesis, 
Dysregulation of such growth control could lead to development of malignancies.
1.5 Autocrine control of B cell development
There are multiple regulatory controls operating during B lymphopoiesis and it has 
become apparent that B cells are able to produce factors which affect their own growth.
These factors have been termed autocrine growth factors. The original observation of the 
existence of autocrine factor production by B cells came from work involving Epstein- 
Barr virus (EBV)-ti’ansformed B cells (Blazar et al., 1983). EBV is a herpesvirus which 
enters B cells via binding to CD21 (Fingeroth et al., 1984). Once EBV has ckcularised, 
the B cells express increased levels of the cellular gene CD23 (Hurley & Thorley-Lawson,
1988) and are immortalised in viti'o. Blazar and colleagues demonstrated that EBV- 
transformed B cells produce an autocrine growth factor after they observed that 
conditioned media from human B cell lines contained a stimuiatory activity which, when 
added back to the same cells cultured at low cell density, reduced the lag phase and 
subsequently enhanced growth of the cells (Blazar et al., 1983). Subsequently, Gordon et 
al., 1984a, reported that EBV-transformed cells, if starved of their autocrine growth 
factor by culture at low cell density, an'ested in the G1 phase of the cell cycle. This was in 
contrast to cells starved of supplements such as transferrin where the cells arrested at the 
G 1/S transition stage. The authors went on to demonstrate that the autocrine activity was 
due to a protein of between 25 and 30 kDa in size. This autostimulatory activity, termed B
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cell-derived B cell growth factor (B-BCGF) also acted in synergy with anti-Ig to stimulate 
proliferation of normal tonsil B cells (Gordon et ah, 1984b).
It has been proposed that the association between EBV and malignancies such as Burkitt's 
lymphoma is due to the induction of autocrine growth factor production by the B ceU and 
subsequent removal of normal growth regulation. However, the pictui'e may not be so 
simple because many EBV-negative cell hnes, and active cycling normal B cells, produce a 
'BCGF arguing that it is not a property specifically induced by EBV transformation 
(Gordon, 1985; Jorgensen et al, 1986). Thus, it appears that autocrine growth factor 
production may be a property of continuously growing cells and, after activation of 
noimal cehs, it may result in clonal expansion (Muraguchi et aL, 1986).
Since these initial observations of autocrine factor production, numerous 'B-BCGF' have 
been recognised and now several cytokines have been imphcated as autocrine factors:
lL-1: In 1984, Scala et al reported that an EBV-transformed cell line could produce IL- 
l a  and that it had an autostimulatory effect on the cehs. There have been several other 
reports of IL-1 or IL-l-hke activity acting as an autocrine gi'owth factor and there are 
several demonstrations of B cell chronic lymphocytic leukaemia (B-CLL) clones 
producing IL-1 (Gordon & Cahns, 1992). IL-1 is most prominently produced by 
monocytes and, indeed, IL-1 production appears to be restricted to B-CLL cases 
expressing the monocyte-associated antigen, CD 14 (Morabito et al., 1987). In B-CLL, 
the leukaemic cells do not divide in the blood but presumably are produced by rapidly 
dividing progenitor cells in the bone marrow. In most cases the leukaemic cells are 
refractory to the effects of autologous IL-1 but it is possible that the progenitor cells use 
IL-1 to sustain their own growth.
TNF-a: Tumour-necrosis factor has been imphcated as an autocrine factor for B-CLL 
cells (Cordingley et al., 1988), and recently, for normal human splenic B cells (Boussiotis 
et al., 1994). When the B cells are activated with either anti-CD40 antibodies and IL-4, 
i.e. mimicking activation by T-dependent antigen, or with anti-Ig i.e. rnimicking T cell- 
independent antigen, there is induction of TNF-a gene transcription and production of 
TNF-a (Boussiotis et al., 1994). That antibodies to TNF-a inhibit the B cell proliferation 
confirms the autocrine effect and suggests that this regulation might have a role in 
infections where polyclonal B cell expansion occurs.
TNF-P: More commonly referred to as lymphotoxin, TNF-(3 also acts as an autocrine 
factor but only in human EBV- transformed cell hnes (Estrov et al., 1993). No production 
of TNF-a by these cells was evident.
JJu-6: Interleukin-6, although normally produced by fibroblasts, endothelial cells or 
monocytes (Biondi et al., 1989), has been identified as an autocrine growth factor for 
both EBV-immortalised B cells and multiple myeloma cell lines (Tosato et a l, 1990: 
Kawano et al., 1988). The involvement of IL-6 in multiple myeloma, where neutralising 
antibodies to IL-6 inhibits the in vitro proliferation of the ceUs, demonstrates that 
autocrine growth regulation can contribute to pathogenesis of a B cell malignancy 
(Kawano, 1988).
Lactic acid: In the EBV-immortalised ceü hnes reported by Tosato and colleagues, 1990, 
IL-6 did not appear to be the sole autocrine growth factor since a low-molecular weight 
fraction (<5000 Da) contained a large proportion of the stimulatory activity. This activity 
has surprisingly been identified as lactic acid, a metabolic product of glycolysis (Pike et 
al., 1991). Lactic acid alone was found to account for gi'eater than 70% of the autocrine 
activity in serum-ffee supernatants from EBV-immortalised B ceüs. That the majority of 
the stimulatory activity is due to lactic acid may explain why previous studies using anti- 
IL-6 neutralising antibodies failed to inhibit autocrine activity of unfractionated 
supernatants from lymphoblastoid cell hnes (Tosato et al., 1990).
Thioredoxin: A stmctui'ally novel 12 kDa protein with IL-l-hke activities was reported 
to be an autocrine factor for EBV-ti'ansformed B cehs. The factor was termed 3B6 IL-1 
(Wakasugi et al., 1987) but is now known to belong to the famüy of reducing enzymes 
cahed thioredoxins (Bertoglio et al., 1989). Thioredoxins are found in almorf ah ceU types 
and are attributed with numerous properties ranging from hydrogen donor for 
ribonucleotide reductase in DNA synthesis, to degradation of msulin. Recently, 
thioredoxin has been shown to be mvolved in autocrine growth stimulation of EBV- 
transformed cells after it was discovered that it can increase ceh proliferation by triggering 
protein kinase C translocation (Biget et al., 1994). It is possible that, by amplifying 
intracehular signals, thioredoxin can make EBV-positive cells more sensitive to sub- 
optimal concentrations of growth factors to which normal cells would not respond.
Other cytokines: Several other cytokines are thought to act as autocrine factors for B 
cehs, including IL-2, IL-5 and IL-10. Leukaemic ceh hnes of pre-B ceh origin produce IL- 
2 and also synthesise IL-2 receptors; but there has been no direct demonstration of 
autocrine activity (Holan et al., 1993).
In 1990, Paul and colleagues discovered that EBV-transfomied B cehs produce hL-5 
(Paul et al., 1990) and in 1992 they went on to show that IL-5 was, indeed, acting as an 
autocrine factor (Baumann & Paul, 1992). As yet, there is no evidence of IL-5 acting as 
an autocrine factor for non-EBV transformed human B cehs but it is possible that the 
response is inducible if the cehs are appropriately activated.
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With respect to IL-10, it has been shown that the IL-10 coding sequence is highly 
homologous to an EBV open reading frame gene, BCRFl (Moore et a i, 1990). Human 
IL-10 enhances the viability of resting B ceUs and the proliferation of activated B cells and 
the EBV-encoded product has the same biological activities, so was termed viral IL-10 
(vIL-10) (Stewart et al., 1994). It is possible that EBV uses the vIL-10 to keep cells 
proliferating while it is actively replicating and spreading during the early stages of 
infection. IL-10 is produced by activated T cells, activated monocytes and some B cells. 
Some Burkitt's lymphoma cell lines produce IL-10 (Stewart et al., 1994) and CD5- 
positive B cells, capable of self-renewal, produce high levels of IL-10, as detected by PCR 
(Raveche et al., 1992). In fact, murine B-1 cells are known to constitutively produce 
elevated levels of IL-10 and mice treated with a neutralising anti-IL-10 antibody from 
bii’th lack B-1 cells (O'Garra and Howard, 1992). This appears to be due to elevated 
endogenous IFN-gamma but does demonstrate a role for IL-10 in B-1 cell development. 
IL-10 appears to be expressed at a discrete stage of B ceh differentiation coiresponding 
to mature and/or activated B cells. It is not clear whether IL-10 acts as an autocrine factor 
for normal cehs but it may be important in B ceh mahgnancies.
IL-7: Expression of IL-7 has not been detected in normal B cehs but malignant B ceh 
phenotypes, including lymphoblastoid ceh lines and Burkitt's lymphoma ceh lines, have 
been shown to constitutively secrete IL-7 and some mature B ceh lines express IL-7 
receptors. Numerous human B ceh lines express IL-7 transcripts but only EBV-positive 
ceh lines constitutively secrete IL-7; the ceh lines which express IL-7 receptors do not 
secrete IL-7, arguing against an autocrine effect (Benjamin et al., 1994). At present there 
are no reports of IL-7 acting as an autocrine growth factor for B cehs except a report 
where IL-7-bearing retroviruses were used to transform IL-7 dependent ceh lines. 
Subsequently these ceh lines became independent of exogenous IL-7, their proliferation 
was inhibited by anti-IL-7 antibodies and they were acutely tumorigenic in syngeneic hosts 
(Overeh er a/., 1991).
CD23: CD23 is a 45kD type-II tiansmembrane glycoprotein and a member of the C-type 
lectin superfamily (see section 1.5 for more details). It was first described as the EBV ceh 
suiface antigen (EBVCS) by Kitner and Sugden (1981), and expression of CD23 was 
shown to be a requirement for u ansformation of B cehs suggesting that it was involved in 
gi'owth stimulation. It is now apparent that noimal cehs also express CD23 when 
activated (Walker et al., 1986) but, in EBV-transformed B cehs, CD23 appears to be 
superinduced and constitutively expressed (Thorley-Lawson et al., 1985). Swendeman 
and Thorley-Lawson, 1987, observed that CD23 is released into the supernatant as a 
soluble molecule of 25kD molecular weight (sCD23) which is involved in autocrine 
proliferation of EBV-infected B lymphoblasts and is a growth factor for normal, receptor-
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Stimulated, B cell blasts. However, production of CD23 by EBV-ti'ansformed cells does 
not correlate with their tumourigenicity and, in fact, there may be an inverse relationship 
between these two factors (Gordon et al., 1985; Klein & Klein, 1985).
Synergistic effects: As mentioned with respect to IL-6 and lactic acid, it is possible that 
more than one autocrine factor is present in the supernatant of autonomously growing 
cells. This can make identification of factors very difficult. A paper by Abken et al, 1992, 
actually indicates involvement of four secreted cytokines which act synergistically to 
maintain long-term proliferation of EBV-negative human B ceh lines. IL-1 a , IL-6, TNF-a 
and TNF-p are ah necessary for the continued growth of some estabhshed human B ceh 
clones. These cytokines appear to regulate and balance production of one another since 
the IL-6 promotor is activated by TNF-a and IL -la  and, furthermore, IL -la  induces 
transcription of TNF-a and TNF-p mRNA (Abken et al, 1992). Each of these cytokines 
has independently been shown to modulate neoplastic ceh growth in various ceh systems
Autocrine factors in tumorigenesis: Several investigators have demonsti’ated that, for B 
cehs, the production of and dependence upon autocrine stimulation is inversely 
proportional to the degree of tumourigenicity (Gordon et al., 1985; Klein & Klein, 1985;
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but the human B cell clones tested by Abken and colleagues aie non-tumorigenic.
It is possible that normal B cells actively control their own growth, since mitogenicaUy 
stimulated B cells from peripheral blood secrete very high levels of IL -la, IL-6, TNF-a
..and TNF-P (higher than the cell hnes). However, the normal B cells do not proliferate 
continuously in the presence of these cytokines. It is not clear whether the cells are 
refractory to high concentrations of the cytokines or they may also produce growth 
inhibitory cytokines such as TGF~p.
Negative autocrine factors: It is hkely that the estabhshment of an imniortahzed ceh hne 
will depend partly on the balance of autocrine stimulatory and inhibitory factors that the 
cells produce. In the first description of B-BCGF production, Vesole et al., 1979, 
reported an inhibitory activity which could be separated from the SOkDa stimulatory 
activity. Kerhl et al., 1986 showed that activated B cells release TGF-^ into the 
supernatant and that it is capable of inhibiting B cell growth stimulation, depending on the 
concentration of stimulatory cytokine present. Examples of mechanisms which could 
circumvent negative factors include: loss of receptors for the cytokine, for example, an 
EBV-ti'ansformed B ceU line which lacks TGF-p receptors and falls to be inhibited by 
TGF-|3; and the production of soluble cytokine receptors, for example, IL-1 receptors 
released by cells to downregulate the stimulatory effects of autocrine growth factors 
(Gordon and Cairns, 1991), Thus, the deregulation of negative control factors may play 
an important role in the development of leukaemias and lymphomas.
I___
Abken et al., 1992). In agi'eement with this, Swendeman and Thorley-Lawson, 1987, 
showed that EBV-transformed cell lines, although expressing the highest CD23 levels, are 
less tumourigenic than the EBV-negative Burkitt's lymphoma cells which have low levels 
of CD23. Thus, autocrine growth factor production is apparently not the sole requirement 
for transformation of B cells; an idea supported by Young et al, 1991, who overexpressed 
IL-7 in pre-B lymphoid cell lines which subsequently attain autocrine growth and secrete 
biologically active IL-7 but rarely acquire a tumorigenic phenotype. They concluded that, 
at least with regard to IL-7, autocrine production may be one of several synergistic events 
which can lead to malignant conversion. Indeed, OvereU and colleagues found that 
transformation of murine pre-B cell hnes with an IL-7-bearing retrovirus occurred at a 
low level, indicating that secondary events were required. However, the transformation 
involved an autocrine mechanism and the "IL-7-independent" cells were tumouiigenic, in 
contrast to their parental IL-7-dependent cells (Overeh et al., 1991).
Internal autocrine factors; Another hypothesis for autocrine growth contiol is the 
existence of mtemal autocrine regulation (Goldwasser et al., 1991). There is not much 
information about this potential mechanism, but it may exist with respect to erythropoietin 
(EPO) in haematopoietic stem cells where antisense to EPO suppresses both colony 
number and cell growth but neutralising antibodies to EPO have no effect. This effect is 
also seen with GM-CSF antisense in normal mouse bone marrow (Goldwasser et al.,
1991). The authors hypothesise that this mechanism is used for proliferation of the 
multipotent cells but, as differentiation occurs, the ceils express specific external receptors 
for the various ligands, and the internal autocrine mechanism ceases to function with the 
receptor expressed on the cell membrane and the cell dependent on external, possibly still 
autocrine, signals.
Platelet derived growth factors (PDGFs): These have also been implicated as having a 
role in internal autocrine regulation. PDGFs are a family of closely related proteins which 
exist as approximately 30kDa disulphide-bonded dimers. The three isofoims of PDGF - 
aa, aP, and p(3 are encoded by two genes termed PDGFA and PDGFB. The a  and (3 
chains are 60% homologous in amino acid sequence (Westeimark and Heldin, 1991). 
Megakaiyocytes, monocytes, and to a much lesser extent, T cells have been shown to 
produce PDGF. In 1983, Doolittle and colleagues demonstrated that the simian sarcoma 
virus oncogene, v~sis, is derived from the genes encoding platelet-derived growth factor 
(PDGF) (Doolittle et al., 1983). The demonstration that antibodies against PDGF, and 
also treatment with suramin (a drug which prevents surface ligand/receptor interactions), 
can inhibit or reverse simian sarcoma virus transformation of cells and prevent their 
growth, has shown that transformation by the sis gene occurs by an autocrine mechanism, 
m cells which express the appropriate PDGF receptor (Betsholtz et al., 1986; Tsai et al.,
1994). There are also two forms of PDGF receptor, PDGFR-a and PDGFR-[3. The a-
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receptor binds all three isoforms with high and approximately equal affinity, whereas the 
p-receptor preferentially binds (3p homodimers and interacts with aP heterodimers with 
reduced affinity (Hart et a l, 1988). Both receptors have intrinsic protein-tyrosine kinase 
activity in their cytoplasmic domain and this is thought to be activated by conformational 
changes caused on dimérisation of the receptors (Westeimark & Heldin, 1991). Fleming et 
al., 1992 demonstrated that in human sarcoma tumour cells expressing PDGF Ligands and 
receptors, the receptors were phosphorylated on tyrosine residues in the absence of 
exogenous ligand, suggesting chronic receptor activation. In some of these cell lines, anti- 
PDGF neutralising antibodies caused a reduction in DNA synthesis, suggesting that 
autocrine PDGF stimulation contributes to the proliferation of these tumours (Fleming et 
al., 1992). They also found that the anti-PDGF decreased receptor phosphorylation, 
ai'guing that it was autocrine stimulation rather than genetic mutation which lead to the 
constitutive activation of the receptors. However, in some cell lines, anti-PDGF has no 
inhibitory effect on proliferation and it has been demonstrated that autocrine activation of 
PDGFRs can occui' interaahy (Huang et al., 1984; Fleming et al., 1989), but that 
activated receptors must achieve a ceU surface location in order to couple with 
intracellular signalling pathways (Johnsson et al., 1985; Fleming et al., 1989). This may 
explain why, in some situations, anti-PDGF can cause a reversion of the v-sisfPDQP B- 
transformed phenotype (Tsai et al., 1994). Recent work from this laboratory also showed ; 
the expression of PDGF and its receptors by two pre-B acute lymphocytic leukaemia cell 
lines which suggests that PDGF may act as a lymphokine and lends the possibility that 
PDGF may act as an autocrine factor for B cells (Tsai et al., 1994).
In conclusion, it was originally proposed that the production of autocrine growth factors 
is restricted to EBV-transformed and neoplastic cell lines and is the reason they grow 
autonomously and cause tumours such as Burkitt's lymphoma. However, autocrine factor 
production has been obseiwed by EBV-negative cell lines and by normal cells, if 
appropriately activated. It now appears that production of autocrine factors is a property 
of actively cycling cells - cells which are transformed or stimulated, for example with anti- 
Ig and anti-CD40. The development of tumours apparently requires the simultaneous 
presence of several molecular perturbations but autocrine factor production is one such 
perturbation. Gordon et al., 1985, actually showed an inverse correlation between CD23 
production and tumourigenicity in EBV-transformed cells; thus, although essential for 
growth of the cells, production of autocrine giowth factors does not correlate with
tumourigenicity. Experiments where immortalised cells are transformed with growth 
factors and growth factor receptors show that the autocrine factors in each case increase 
the tumourigenicity of the cells. In contrast, if primary cells are manipulated in this way, 
no cellular transformation is evident.
*
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1.5.1 Distribution: CD23 is a ceil surface antigen expressed by numerous human cells 
including T and B lymphocytes, NK cells, macrophages, eosinophils, a subset of platelets, 
follicular dendritic cells, epidermal Langerhans cehs, and by some epithelial cell types 
(Capron et al., 1986; Sarfati et al., 1986; Bieber et al., 1989; BiHaud et al., 1989). It was 
originally identified as the low-affinity IgE receptor (FcsRII) (Gonzalez-Molina et al., 
1976), then independently described as a B cell activation marker on EBV-transformed
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That normal activated cells do not become malignant by production of autocrine factors 
may be due to production of negative regulatory molecules such as transforming growth 
factor-j3 (TGF-P). If this pathway becomes deregulated it could lead to loss of a 
controlling negative signal and subsequent continued growth of the cells (Gordon &
Cairns, 1991). Malignancies may also develop if a mutation perturbs the differentiation 
potential of the cell, causing a differentiation block.
Autocrine factors may be involved in transfoimation of cells if there is deregulation of 
positive or negative growth signals, or mutation of growth factor receptors. Indeed, m 
vitf'O transformation of murine pre-B cells was achieved with v~mpl, a truncated form of a 
cytokine receptor related to the haematopoietin receptor superfamily and contained in 
myeloproliferative leukaemia virus ( MPLV). This constitutively activated growth factor 
receptor induced high rates of proliferation of transformed cells, but did not affect their 
ability to differentiate (Fichelson et al., 1995).
In the case of thioredoxin, an autocrine factor may increase the sensitivity of cells to low 
levels of growth factors by amphfying receptor signalling. The production of lactic acid 
could be important in solid lymphoid tumours where the centre of the mass is starved of 
oxygen. Anaerobic respiration may occur leading to the production and subsequent 
growth promoting activities of lactic acid. The deregulation of autocrine factors may be 
important in immunodeficiency disease, for example, iti Wiskott-Aldrich syndrome 
(WAS), B cells fiom patients are transformed by EBV, shown to have defective 
expression of CD23 and lack of autocrine growth-stimulation (Simon et al., 1992).
However, most of the information regarding autocrine factors and their role m malignant 
transformation, involves mature B cells with little evidence of a role for autocrine growth 
regulation in early B cell development.
1,5 CD23 - adhesion molecule and cytokine
CD23 has been mentioned previously with respect to its involvement in autocrine growth 
stimulation of EBV-transfoimed B cells. It also appears to have roles in haematopoietic
:r:cell development, antigen presentation, IgE regulation and prevention of apoptosis. The 
tissue distribution, structure and other properties of CD23 will now be discussed.
cells (Kitner & Sugden, 1981). Subsequent studies have demonsti'ated that the CD23 
antigen has numerous roles as an adhesion molecule and cytokine (Bonnefoy et al., 1987; 
Yukawa et al., 1987).
1.5.2 CD23 Structure: The single CD23 gene is located on chromosome 19 (Suter et 
al., 1988; Wendel-Hansen et al., 1990); two transcripts (a and b), which differ only in the 
inü’acytoplasmic region where the N-terminal 7 amino acids of CD23a are replaced by 6 
amino acids in CD23b, are generated by use of alternate initiation sites (Yokota et al., 
1988). CD23a expression is restricted primarily to B cells but the CD23b isoform is 
inducible by IL-4 on a variety of haematopoietic cells (Coni'ad, 1990). In contrast to other 
Fc receptors, CD23 does not belong to the Ig superfamily but is a type II transmembrane 
receptor and a member of the calcium-dependent (C-type) lectin family (Delespesse et al.,
1992). CD23 contains a conserved, cysteine-rich lectin homology domain in common with 
several other proteins that bind specific carbohydrates in a calcium-dependent fashion 
(Drickamer, 1988) (see figui’e 1.2). The existence of this lectin domain, the inverted 
membrane orientation, other conserved residues and conserved sugar motifs, including 
sialic acid, classify CD23 as a member of a novel superfamily of type II intergral 
membrane proteins, the prototype of which is the asialogiycoprotein receptor (Wong et 
al.,1991) (see table 1.1). CD23 has several distinct domains (see figuie 1.2) including 
epitopes involved in binding IgE, which aie found in the aforementioned lectin-homology 
domain. Near the carboxyl teiminus is a triplet of amino acids "DGR" (Asp, Gly, Arg) 
which, in reverse configuration, i.e. "RGD", is a common recognition site of the integrin 
receptors but at present there are no data to suggest that this domain is involved in CD23 
function (Delespesse et al., 1992). Another feature of CD23 is the presence of 3 short 
consensus repeats of 21 amino acids and within this region are five heptadic repeats of 
leucines or isoleucines which foim a "leucine zipper" motif.
Murine CD23 is a 49kD sialoglycoprotein which differs from human CD23 in that: 1) it 
has four instead of three short consensus repeats; 2) it has an extra N-glycosylation site; 
and 3) there is deletion of the DGR motif at the C-terminus (Bettler et al., 1989a; GoUink 
et al., 1990). Murine CD23 may also exists in two isoforms with the b isoform having an 
amino terminus distinct fr'om that of human CD23b (Richards, 1991), although the 
existence of a murine CD23b form has recently been disputed (Conrad et al., 1993).
The leucine-zipper motif, between the transmembrane and the lectin domains is now 
known as the "stalk region". Beavil et al., 1992 found that the heptad repeats in this region 
are characteristic of an a-helical coiled-coil, implying that CD23 would be expressed as a 
dimer or trimer. This structural motif is present m other members of the C-type lectin 
superfamily and suggests that the proteins exist as extracellular lectin "heads" separated 
from the membrane by the a-helical coiled-coil "stalks" of various lengths, with these
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stalks providing a mechanism for protein subunit dimérisation (Beavil et al., 1992). A 
recent paper demonstrates that human CD23, if subjected to protein-protein chemical 
cross-linking, can form trimers on the cell surface (Beavil et at., 1995). There is evidence 
that murine CD23 forms oligomers but whether they are dimers or trimers is not yet 
determined (Dierks et at., 1993). Dierks and colleagues have evidence to support their 
theory that IgE requires at least dimers of murine CD23 to bind to cells and that the IgE 
probably stabilises the oligomeric structure.
Similar to most FcR, there is a soluble form of CD23 (sCD23) which is released from the 
surface of cells into the extracellular fluid. Numerous biological activities have been 
attributed to sCD23, in addition to the ability to bind IgE; CD23 is the membrane 
precursor of a pleiotropic cytokine. Cleavage of CD23 occurs at the residues indicated in 
figure 1.2, with initial release as an unstable 37 kDa fragment which then continues to be 
cleaved into 33, 29, 25 kDa and finally 16kDa molecules. The 25kDa form (sCD23) is the 
most stable (Lettelier et ah, 1989) and the form to which most biological activities are 
attributed. Ah cleavage products retain the ability to bind IgE (Delespesse, 1992). It has 
been demonstrated that CHOI-7 cells transfected with CD23 cDNA augment proteolysis 
of 45kDa CD23 in solution but untransfected cells do not. Highly purified 37kDa and 
recombinant 29kDa sCD23 also cleave the 45kDa foim into 25kDa fragments. Thus, the 
release of sCD23 may be due to autoproteolysis (LeteUier et al., 1990).
After chemical cross-Hnking, human CD23 exists as hexamers in solution (Beavh et at., 
1995). It was expected that only the 37 and 33kDa sCD23 fragments would be capable of 
oligomerisation because they ai’e the only fragments which possess a region of coiled coh 
but the 25 and 16kDa forms also form oligomers. Thus, it is apparent that the lectin heads 
can self-associate in solution and although the cohed-coil region is responsible for 
trimerization on the ceh surface, additional interactions between the lectin heads result in 
formation of hexamers in solution.
.'f
These obseiwations present the possibhity that CD23 could bind to IgE with two lectin 
heads leaving a third free to interact with CD21, or indeed, it could bind to three CD21 
molecules providing an avidity effect on the interaction (Beavh et al., 1995). The situation 
with murine sCD23 oligomeiisation is not clear but it appears to interact with IgE in a 
univalent manner. The differences in biologic activity observed in mouse and man 
(discussed later) may be explained by differences in abhity to foim ohgomers in solution.
; :
Binding of IgE to CD23 is calcium-dependent and appears to involve protein-protein 
interactions since deglycosylated native IgE peptides are able to bind to CD23 (Vercelh et 
al., 1989). However, Delespesse et al., 1992, showed an abhity of fucose-1 -phosphate to 
inhibit the binding of native IgE to soluble CD23. Thus, it appears to be the lectin-
23 " 'I
homology domain which is involved in interaction of CD23 with IgE and this domain must 
have both carbohydrate- and protein-binding domains (Bettler et al., 1989b & 1992; 
Bardones, 1988).
able 1.1
Superfamily o f type II membrane proteins with lectin-like domain
Liver asialogiycoprotein receptors 1 & 2 (galactose-specific lectin)
Macrophage asialogiycoprotein receptor (galactose-specific lectin)
Ly-49, A,B,C. (NK cell antigen)
- NKR-Pl (signal transducing molecule on NK cells)
-CD72 (ligand for CD5)
- Al ( a T cell antigen)
- CD23 _____________________  Taken h orn - Delespesse et al., 1992
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1.5.3 Regulation ofCD23 Expression
The CD23a isoform is found exclusively on B cells and is present in small amounts on 
normal, peripheral B cells. This expression does not appear to be constitutive because the 
cells lose CD23 mRNA and protein after incubation at 37°C in the absence of stimulant 
(Delespesse et a l, 1989). However the addition of IL-4 to resting, normal human B cells 
induces expression of substantial amounts of CD23a and CD23b with a predominant 
effect on type b (Yokota et al., 1988). This effect is not accompanied by activation of the 
ceUs, which remain at the GO stage of the ceU cycle (Gordon et aL, 1986). Expression of 
CD23b is also induced on other cell types including T cells and monocytes, after 
activation with IL-4 (Delespesse, 1992). IL-4 enhances CD23 expression on murine B 
cells, where an IL-4 enhancer element has recently been characterised in the CD23 gene 
(Richards & Katz, 1994). In humans, the expression of CD23 appears to be associated 
with that of IgD and even addition of IL-4 wiU not induce its expression on IgD-negative 
B cells (Kikutani et al., 1986), although malignant pre-B cells from ALL patients may 
express CD23 after stimulation with IL-4 (Law et al., 1991) and hgation of CD40 can 
induce expression of CD23 on normal human pre-B cells (Saeland et al., 1993).
Similarly, expression of CD23 cannot be induced in normal B cells after class svvdtching to 
IgG, IgA or IgE (Waldschmidt et al., 1988) but some transformed or leukaemic cells, 
such as RPMI 8866 which secrete IgG, stül express CD23 after class switching 
(Delespesse et al., 1991). Interleukin 13 has been shown to induce CD23 expression on 
human B cells in an IL-4-independent fashion and there is no synergistic effect between 
the two cytokines (Punnonen et al., 1993).
A
IgE is also implicated in increasing the cellular density of CD23 on B cells but not by 
increasing its expression; IgE appears to protect surface CD23 from proteolytic cleavage 
(Lee et a l, 1987). The mechanism of this protection is thought to be steric hinderance of 
proteolytic enzyme activity (Bonnefoy et a l, 1990). However, a recent investigation 
reports that anti-IgE treatment of mice inhibits CD23 expression, along with IgE 
production (Haak-Fredscho et a l, 1994). They propose that anti-IgE may act to prevent 
the up-regulation of CD23 expression usually seen on immunisation and so prevent 
CD23/CD21 interactions and diminish the IgE response.
A recent paper by Matsui and colleagues demonstrates the existence of alternative 
transcripts of CD23a and -b which lack the transmembrane region and the anchoring 
region of the cytoplasmic tail. They suggest that these may encode secretory forms of 
CD23 or may function as regulatoi'y transcripts involved in the conUol of CD23 
expression (Matsui et a l, 1993).
1.5.3-1 EBV-regulation of CD23 expression'. EBV exists in a latent state once it 
transforms B cells and the viral genome expresses only a few proteins. The proteins most 
closely related to the transformation process are EB nuclear antigen (EBNA)2 and latent 
membrane protein (LMP)l (Rousselet & Tursz, 1992). As mentioned previously, EBV 
immortalisation of B cells induces expression of CD23; CD23a and CD23b are induced by 
EBNA2 and LMPl, respectively, and these proteins appear to synergise to induce 
membrane expression of CD23 (Wang et a l, 1990).
The enhancing effect of IL-4 on CD23 expression can be inhibited at the protein and 
mRNA levels by IFN-y, IFN-a , TGF-P and anti-CD 19 antibodies (Gordon et a l, 1991). 
Signals known to synergise with IL-4 in enhancing CD23 expression are contact with 
cognate T ceUs, and engagement of sig, CD40 or CD72 ( Keegan et a l, 1989; Gordon et 
a l, 1991; Katira et a l, 1992). The engagement of CD40 appears to override the 
suppressive effects of IFNs, TGF-p and anti-CD 19 on the IL-4-induced CD23 expression 
(Gordon et a l, 1991) and CD40 ligation induces CD23 on human B cell precui'sors 
(Saeland et a l, 1993). Ligation of sIgM counteracts the negative influence of IFN and 
TGF-p on CD23 production, and ligation of CD72 overrides inhibition of this change due 
to TGF-p. Thus, the expression of CD23 on B cells is a complex and tightly regulated 
process.
1.5.3-2 Other cell types: It has not yet been clearly estabhshed whether unstimulated T 
cells express CD23 but, on activated-T cells, CD23 expression is induced by IL-4; the 
activated phenotype of the T cells is in accordance with the observation that many HTLV- 
1+ T ceh hnes express CD23 (Maekawa et a l, 1992). Under normal conditions, this 
expression is probably induced by cocultme with B cells.
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i;Human monocytes, or alveolar macrophages express little or no CD23 but in pathological ■Ifirconditions associated with increased IgE levels, such as allergic asthma, CD23-positive 
monocytes have been described (Spiegelberg, 1987). It appears that this CD23 is of the 
type b isoform and can be induced on normal macrophages by IL-4 (Yokota et a l, 1988).
Unlike the situation in B cells, IFN-y actually increases CD23 mRNA (Mayumi et al.,
1988) and also the release of sCD23, possibly by increasing cleavage from the cell surface 
(te Velde et al., 1990). IL-6 may also increase CD23 expression on U937 cells in synergy 
with IL-4 (Boitz-Nitulescu et al., 1990). f
Thus, control of expression of the two CD23 isoforms is very complex and tightly |
regulated and may be a reflection of its multi-functional nature.
1.5.4 Ligands fo r  CD23 other than IgE
■:X.The IgE-binding ability of CD23 is retained by all sCD23 fragments because they contain 
the lectin domain. However, the various cytokine effects of sCD23 (described later) 
appear to be mediated by a domain which is overlapping, but distinct from, the IgE- 
binding domain (Mossalayi et al., 1992).
The existence of a different ligand for CD23 was suggested by the numerous reports of 
non-IgE related activities athibuted to CD23, including promotion of B cell growth 
(Gordon et al., 1988), germinal centre B cell survival (Liu et al., 1991) and prothymocyte 
differentiation (Mossalayi et al., 1990), A proposed role in antigen presentation (Flores- 
Romo et al., 1990), together with the observation that CD23 is associated with the MHC 
class II molecule, HLA-DR on the B cell surface (Bonnefoy et al., 1988), suggest that
■CD23 may be involved in T/B cell interactions. The discovery of a ligand for CD23 other 
than IgE was made by Pochon et al., 1992 using recombinant CD23 incorporated into 
fluorescent liposomes. This group went on to show that CD21 is an alternative ligand for 
CD23.
■Vi'..
CD21; Human CD21 is an approximately 140kD phosphoprotein found on B cells, some 
T cells, follicular dendritic ceils and pharyngeal epithelial cells (Aubry et al., 1992). It is a 
receptor for the complement degradation products, C3dg and iC3b (Weis et al., 1984),
EPN-a (Delcayre et al., 1991) and also for the gp350/220 envelope glycoprotein of EBV 
(Tanner et al., 1987). CD21 is pait of a membrane complex on B cells which includes 
CD 19, TAPA-1 and Leu 13 and appears to form a pre-existing signal transduction 
complex of the B cell (Matsumoto et al., 1993). As such, CD21 has been implicated in B 
cell activation on triggering by EBV, C3d fragments or anti-CD21 antibodies (reviewed 
by Aubry er <3/., 1992).
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Structurally, the extracellular domain of CD21 is composed of 15 or 16 short consensus 
repeats (SCR), which are repetitive units of 60 to 75 amino acids, and the amino acid 
sequence has 11 potential sites for N-linked giycosylation. There is a 24 amino acid 
transmembrane region and an intracytoplasmic region of 34 amino acids (Weis et a i, 
1988). The interaction of CD23 with CD21 appears to be via a newly recognised, 
functional extracytoplasmic domain of CD21 which contains N-linked oligosaccharides 
(Aubry et al., 1994). Using CD21 mutants with deletions of extracytoplasmic SCRs, 
Aubry and colleagues mapped the binding sites of a panel of anti-CD21 mAbs and then 
demonstrated that the strongest inhibitors of the CD21/CD23 interaction bound to SCRs 
5 to 8 . Point mutations of asparagine residues indicate that sugars in SCRs 5 to 8  are 
involved in binding to CD21; it was also demonstrated that SCRs 1 and 2 participate in 
the interaction (Aubry et a l, 1994). Interestingly, SCRs 1 and 2 are the binding sites 
previously described for EBV, C3d and C3g. (Lowell et al., 1989; Molina et al., 1991). 
Tunicamycin treatment of the CD21-transfected K562 cells does not completely inhibit 
binding of the CD23-containing liposomes suggesting that the binding site recognised by 
CD23 is not soley a carbohydrate structuie (Aubry et al., 1994). It does not appear that 
the contribution of SCRs 1 and 2 is via a carbohydrate structure but it may involve a 
conformational change. The CD23-CD21 interaction is thought to be of a low affinity that 
relies on oligomerisation of CD23 for binding avidity (Aubry et al., 1992; Beavh et al., 
1992 and 1995; Dierks et al., 1993).
It is not entirely clear whether ah the reported functions of CD23 on B cells occur via 
CD21 but it has been suggested that,for example, in EBV-transfomied cehs, where there 
is increased expression of CD21 concomitant with that of CD23 (Cordier et al., 1990), 
the CD23/CD21 interaction may weh contribute to the autocrine growth stimulation of 
these cells (Aubry et al., 1992). ■s
C D llb  / CD llc: Recent data have described the p2-i^l6 grin molecules CDllb-CD18 and 
CDllc-CDlS as alternative ligands for CD23, with these interactions apparently able to 
regulate monocyte activation and cytokine release (Lecoanet-Henchoz et a/., 1995). 
CDllb-CD18 (Mac-1) and CD 11c-CD 18 (pi50,95) aie members of the integrin 
superfamhy; membrane glycoproteins involved in cell-ceh adhesion which exist as 
heterodimers of distinct a  subunits (Mj- 17,000 and 15,000, respectively) and a common (3 
subunit (Mj- 95,000, in the case of the (32~integrins) (Kurzinger & Springer, 1982; Corbi 
et al., 1988). The third member of this group is leucocyte function-associated antigen-1 
(LFA-1) which is found on almost all leukocytes and binds to ICAM-1. CDllb-CD18 and 
CDllc-CD18 are expressed on monocytes, granulocytes and some activated lymphocytes 
and, as well as their roles in cell-cell interactions, they are also complement receptors for 
C3bi (Anderson & Springer, 1987).
y-.':':
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With respect to binding of CD23, the CD llb and C D llc a  subunits appear to be 
involved, since LFA-1 (which shai'es the CD 18 (3 subunit) does not bind CD23 (Lecoanet- 
Henchoz et al.,1995). As with binding of CD23 to CD21, the interaction with CD llb/c is 
dependent on sugars, but not sialic acid residues, and it appears to be a low affinity 
interaction. The DGR triplet of amino acids found on CD23, which in reverse orientation 
is a common recognition site for other integrin receptor families, does not appear to be 
involved in the interaction with CD llb/c since antibodies against the site do not inhibit 
CD23 binding. Thus, CD23 appears to be acting as a C-type lectin recognising 
carbohydrate and also protein stinctures. The result of sCD23 binding to activated 
monocyte is an increase in nitiic oxide production along with release of IL-ip, IL-6 and 
TNFa " proinflammatory cytokines. (Lecoanet-Henchoz et a/.,1995). Interestingly, 
sCD23 has previously been shown to potentiate the IL-1-induced secretion of IL-6 and 
IL-1-receptor antagonist by human monocytes, although the receptor through which it 
was acting was not known (Herbelin et al., 1994). Thus sCD23 may help to modulate 
activation of monocytes in sites of inflammation.
1,5.5 Functions o f  membrane-bound CD23 - with respect to B  cells
Like most receptor molecules, CD23 has multiple functions. Eaiiy studies showed that 
antibodies to CD23 were co-stimulatory with PMA in induction of proliferation of resting 
B cells (Gordon et al., 1986). As the low-affinity IgE receptor, CD23 has been implicated 
in IgE regulation after the demonstration that, in vitro, specific anti-CD23 antibodies 
block the spontaneous release of IgE by PBL from atopic patients (Sarfati and Delespesse,
1988), as well as IgE production by IL-4 treated noimal peripheral blood lymphocytes 
(PBL) (Pene et al., 1988). Bonnefoy and colleagues, 1990, demonstrated that this 
inhibition is restricted to certain CD23 epitopes involved in IgE-binding; they suggest that 
the anti-CD23 antibodies bind to suiface CD23 and interfere with the T cell/B cell 
interaction necessary for Ig production. T cell/B cell conjugate formation is now known to 
involve interaction between CD23 and CD21 (Aubry et al., 1992 and 1993) and IgE 
production is increased on engagement of CD21 by recombinant soluble CD23 or by anti- 
CD21 antibody (Aubi-y et al., 1992). Also, data from in vivo studies show inhibition of an 
antigen-specific IgE response using a polyclonal anti-CD23 antibody (Flores-Romo et al.,
1993). These data all suggest a centi'al role for CD23 in IgE production with two possible 
mechanisms:
1) That CD23 expressed on B cells interacts with CD21 on T cells as an adhesion 
molecule to enhance the signals for IgE production (Fischer et al., 1991; Pochon et al.,
1992)
2) Since triggering of CD21 on B cells enhances IgE production even in the absence of T 
cells (Aubry et al., 1992) and allergen-activated T cells can be induced to express CD23 
by IL-4 (Prinz et al., 1990), it is possible that T cell-associated CD23 interacts with 
CD21, expressed on B cells, to enhance IgE production.
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CD23 has been shown to be physically associated with the MHC class II molecule, HLA- 
DR, on B cells which indicates that it could act as an accessory molecule in T cell 
interactions with antigen-presenting cells (Bonnefoy et al., 1988; Flores-Romo et al.,
1990). Flores-Romo et al., 1990 demonstrated that occupancy of CD23 prevents B cells 
from stimulatmg allogeneic T cells, and a recent investigation showed that the 
CD23/CD21 interaction is required for presentation of conventional, soluble protein 
antigens by B ceU lines to CD4+ T ceU clones (Grosjean, 1994). Thus, CD23 may not 
only strengthen B-T conjugation but simultaneously provide a co-stimulatory signal to the 
antigen-primed T cell.
Homotypic aggregation of B cells is thought to be important in the later stages of 
activation and differentiation, possibly to facilitate the exchange of autocrine factors
29
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.(Bjork & Pauiie, 1993). CD23 and CD21 function as adhesion molecules in homotypic 
aggregation of human B cells (Bjork et al., 1993) and if antibodies to CD23 aie used in
conjunction with anti-LFA-1 then aggregation is often completely inhibited, suggesting 
that LFA-1/ICAM-1 and CD23/CD21 are the major molecules involved in homotypic 
aggregation of human B cells.
.4;
The question of homotypic interactions between CD23 molecules is subject to 
controversy. Several reports that CD23-ti'ansfected B lymphoma cells do not foim 
aggregates and that neither purified recombinant CD23, nor CD23-liposomes, bind to
CD23-transfected cell lines (Pochon et a/.,1992) are in contrast to a recent report by 
Moulder et al., 1993 where they demonstrate clustering of RPMI-8866 cells mediated 
solely via CD23. The consolidating factor may be that the CD23-mediated adhesion 
occurs via the portion of CD23 remaining on the cell surface after cleavage of sCD23. 
Apparently, proteolysis is required to induce CD23-mediated cell adhesion and the 
proteolysis does not occui' in the absence of serum, unless sCD23 (which has inherent 
proteolytic activity) is added (Moulder et a l, 1993).
That CD23 can function as an adhesion molecule is consistent with its classification as a 
C-type lectin since other members of this family, such as CD72, are involved in 
endocytosis and adhesion reactions.
1.5.4 Functions o f  soluble CD23 » with respect to B cells
While the soluble fragments of CD23 retain IgE-binding activity, they have also been 
ascribed numerous cytokine-like functions. With respect to IgE, sCD23 has been 
described as an IgE régulant which, in synergy with IL-4, can upregulate IgE synthesis. 
This property, however, may be confined to transient intermediate cleavage fragments 
(Delespesse et a l, 1989) and thus depend on the proteolytic capabilities of the fragment.
'iV,■4'
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As mentioned previously, sCD23 has been implicated as an autocrine growth factor for 
normal receptor-activated B ceU blasts and EBV-transformed B lymphoblasts 
(Swendeman & Thorley-Lawson, 1987). However, the 25kDa form of sCD23 co-purifies 
with a 12kDa protein which may be either a further cleavage product of CD23 or else a 
separate protein which tightly co-purifies with CD23. The presence of this 12kDa 
molecule was used by Uchibayashi and colleagues to explain their contradictory 
observation that sCD23 has no B cell gi'owth-promoting ability (Uchibayashi et ciL, 1989). 
Using sCD23 derived from a construct containing cDNA which coded directly for the 
25kDa secretory form of CD23, as opposed to a cleavage product of the membrane 
receptor, they demonstrated that sCD23 could bind IgE but had no B cell growth activity. 
Other reports disagree and support the observations of Swendeman and Thorley-Lawson 
(Gordon et aL, 1988; Armitage & Goff, 1988). To add to the confusion, in 1990, Cairns 
and Gordon reported that only the intact, 45kDa form of CD23, purified from lysates of 
RPMI 8226 cells, was consistently mitogenic for pre-activated normal and transformed B 
lymphoblasts. They found that isolates of sCD23 species were of highly variable efficiency 
in stimulation assays. In an attempt to consolidate the situation, several explanations are 
proposed :
1) That the BCGF activity is highly labile; thus, the BCGF activity of CD23 is present in 
the 45kDa form, and retained m a transient initial cleavage product (35kDa) but quickly 
degrades to the 25kDa fragment.
2) That the 45kDa form is actually converted to a lower molecular weight form, with 
growth-promoting effects. This idea is supported by the fact that stimulatory activity of 
25 kDa CD 23 was only observed in already substantially activated cells and may explain 
why Uchibayashi et al., 1989, (who used B cells triggered with sub-mitogenic amounts of 
anti-Ig) saw no growth promoting effects.
For whatever reasons these discrepancies exist, sCD23 has since been attributed with 
several other B-cell-related biological functions, albeit effects which aie usually seen in 
synergy with IL-1.
Early work showed that sCD23 can promote differentiation of CD 19"*' CD20" antibody- 
producing B cells (Kagan et al., 1989) and then, in 1991, Liu et al. discovered that 
recombinant 25kD sCD23, in synergy with IL-la, promotes the survival of germinal 
centre B cells (Liu et al., 1991a). There are two distinct populations of B cells in germinal 
centres - rapidly dividing centroblasts, which populate the dark zone, and their progeny, 
centrocytes, which populate the light zone. The light zone is also home to specialised 
antigen presenting cells called foUicular dendritic cells (FDC) and in the 'apical' light zone, 
but not in the 'basal' light zone, FDC have high levels of cytoplasmic CD23 (Gordon et al.,
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1989). Freshly isolated geiminal centr e B cells die by apoptosis when placed into tissue 
culture and this process can be prevented if they are activated both through theh" antigen 
receptors and CD40 or by sCD23 and IL -la  (Liu et a l, 1989 & 1991a). Prevention of 
apoptosis provides a way to select for cells which have somatically-mutated antigen 
receptors with a higher affinity for antigen since they will compete for the limited antigen 
on the FDC (Liu et al., 1989). The finding that sCD23 and IL -la  also drive B cells 
towards a plasmacytoid pathway of differentiation suggests a bifurcation m the 
development of centrocytes after rescue from apoptosis. The suggested model is that 
centrocytes are initially rescued from apoptosis through re-encounter with antigen, and 
then they develop along one of two pathways; signalling through CD40 induces memory 
cell development whereas sCD23 and IL -la  signal for plasmacytoid differentiation (Liu et 
al., 1991a). Thus, sCD23 can prevent apoptosis and promote differentiation of germinal 
centre B cells.
It is assumed that the sCD23 in germinal centres signals B-cells through CD21 to prevent 
apoptosis. This assumption has the support of a recent report from Bonnefoy et ah, 1993 
who showed that a subset of anti-CD21 antibodies prevent apoptosis of germinal centre B 
cells. These antibodies also promote a plasmacytoid appearance in the rescued cells and 
upregulate expression of the bcl-2 proto-oncogene. However, CD21 also binds C3d, 
which is abundant on immune complexes held by FDC, and C3 activation is required for 
geiminal centre formation (Klaus & Humphrey, 1977). In addition, CD21 is also a 
receptor for IFN-a (Delcayre et al., 1991) and IFN-a can also rescue germinal centre B 
cells from apoptosis (Holder et al., 1992). Thus, it will be difficult to determine the 
physiological role of these interactions and whether CD23 is, indeed, binding to CD21 or 
another receptor to prevent apoptosis of centrocytes. Another unanswered question is 
whether the CD23 on FDC acts as a membrane-anchored or a soluble molecule. It would 
be inappropriate for CD23 in germinal centres to influence ’nonselected’ cells; thus, it may 
be membrane bound to localise the effects, or the highly labile nature of sCD23 may 
ensure it is active only in the immediate proximity of its production (Shields et al., 1992).
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At present there has been no role described for CD23 in the antigen-independent phase of 
B cell development in the bone marrow, but most of the other cytokine functions ascribed 
to sCD23 involve myeloid and T cell precursors suggesting a role for CD23 in 
haematopoiesis. It is, however, difficult to determine if the true functions would be 
performed by soluble or membrane-bound CD23.
1.5.6 CD23 expression and function in the bone marrow and thymus
Fourcade et al. (199Z) examined the expression of CD23 by human bone man ow stromal 
cells. They showed that freshly isolated BM-ceUs have veiy low levels of CD23 
expression but a subset of long-term BM-culture (LTBMC)-derived stromal cells express
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CD23 mRNA at high levels and secrete soluble CD23 into their culture supernatants. The 
adherent stromal cells in LTBMCs are a heterogeneous population consisting of 
mesenchymal cells (mainly fibroblasts) and monocytes/macrophages (Fourcade et al.,
1992). It appears that only a subset of these cells, probably the monocytes/macrophages 
express high levels of CD23 on then surface but it is possible that these cells are activated 
by the in vitro culture conditions. However, Fouicade and colleagues demonstrated that 
addition of neutralising anti-CD23 antibodies to LTBMC leads to a significant decrease in 
total numbers of haematopoetic cells and CFU-GM recovery (Fourcade et al., 1992).
Also, proliferation and maturation of human BM-derived CD34+ myeloid precursors is 
induced following sequential incubation with IL -la  and sCD23. The sCD23 induced 
colonies are composed of 20-30% basophilic cells, which could have implications during 
the allergy process (Mossalayi et at., 1990a). Thus, CD23 expression by human stromal 
cells appears to regulate haematopoietic cell development and sCD23 has an effect on 
myeloid precursors, although whether physiological effects are mediated through 
membrane bound or soluble CD23 is not clear.
Previous work has indicated an effect of sCD23 on human T-cell precursors. Mossalayi et 
al. (1990b) showed that CD7+CD2“CD3"CD4"CD8" precursor T cells, which appear to 
represent recent thymic immigrants, can be induced to mature by sequential incubation 
with recombinant IL -la  and recombinant sCD23. Le et al., 1987, have documented IL-1 
production by human thymic epithelium after in vitt'o incubation with autologous 
thymocytes. The source of_CD23 in the thymus is thought to be thymic epithelial cells in 
the outer cortex region (Mossalayi et al., 1991) - the point of entry for early thymocytes 
(Janossy et al., 1981). Of interest, in situ, cortical epithelial cells also express IL-4 
receptors, thus CD23 expression by these cells may be increased by IL-4 (Mossalayi et 
al., 1991).
Soluble CD23, in synergy with IL -la, also increases the proliferation of mature CD4+ T 
cells in response to mitogens such as PHA (Bertho et al., 1991). Membrane-bound CD23 
may also contribute to CD4+ T cell proliferation by enhancing adhesion between antigen- 
presenting cells and CD4+ T cells, possibly because CD23 is linked to HLA-DR 
(Bonnefoy et al., 1988).
The role of CD23 in haematopoiesis was recently disputed by Fujiwara and colleagues,
1994, who demonstrated that in CD23-knockout mice, there is normal lymphocyte
...differentiation and the mice can mount normal IgE responses. Germinal centre formation 
and the in vitro response of B cells are not affected in the mutant mice. The only 
phenotype that they noted is a severe impairment of antigen-specific IgE-mediated 
enhancement of the antibody response. This controversy may, however, be explained by 
redundancy in the immune system or by differences between murine and human CD23. As
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discussed previously, the expression of CD23 differs, with mice lacking the human CD23b 
isoform, and murine CD23 is a larger molecule which lacks the 'RGD' domain. Bartlett 
and Com’ad (1992) in their aihcle entitled 'Murine soluble FcsRII: a molecule in seai’ch of 
a function' discuss the fact that they were unable to repeat any of the assays for sCD23 
function observed in the human system with murine sCD23. They suggest that differences 
in ability of human and mmine sCD23 to bind IgE could reflect a broader difference in 
function. In the mouse, cleavage of sCD23 from the cell surface removes regions of the 
stalk which are required for IgE binding as well as for oligomerisation (Dierks et al., 1993 
& 1995). It is possible that formation of multimers is important for biological activity of 
sCD23.
Thus, there appear to be differences between human and murine CD23 which have caused 
controversy about the in vivo role of CD23. However, there is overwhelming evidence 
that human CD23 is a biologically active molecule which can function both as an adhesion 
molecule and as a soluble cytokine. This is reflected by the implication of CD23 in several 
disease states.
1.5.7 The role o f  CD23 in disease
CD23 has been implicated in various pathological conditions, including allergy, 
rheumatoid aithritis and B-chronic lymphocytic leukaemia, mainly due to the presence of 
elevated serum levels of sCD23.
Allergic diseases: Atopic diseases are associated with production of specihc IgE wliich 
appears to interact with the high affinity IgE receptor (FcsRl) present on mast cells and 
basophils. Cross-linking of IgE by allergen activates this receptor, leading to 
degranulation of the cells and release of various inflammatory mediators, including 
cytokines such as IL-4 and IL-5, and to immediate allergic symptoms (Dugas et al.,
1992). CD21 expressed on basophils is involved in histamine release triggered by CD23, 
suggesting that CD23 may have a direct role in mediator release (Lecoanet-Henchoz et 
al., 1995). However, these mediators could also play a role in the late allergic reaction 
since IL-4 can induce CD23b expression on vaiious cells including monocytes and 
macrophages, allowing these cells to bind IgE and thus release more inflammatory 
cytokines. Indeed, the number of CD23-positive peripheral blood monocytes and B cells is 
increased in atopic individuals compared to normal subjects (Melewicz et «/.,1981; 
Spiegelberg, 1987; Borish et al., 1990). Serum sCD23 levels are reported to be 
significantly higher in atopic compared to normal individuals (although this has recently 
been disputed (Wilhelm et al., 1994)) and are weakly but significantly coiTelated with 
levels of IgE (Yanagrhaia et al., 1990). Both soluble and membrane forms of CD23 could 
contribute to the pathogenesis of atopic disease by: 1) regulation of IgE production 
(Sarfati et at., 1984 & 1988; Pene et a/., 1988; Flores-Romo et al., 1993; 2) direct
v-
‘4 1
interaction with CD21 to induce histamine release from basophils (Bonnefoy et al., 1993);
3) IgE-dependent release of inflammatory mediators by monocytes, eosinophils etc.; 4) 
activation of monocytes and macrophages via the GDI 1-CD18 family of intergiins and the 
consequent release of inflammatoi'y cytokines (Lecoanet-Henchoz et al., 1995).
Rheumatoid arthritis: Patients with rheumatoid arthritis (RA) have an increased number 
of circulating CD23-positive B cells. Also, elevated levels of sCD23 have been discovered 
in the serum and synovial fluid of these patients (Ikizawa et al., 1993; Bansal et al., 1993).
It has been suggested that CD5+ B cells of RA patients may be specifically activated 
leading to the constitutive expression of CD23a mRNA and accelerated release of sCD23 
(Ikizawa et al., 1993). That sCD23 plays a role in arthritis is supported by data from 
Plater-Zyber and Bonnefoy (submitted) who demonstrated that administration of anti- 
CD23 IgG in a murine arthritis model results in amelioration of estabhshed disease.
Chronic Lymphocytic Leukaemia: Chronic lymphocytic leukaemia (CLL) is defined as 
the proliferation and accumulation of monoclonal CD5"  ^B cells "arrested" at the mature 
sIgM+/sIgD+ stage of differentiation (Sarfati, 1993). Sera from CLL patients can contain 
up to 500-fold more sCD23 than that from noimal individuals or patients with other B cell 
lymphoprohferative disorders (Sarfati et al., 1988). As well as increased numbers of 
CD23-positive B cells, B-CLL cells also overexpress CD23 on their surface and TNFa 
enhances the expression but has no effect on normal B lymphocytes (Sarfati, 1993). It has 
been proposed that deregulation of CD23 expression may not be simply a marker of CLL 
but may also be involved in the proliferation of the leukaemic B cells (Sarfati, 1993). 
Cross-linking of CD23 by anti-CD23 antibodies suppresses normal and leukaemic B cell 
proliferation (Fournier et al., 1992; Luo et al., 1991) with consequent biochemical 
changes compatible with cell activation (Kolb et al., 1990). However, it is also possible 
that sCD23 could act to allow the CLL cells to proliferate as is the case with EBV- 
ti'ansfoimed B cells. The balance of CD23a and CD23b forms, induced by cytokines such 
as IL-2, IL-4 and IFN-y, may be important in CLL proliferation allowing accumulation of 
long-lived and slowly-dividing malignant B cells arrested at the GO/Gl stage of the cell 
cycle (Saifah, 1993).
The clinical significance of CD23 in these cases is not absolutely clear, however, there is 
strong circumstantial evidence that CD23 plays role in the pathogenesis of these diseases 
and is clinically important.
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1.6 Apoptosis - Programmed cell death
Views on ceil death were, until relatively recently, dominated by the idea that death was a 
degenerative phenomenon caused by injury (Virchow, 1858). The fact that cell death can 
occur as a controlled event in normal, healthy animals and, moreover, that tliis 'normal cell 
death' might be a process of active self destruction was not highlighted until 1972, by Kerr 
and colleagues. It is now possible to categorise most dying cells into one of two discrete 
and distinctive patterns of morphological change; either necrosis or apoptosis. The first of 
these, necrosis, is characterised by cell swelling, rupturing of plasma and organelle 
membranes and finally disintegration of the cell (Wyllie et ah, 1980). This is usually 
caused by severe and sudden injury e.g. hyperthermia, or physical or chemical trauma, 
which results in an inability of the cell to maintain homeostasis and subsequently 
unconti'olled osmotic pressure causes cell swelling. After ruptui'e of the cell, the contents 
are spilled into the surrounding tissue provoking an inflammatoiy response which may aid 
removal of debris and repair of the damaged tissue (Cohen & Duke, 1992).
Apoptosis involves a more ordered cell death mechanism. It is associated with normal 
processes of tissue regulation and maintenance of a steady-state condition, since if cell 
division is not exactly matched by cell death, the tissue or organ will enlarge - representing 
uncontrolled growth i.e. neoplasia. This is of particular importance in the human immune 
system where, for example, 5 x 10^ polymorphonuclear leukocytes (neutrophils) are in 
circulation at any given time. Neutrophils have a life expectancy of only one day after 
which they undergo apoptosis, apparently under the control of an "internal clock", 
allowing numbers of neutrophils to remain remarkably constant (Cohen & Duke, 1992). 
Some workers refer to apoptosis as programmed cell death but that term may be more 
appropriately used to describe situations, for example in invertebrates, where the death of 
individual cells can be accurately predicted (Ellis & Horvitz, 1986; Malayapa & Sawada,
1991). In vertebrates, most demonstrations of apoptosis are more random with respect to 
the individual cells affected, even though the internal death programme they follow is 
ordered. Examples of apoptosis include morphogenetic death of cells during embryonic 
development, elimination of self-reactive T and B cells and death of short-lived cells such 
as neutrophils (Cohen, 1993). In each case, the trigger for apoptosis is probably different, 
for example, withdrawal of a gi'owth factor or some form of internal clock, but the final 
mechanism appears the same. Not all apoptosis-inducing signals seem physiological, for 
example, thymocytes will apoptose if exposed to ionising radiation (Sellins & Cohen, 
1987), or to certain cytotoxic drugs (McConkey et al., 1988). It is possible that these 
situations reflect a broader role for apoptosis - removal of damaged cells which may have 
harmful mutations.
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1.6.1 The role o f  apoptosis in B cell development
During B cell development there are several stages of differentiation at which cells are 
susceptible to apoptosis.
Pro-B: When a pro-B cell undergoes Ig gene rearrangement there is a significant chance 
that the rearrangement will be non-productive. It has been estimated that about 15% of 
developing B cells are eliminated at the transition from the pro-B cell to the small pre-B 
cell stage (Osmond et al., 1992). It is assumed that the remainder of the cells die, probably 
by apoptosis - a view supported by the presence of macrophages in the bone marrow 
which phagocytose apoptotic cells (Cohen & Duke, 1992).
Immature B cell: The next stage of development where B cells are subject to apoptosis is 
at the immatui'e B cell stage when they begin to express surface immunoglobulins. These 
cells ai*e subject to clonal deletion by antigen to avoid expansion of anti-self reactive B 
cells - a process termed negative selection (Nossal, 1983). This has been cleaily 
demonstrated using mice bearing ti'ansgenes for rearranged Ig because when the mice co­
express the cognate antigen, they have very few B cells (Nemazee & Burki, 1989a and 
1989b). That this deletion occurs by apoptosis has not been shown conclusively but cell 
lines "frozen" at the immature B cell stage can be induced to apoptose by anti-IgM 
antibodies (Benhamou et al., 1990). It will be interesting to determine the differences in 
signal coupling between immature and mature B cells which determine that immature cells 
apoptose and mature cells proliferate in response to the same stimulus.
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Germinal centre B cells: B cells aie also subject to apoptosis in germinal centres, where 
antigen-driven positive selection occurs. To produce liigh affinity antibodies during 
secondary responses to T-ceil-dependent antigens, the Ig genes undergo a process 
refeixed to as somatic hypermutation. Hypermutation occui's in rapidly dividing 
centroblasts within the dark zone of the germinal centre and these cells subsequently move 
to the Hght zone and become non-dividing centrocytes wliich are subject to selection on 
the basis of their ability to receive a positive signal from antigen (MacLennan & Gray,
1986). If the centrocytes do not receive the positive signal then they rapidly die by ■ :apoptosis. The signal which saves centrocytes from apoptosis is delivered via the antigen 
receptors and the surface antigen, CD40, and causes differentiation to resting, memory B 
cells (Liu et al., 1989). Apoptosis of centrocytes is also prevented by a combination of 
soluble CD23 and IL -la , which induce a plasmablast phenotype (Liu et al., 1991). This 
whole process allows selection of B cells expressing mig with high affinity for the antigen 
and elimination of cells with low affinity for the antigen and, potentially, mutations which 
could result in specificity for self.
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Therefore, apoptosis is of extreme importance in the immune system to avoid 
development of leukaemia or autoimmune disease. This theory was described by John 
Cohen as "altruistic suicide" where the cell's suicide insures the gamete's survival (Cohen,
1993). Indeed, apoptosis was the ancient Greek term for leaves failing off trees in the 
autumn and the word was chosen to suggest that cell loss is desirable for the survival of 
the host (Touchette & Fogle, 1991).
It has become obvious that apoptosis induced by different stimuli may proceed through 
different pathways. In the case of glucocorticoid-induced and activation-induced 
apoptosis, each mode of induction mutually inhibits the apoptosis induced by the other 
(Zacharchuk et al., 1990) but all apoptotic death can be characterised both 
morphologically and biochemically.
1.6.2 M orphology o f  apoptotic cells
It is still not clear exactly which of the numerous morphological changes in apoptotic cells 
are directly associated with death. One of the first features is that the cells appear to 
shrink, possibly due to structural changes in the cytoskeleton. The plasma membrane 
becomes 'untethered' and undergoes rapid blebbmg, or "zeiosis" - a characteristic sign of 
apoptosis (Cohen & Duke, 1992). Amenta et at., 1989, described a generalised increase in 
the level of internal proteolysis in apoptotic cells which may lead to non-specific 
degradation of the cytoskeleton. Another hallmark of apoptosis is the collapse of the 
nucleus; the other organelles remain intact but are compacted by cytoplasmic "shrinking". 
The overall compaction of the cytoplasm is associated with development of translucent 
cytoplasmic vacuoles (Wyllie et aL, 1980). The nucleus shrinks and its chromatin becomes 
very condensed often collapsing into crescents around the nuclear envelope before, in 
some cell types, finally forming very dense spheres. At this stage, cells may break up into 
membrane-bound apoptotic bodies which are still in a state of osmotic balance and able to 
exclude vital dyes. Some investigators beheve that formation of apoptotic bodies helps 
ingestion of the apoptotic cell by phagocytes (Cohen, 1993).
Biochemical Changes: the tkning of biochemical events in relation to moiphological 
changes is not fully understood. Synthesis of RNA and protein appears to decrease rapidly 
with a concomitant increase in their degradation (Cidlowski, 1982). However, there are 
reports which demonstrate a requirement for new gene expression in the apoptotic 
process and indeed, in these systems, apoptosis can be blocked if mRNA or protein 
synthesis are inhibited. Examples include apoptosis induced by growth factor removal, and 
activation-induced apoptosis in T cell hybridomas (Shi et al., 1992). These models have 
been referred to as "induction" mechanisms and led to the idea of "death genes" which are 
activated during apoptosis (Cohen, 1993). A candidate 'death gene’ is transglutaminase 
(Owens et al., 1991). Another model, referred to as "release", has been described for the
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situation where, for example, HL-60 cells are triggered to apoptose by the inhibition of 
mRNA or protein synthesis (Martin et a i, 1990). The cells respond as if the suicide 
program or "death genes" are constitutively expressed but held in check by smwival factors 
with short half-lives.
The condensation of chromatin indicates that apoptosis results in extensive damage to 
DNA. DNA exists as double strands wound ai ound histones to form nucleosomes. One of 
the original demonstrations of apoptosis in thymocytes showed that chi'omatin is degraded 
by random cleavage at the linker regions between nucleosomes (WyUie, 1980). Since 
nucleosomes are spaced regularly at 180-200 base pair intervals along eukaryotic 
chromatin, a characteristic pattern of DNA cleavage into multiples of 200 bp 
oligonucleosome fragments (a DNA ladder) is produced on gel electrophoresis of DNA 
from apoptotic cells. This intemucleosomal cleavage of DNA is considered to arise 
enzymatically from the activation of an endonuclease(s). Cohen and Duke, 1984, showed 
that thymocytes contain detectable endogenous endonuclease activity which, when 
activated in isolated nuclei by addition of Ca^+ and Mg^+, forms 180bp nucleosomal 
fragments indistinguishable from those seen in vivo. Whether this is the precise enzyme 
involved in apoptosis is not clear and there are numerous other enzymes purported to 
have similar effects. Recently, it has been suggested that the endonuclease initiating 
apoptosis may be NUC-18 (Caron-Leslie et a l, 1991), DNase I (Ucker et al., 1992: 
Peitsch et al., 1993) or DNase II (Barry & Eastman, 1993). The relationship between the 
appearance of condensed chromatin and the endonucleolytic cleavage of DNA is still 
uncertain. A number of studies have shown cell types where there is chromatin 
condensation but no evidence of a classical DNA ladder, and flow cytometric analysis of 
apoptotic thymocytes has suggested some changes in chromatin structure which precede 
tlie initiation of intemucleosomal DNA cleavage (Oberhammer et al., 1993).
Conventional gel electrophoresis of DNA, which shows the laddering pattern of cleavage 
in apoptosis, is restricted to analysis of DNA fragments of approximately 20 kbp and 
below. Walker et al. ( l9 9 l)  showed that using field inversion gel electrophoresis (which 
allows analysis of fragments up to 2 Mbp) they could detect distinctive fragment of 50 and 
300 kbp in apoptotic thymocytes. This work involved the use of DNA-damaging drugs 
and it has been suggested that the 300 kbp fragments were formed by the interaction of 
the drugs with topoisomerase II molecules located at approximately 300 kbp along 
chr omatin (Filipski, 1990). However, the 50 kbp fragments appear to be generated by 
endonucleolytic activity at the sites of the anchorage of loop domains of chromatin to the 
nuclear membrane and matrix (Oberhammer et al., 1993). Subsequently, this group have 
shown that in epithelial cells, cleavage of DNA to 300 and/or 50 kbp fragments occurs 
before or even in the absence of intemucleosomal fragmentation. This supports the idea 
that the degradation of DNA to oligonucleosome fragments is a late event, or even absent
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ill apoptosis. DNA dégradation may serve to limit potentially dangerous viral genetic 
infonnation from spreading from dying cells (Sellins & Cohen, 1989).
1.6.3 Genes involved in apoptosis
As mentioned previously, there are cases where the de tiovo expression of mRNA is 
required for apoptosis to occur i.e. the ceUs actively "commit suicide". Several genes have 
been the subject of interest regarding a possible role in apoptosis including c-myc, Fas and 
pdd.
p53: has been teimed an anti-oncogene and is associated with apoptosis. The p53 gene 
product is a transcription factor and may downregulate expression of genes, such as c-fos 
and c-jim, but induce expression of other genes such as WAFl/p21-a potent inhibitor of 
cyclin-dependent kinases (Prokocimer & Rotter, 1994; El-Diery et al., 1994), Thus, p53 
an'ests proliferation of ceUs, possibly switching the ceU to differentiation, but more likely, 
the role of p53 is to hold a damaged ceU in G1 while the damage is repaired. CeUs which 
try to oppose the G1 block may activate the apoptosis pathway (Cohen, 1993). Mutations 
in p53 are found in almost 50% of human primary tumours and these mutated products 
are inactive with respect to arresting ceU growth (Pi'okocimer & Rotter, 1994). In some
-reports of Abelson murine leukaemia virus (Ab-MuLV)-tiansformed pre-B ceUs, the p53 
gene is inactivated by integration of viral sequences into the p53 gene (Wolf et al., 1983). 
However, the expression of wild type p53 can occur in transformed cells but it is inactive 
due to complex formation with viral proteins, for example, large T antigen of SV-40 or 
EBNA of Epstein-Barr virus (Levine & Momand, 1990; Szekely et al., 1993). Apoptosis 
involving induction of p53 is mainly associated with stress or exposure to agents which 
damage DNA (El-Diery et al., 1994),
c~myc: the c-myc proto-oncogene appears to have a role in regulating the choice between 
cell proliferation and apoptosis. c-myc is a potential candidate for a gene able to influence
:the induction of apoptosis since its induction is an early response to mitogenic stimuli 
from multiple growth factors, including IL-3, and its expression diminishes as ceUs enter a 
quiescent state (Dean et al., 1987: Cleveland et al., 1989). Askew et al. (1991) used an 
IL-3-dependent myeloid precursor ceU line, which was incapable of autonomous growth, 
to demonstrate that constitutive expression of murine c-myc suppresses G1 arrest and 
accelerates apoptosis on withdrawal of IL-3. Overexpression of c-myc may override cell 
cycle regulatory controls via constitutive induction of the ornithine decarboxylase (GDC) 
gene required for entry into S-phase (Bowlin et al., 1986). Apparently, c-myc can only 
provide a partial proliferative signal to the cells which is insufficient to replace the 
additional mitogenic stimuli provided by IL-3, or other growth factors.
:
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It is not entirely clear exactly which function is most important in induction of apoptosis 
and although expression of c-myc is necessary for activation-induced apoptosis it does not 
appear to be sufficient.
The induction of c-myc in cells grown in the presence of appropriate growth factors (or 
CO-expressing other "survival" genes, such as bcl-2) causes ceU proliferation. In the 
absence of these factors, c-myc expression causes ceU death.
Fas\ the Fas antigen, also known as APO-1 or CD95, is a 36kD transmembrane receptor 
that is a member of the growing tumour necrosis factor (TNF) receptor/ nerve growth 
factor (NGF) receptor superfamUy, along with CD40. CeUs which express Fas can be 
induced to apoptose by cross-linking with mti-Fas antibody (Itoh et al., 1991). The Fas
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4'R'In 1992, Evan and coUeagues demonstrated that fibroblasts, which usuaUy undergo growth arrest in low serum, are unable to arrest growth if they constitutively express c- 
myc. In addition, the cells die by apoptosis, the amount of death correlates with the level 
of c-myc expression and death occurs at various points in the ceU cycle. Activation- 
induced apoptosis of T-cell hybridomas is prevented by antisense oligonucleotides 
corresponding to c-myc but this treatment does not inhibit another outcome of activation - 
the production of lymphokines (Shi et al., 1992). With respect to the observation that 
dexamethasone can inhibit activation-induced apoptosis, this may be due to the abUity of 
DMSO to inhibit c-myc expression (Yuh & Thompson, 1989). FinaUy, a recent paper, by 
Chemey and colleagues, suggests a role for deregulated c-myc expression in apoptosis of 
EBV-immortaUsed B cells (Cherney et al., 1994). These ceUs, if deprived of autocrine 
growth factors, undergo apoptosis. It was shown that, unUke nomial cells which down­
regulate c-myc expression, the BBV-immortaUsed cells have levels of c-myc comparable 
to those found before factor starvation. The cells continue to proUferate until death, which 
occurrs randomly throughout the cell cycle. Anti-sense oligonuclotides to c-myc prevent 
apoptosis of the starved ceils and suppress growth of non-stai*ved EBV-immoitahsed 
cells. One suggestion made by these investigators was that the expression of c-myc, by 
promoting proliferation of the cells despite factor deprivation leads to faster consumption 
of essential growth factors present in limiting concentrations. They suggest that antisense 
to c-myc, which inhibits cell growth, leads to a decreased demand for the essential factor 
and thus limit or delays cell death.
-The c-myc protein has two distinct properties;
1) It is a DNA binding protein, and after forming a heterodimer with other proteins, such 
as MAX, it can regulate gene transcription (Shi et al., 1992; Fanidi et al., 1992)
2) It can bind to retinoblastoma protein, which in turn regulates cell cycle events through 
cychns (Rustgi et al., 1991).
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IAg is found on numerous cell types, including activated T-, B- and NK cells, thymocytes, myeloid cells and fibroblasts (Eischen et al., 1994). In the thymus. Fas antigen is purported to have an important role in differentiation and maturation by inducing 
apoptosis. Peripheral activated T cells from Ipr (lymphoproliferation) mutant mice have a 
reduced number of APO-1 receptors and a defect in TCR-induced apoptosis (Watanabe- 
Fukunaga et al., 1992). It is possible that their lymphoproliferation is more correctly 
"lymphoaccumulation" because the cells die less readily than normal T cells (Cohen,
1993). The involvement of Fas in T cell apoptosis has been supported recently by two 
reports demonstrating that TCR crosslinking induced Fas, and Fas ligand expression, with 
the ensuing engagement of FasfFas ligand activating the cell death programme (Dheln et 
al., 1995; Shyr-Te et al., 1995). This cell death could be prevented by a soluble Fas-lg 
fusion protein or F(ab')2 anti-Fus which are unable to induce apoptosis because of 
insufficient crosslinking of Fas. Fas ligand, produced in a soluble form by Jurkat T cells, 
can bind to cell surface Fas in an autocrine fashion - with apoptosis occurring even in 
single cell cultures but it is also possible that T-cell apoptosis may occur as 'fratricide' by 
interaction of a membrane bound form of the Fas ligand with Fas expressed on 
neighbouring cells (Dheln et al., 1995). These data strongly implicate Fas and Fas hgand 
as "death genes" whose interactions account for the apparently "autocrine suicide" 
mechanism of activation-induced T-cell death. This correlates with the requii’ement for 
RNA and protein synthesis in T cell apoptosis. Interestingly, adult T-cell leukaemia cells, 
which have an activated T-cell phenotype, express high levels of functional Fas antigen 
raising the possibility of anti-Fo^' antibody treatment in this form of leukaemia (Kotani et 
al., 1994). i|
One possibility for pharmacological intervention in tumours is drugs which can induce 
apoptosis. It is possible that resistance of certain neoplastic cells to apoptosis could 
explain the inherent drug resistance of many tumours. Numerous gene products have been 
implicated in prevention of apoptosis, including A20, a zinc finger protein. A20 is 
inducible by TNF, IL-1 and cross-linking of CD40 on B cell lines (Tewari et al., 1995) 
resulting in a TNF-sensitive fibroblast cell Une becoming resistant to TNF-induced 
apoptosis (Opipari et al., 1992); it also prevents apoptosis of serum-deprived B cell lines. 
Expression of A20 is induced by the latent membrane protein 1 gene product of EBV 
(Laherty et al., 1992) and may play a role in the resistance of these cells to apoptosis.
Another molecule which is thought to play a major role in rescue of cells from apoptosis is 
bcl-2.
1
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bcl-2: the putative oncogene bcl-2 is juxtaposed to the Ig heavy chain locus by the 
t(14:18) chromosomal translocation typical of human foUicular B-cell lymphomas 
(Fukuhara et a l, 1979). The bcl-2 gene product is not altered by the translocation but its 
expression is deregulated leading to constitutively high levels of protein (Cuende et a l,
1993), Bcl-2 has properties of an 'anti-apoptosis' gene; for example, when transfected into 
an IL-3”dependent B ceU line, on removal of IL-3 the cells do not cycle but are suspended 
at Gg/Gp when they would noimally undergo rapid apoptosis (Marvel et a l, 1994). 
Experiments carried out in Chinese hamster ovary (CHO) cells transfected with c-myc 
show that elevated c-myc expression resultsin cell death but that cells co-expressing bcl-2 
are relatively resistant to c-myc induced death (Merino et a l, 1994). A 'two signal' model 
may exists where c-myc can provide the first signal, leading either to apoptosis or to 
proliferation. Certain growth factors may provide a second signal, to inhibit apoptosis and 
allow c-myc to drive the cells into ceil cycle. It is suggested that bcl-2 may substitute for 
the putative survival signal. This would provide a mechanism whereby cells can express c- 
myc without undergoing apoptosis, and may explain why some investigators have shown a 
synergistic relationship between bcl-2 and c-myc in cell transformation (Strasser et a l,
1990).
As well as preventing apoptosis through regulation of cell cycle events, two other models 
for bcl-2 function are: enhancement of antioxidant function and resistance to apoptosis in 
instances of oxidative stress; and regulation of enzymes e.g. mterleukin-1 ^ -converting 
enzyme (ICE) alleged to be involved in a protease ceU death pathway (Hockenbery,
1995).
1,6,4 Bcl-2 expression during B  cell development
As mentioned previously, apoptosis occurs at several stages thioughout B ceU 
development; as pro-B cells rearrange their Ig genes, immature B cells express their 
surface Ig and in germinal centres after centroblasts have undergone somatic 
hypermutation. At all these stages the cells appear to be susceptible to apoptosis as a 
safety measure to ensui’e that B cells which do not have a normal phenotype or are 
specific for self, are removed. The molecular signals which control B cell survival are 
largely unknown but Merino et a/., 1994, suggest that bcl-2 expression may play a major 
role. They demonstrated that there is developmental regulation of bcl-2 protein in B ceUs 
with high levels present in pro-B and mature B cells but down-regulation at the pre-B and 
immature B ceU stages of development. In their hands, susceptibility to dexamethasone- 
induced apoptosis correlates with low levels of bcl-2 and this susceptibility is reversed by 
transfection of the cells with bcl-2. It has been shown previously that bcl-2 expression is 
absent or diminished in germinal centres (PezzeUa et a l, 1990; Hockenbery et a l, 1991) 
and cross-linking of surface Ig, CD40 antibody and sCD23 plus IL -la  (signals known to 
prevent apoptosis of these ceUs) all cause germinal centre cells to express bcl-2 protein
i
(Liu et a l, 1991). These data suggest that bcl-2 is a physiological signal controlling B cell 
death. It could act to protect pro- and mature B cells from a variety of apoptosis-inducing 
signals or, conversely, down-regulated expression at specific stages may facilitate 
apoptotic death of non-functional or anti-self B cells.
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However, in addition to bcl-2, three recently described genes, bcl-x, box, and bak appear 
to control cell death and bcl-2 function (Boise et al, 1993; Oltavi et al., 1993; Farrow et 
al., 1995); thus, regulation of expression of these genes may also have a role in 
determining susceptibility to apoptosis at different stages of development.
1.6.5 The bcl-2 gene family
Briefly, bcl-x is a hc/-2-related gene which exists in two foims, bcl-xj^ (large) and bcl-x^
(small). The large form appears to function hke bci-2 to inhibit apoptosis, whereas the 
small molecule inhibits the ability of bcl-2 to enhance survival of growth factor-deprived 
cells. Bcl-x^ mRNA is expressed at high level in cells with a high rate of turnover, such as 
immature thymocytes undergoing negative selection. In contrast, bcl-xj^ is found in 
mature, post-mitotic neural structures in the absence of bcl-2. Thus, bcl-x may have an 
important function in both positive and negative regulation of apoptosis (Boise et al.,
1993).
■ ;R ,
Bax, a bcl-2 homolog, is able to dimerise with itself and with bcl-2. Korsmeyer and 
colleagues (1993) demonstrated that overexpression of bax promotes apoptosis and thus it 
is a putative "death gene". It has recently been demonstrated that bcl-2 must 
heterodimerise with bax to function (Yin et al., 1994). It appears that the ratio of bcl-2 to 
bax may predetermine the susceptibility of a ceU to a given apoptoic stimulus since the 
presence of bax homodimers would promote death but if bcl-2 levels were high, and bel-
;2!box heterodimers existed, the cell would survive.
FinaUy, bak or 'bcl-2 homologous antagonis^kiUer' adds greater complexity to the issue.
This protein is found in several ceU types and, if overexpressed, it accelerates apoptosis 
induced by growth-factor withdrawal. It appears that bak may act in a shnUar fashion to 
bax but by binding to bcl-xj^ and not to bcl-2 (Farrow et al., 1995).
In the WEHI-231 B ceU lymphoma, anti-membrane IgM-induced apoptosis is thought to
be a model for clonal deletion of immature B cells by antigen. Cuende et al. ( 1993)
showed a specific down-regulation of both bcl-2 RNA and protein on apoptosis induced
by anti-IgM. However, they faUed to show rescue of the ceUs from apoptosis by stable
.transfection of bcl-2, although the transfected cells were more resistant to death induced 
by heat-shock. These observations, along with others, indicate that there are bcl-2~ 
dependent and -independent mechanisms of apoptosis. The reason that bcl-2 cannot
protect in every setting may be partly explained by competing interactions among the 
expanding bcl-2 family which could set switches in individual cells that dictate resistance 
or suscepibüity to 'death' signals. It is also possible that some stimuli, such as the Fas- 
ligand-receptor interaction, are so strong they may break through the checkpoint (Oltavai 
& Korsmeyer, 1994). Thus, regulation of apoptosis appears to be very complex, involving 
numerous induction signals and multiple interacting and opposing gene products which 
promote either cell death or suiwival.
1.7 Acute Lymphoblastic Leukaemia
As discussed above, lymphocyte populations are subject to selection through apoptosis at 
various stages of their development, and it has become apparent that aberrations in the 
capacity to undergo apoptosis can lead to the formation of tumours. African Burkitt 
lymphoma (BL) and foUiculai’ centre cell (FCC) lymphoma are two such examples, 
thought to arise from germinal centre B cells. Constitutive activation of bcl-2, brought 
about by chromosomal translocation (14; 18) of bcl-2 to the Ig heavy chain gene, probably 
contributes to the inability of FCC cells to undergo apoptosis. Burkitt lymphoma cells also 
have deregulated bcl-2 expression possibly brought about by the latent membrane protein- 
1 of resident EBV (Henderson et al„ 1991). Some confusion may arise, however, because 
FCC lymphoma can sometimes undergo a leukaemic blast crisis, with misdiagnosis of the 
tumour as acute lymphoblastic leukaemia. (Kramer et al., 1991).
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Acute leukaemia, although a rare disease, is a major form of malignancy in early B cell 
development, and is the most common foim of childhood cancer. It is characterised by an 
arrest of lymphocyte maturation and the subsequent accumulation of these cells in the 
bone marrow, blood and other tissues (reviwed by Pui et al., 1993). Traditionally, acute 
leukaemias are classified according to their morphological and/or cytochemical features 
and are named according to the assumed normal counterparts which they most closely 
resemble. Greaves et al., 1981 originally postulated that leukaemic lymphoblasts are the 
neoplastic counterparts of nornial lymphopoietic progenitors "frozen" at various stages of 
development.
Classification of childhood B-ALL depends on identification of several B cell 
differentiation antigens such as CD 19, CD22, CD 10 and the state of VpreB expression 
(Bauer et at., 1991) and Ig gene rearrangement, althougli there are leukaemias termed 
nuU-ALL because they expess neither T or B cell markers. Null-ALL cells are thought to 
represent tumours of stem cells which are not yet committed to the lymphoid lineage, and 
they are often CD34+. CD 10, also known as the common ALL antigen (CALLA) was 
among the first differentiation antigen used in classification of acute leukaemias but 
CD 10-negative acute leukaemias do exist (Pui et al., 1993).
Early pre-B-ALL cells account for about 60% of ALL and tend to represent a more 
favourable outcome than pre-B ALL (Crist et al., 1985). The pre-B immunophenotype 
accounts for about 25% of childhood ALL and 94% of cases are CD 10+. B ALL refers to 
acute leukaemia of a more mature B cell stage, which is slg+, and represents 
approximately 2% of childhood ALL. In adult ALL there is a high frequency of T-cell 
(found in the anterior mediastinum) and CD 10-negative B-lineage ALL phenotypes (Thiel 
etal., 1980).
As with nomial haematopoiesis, the majority of leukaemic cells ai’e thought to descend 
from a relatively small number of progenitor cells with a high proliferative activity. In 
most cases the leukaemic blast cells do not actually divide once they leave the original 
mass and enter the blood (Lowenberg & Touw, 1993) and, although the cells may be able 
to proliferate on addition of exogenous mitogens, they do not usually differentiate any 
further (Salem et al., 1989). Some myeloid cell Hnes, for example HL-60, can be induced 
to differentiate by addition of GM-CSF or G-CSF in vitro (Begely et al., 1987), with the 
cells progressively losing self-renewal capabilities until they are terminally-differentiated, 
when they undergo apoptosis (Yamaguchi et a l, 1991).
Acute leukaemia is an extremely heterogeneous group of disorders, both at the clinical 
and biological level and numerous mechanisms have been implicated in the disease 
process. It has been suggested that infection by bacteria or viruses in utero or early 
infancy may greatly increase the chance of developing leukaemia (Greaves & Alexander,
1993). It is possible that viruses may activate proto-oncogenes which can then transform 
cells from the normal to the malignant phenotype. The majority of B-cell leukaemic 
lymphoblasts have non-productive Ig gene rearrangements of heavy or hght chains and 
this is thought to hinder normal development (Greaves, 1986). However, there must be #  
other genetic defects present in the cells since non-productive Ig gene rearrangements 
usually result in cells undergoing apoptosis and leukaemic cells are able to survive. The 
mechanisms of leukaemic cell survival are not entirely clear but may involve deregulated 
growth factor production or changes in the ability to receive growth factor receptor 
signals i.e. increased numbers of receptors, expression of receptors not usually present on 
the cells, increased affinity of cell surface receptors or deregulation of intracellular |
signalling pathways. Examples of some of these mechanisms will be discussed below.
More that 90% of childhood ALL cases have clonal chromosomal rearrangements, with 
the karyotypic abnormalities more commonly found in B-lineage leukaemias than in those 
of T cell origin. There are an increasing number of apparently non-random chromosomal 
abnormalities associated with specific hnmunophenotypes, suggesting a relationship to 
leukaemogenesis (Pui et a l, 1993).
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The Abelson murine leukaemia virus (Ab-MLV) encodes v-abl, an oncogene derived from 
the cellular gene, c-abl, but lacking the Src homology (SH) 3 domain. The protein 
tyrosine kinase encoded by v-abl allows the virus to transform B lymphocyte precursors, 
mostly CD45R+, CD43+, HSA+ cells which are actively cycling (Hardy et aL, 1991; 
Rosenberg & Kinade, 1994), and the cells become arrested at the stage of hght chain gene 
rearrangement. Aberrant abl expression in man, due to the t(9:22) translocation, also
1.7.1 Translocations
Up to 50% of childhood ALL have gene translocations and these have helped to identify 
genes with a possible function in malignant transformation and proliferation. Most B-ceU 
ALL cases have translocations involving Ig genes suggesting that Ig recombinase (RAG- 
1) or clas8-switch enzymes are involved in the mterchromosomal movement (Cleary et a l,
1991). Common translocations include the myc proto-oncogene on chromosome 8(q24) 
being juxtaposed to the Ig heavy chain enhancer on chromosome 14 or the k  hght chain 
promotor on chromosome 2, leading to abberant activation of myc (Eiikson et al., 1983; 
Taub et al., 1984).
Numerous translocations imphcated in acute leukaemias involve transcription factors. The 
most common translocation of childhood pre-B ALL (approx. 25%) is the 
t(l;19)(q23;pl3). This ti'anslocation involves the E2A gene which encodes a transcription 
factor thought to be essential for expression of Ig genes (Staudt & Lenardo, 1991) and 
initiation of Ig gene recombination (Schhssel et al, 1991); E2A is mandatory for B 
lymphopoiesis. The E2A gene is fused into a homeobox gene known as PBXl to form a 
chimeric protein. As weh as effects on Ig genes, pre-B cells with t(l;19) have insulin 
receptors with 2 fold-higher affinity for insulin and 4 -fold higher basal and insuhn- :
stimulated receptor kinase activity compared to receptors on a B-ceh line (with no
translocations), from the same patient (Greaves, 1981).
As weh as transcription factors, some translocations involve haematopoieitc growth 
factors. In ALL, the translocation (5;14)(q31;q32) has been associated with autocrine 
growth stimulation due to juxtaposition of the IL-3 gene with the J region of the IgM 
gene and subsequent overexpression of IL-3 (Grimaldi & Meeker, 1989).
However, in at least two types of leukaemia, Philadelphia-positive ALL (mostly of pre-B 
or early pre-B ceh) and chronic myeloid leukaemia (CML), deregulation of a tyrosine 
kinase activity is actively involved in leukaemogenesis (Katz et al., 1994), This 
ti'anslocation - (9;22) - juxtaposes the c~abl gene on chromosome 9 with the breakpoint 
cluster region {bcr) on chromosome 22. The Q-abl encodes a tyrosine kinase activity and 
the result of the translocation is a chimeric protein increased in size from 145kDa to 
210kDa, and with enhanced activity (Konopka et al., 1984).
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involves differentiation arrest of pre-B cells at the same stage. Temperature-sensitive 
Abelson virus mutants have been used to demonstrate that virus-transformed cells 
undergo light chain reanangement once they are switched to the non-perraissive 
temperature (Takemori et <3/., 1987). V-abl protein has lost locatisation to the nucleus and 
is found at the plasma membrane of the B ceU. The high level of phosphorylation events, 
especially with the altered subcellular localisation, must perturb the tyrosine kinase- 
regulated signalling pathways that normally control the growth and differentiation of B- 
cell precursors and expression of genes central to antigen receptor gene rearrangement, 
but the nature of these pathways is not understood (Rosenberg, 1994).
Thus, translocations allow identification of genes involved in leukaemogenesis and help to 
illustrate mechanisms whereby leukaemic cells can overcome normal growth regulation.
The studies presented here describe one of those mechanisms - autocrine growth factor 4',.'production by a pre-B acute lymphocytic leukaemia cell line called SMS-SB.
1,8 SMS-SB cell line
The SMS-SB cell hne was characterised by Smith et aL,'m 1981. The cells were derived 
from the leukocytes of a 16 year old girl in the leukaemic phase of a lymphoblastic 
lymphoma. Most lymphoblastic lymphomas are of T-cell origin and are found in the 
anterior mediastinum and cervical lymph nodes with subsequent spread into the bone 
marrow. The original tumour from patient SB was unusual because it was present as lytic 
bone marrow lesions and a paraspinal mass with no involvement in the anterior 
mediastinum (Smith et al., 1981). This distribution of cells in the bone marrow and 
vertebrae is typical of lymphomas induced in mice by the Abelson murine leukaemia virus. 
Mice infected with this virus develop lymphomas that have no thymic involvement and 
frequently have solid paravertebral tumour masses (Abelson & Rabstein, 1970b). Cultured 
SMS-SB cells do not display T-cell specific smface markers and, unlike most 
lymphoblastic lymphomas have only very low levels of the enzyme TdT. The cells are 
designated as 'pre-B' by virtue of the presence of 70kDa cytoplasmic p-chains and the 
absence of surface Ig, along with expression of several B cell specific markers. In several 
ways, SMS-SB ceUs bear a resemblance to normal bone marrow late pre-B cells; for 
example, they express only one specificity of \i heavy chain with no light chains and they 
do not express CDIO (CALLA), but they express HLA-DR surface antigens. These 
phenotypic featui’es distinguish SMS-SB from most other cultured pre-B cells (Smith, 
1984). Karyotypic analysis has shown that although SMS-SB cells contain two 
submetacentric marker chromosomes, there are no other chromosomal abnormalities, and 
the Philadelphia translocation is not present. It is also of interest that SMS-SB cells do not 
contain the EBV nuclear antigen, indicating that their transformation was not a result of 
infection by this virus (Smith, 1981).
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The similarities between the SMS-SB tumour and Abelson virus induced disease led 
Ozanne et al. ( 1982) to investigate the genomic rearrangement and expression of the 
cellular homologue of the Abelson viral oncogene, c-abl, in SMS-SB cells. They 
discovered that there is no gross rearrangement of the human c-abl sequence but the gene 
is transcribed in an abberant fashion. The cells contain two extra ab/-related transcripts of 
6.2 and 6.8kb in addition to the 5.2 and 5.4kb mRNAs found in normal cells. These data 
suggest that altered expression of c-abl may have contributed to the transformation of 
SMS-SB cells.
On examination of SMS-SB cells it was discovered that they have normal expression of c- 
myc, c-myb and c-jun but overexpress the c-fos proto-oncogene when compared with 
other ceh lines and to peripheral blood lymphocytes which normahy express undetectable 
levels of c-fos mRNA (Tsai et al., 1991). The c-fos gene does not appear to be grossly 
altered in SMS-SB cehs and the transcription rate and mRNA levels can be up-regulated 
by serum.
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The leukaemic cehs, taken from SB, grew spontaneously m culture and did not go 
through a crisis phase. The cells can be cultured in serum- and protein-free media without 
the addition of exogenous mitogens. That the cehs proliferated with high viabhity when 
first placed in culture was unusual for human leukaemias and the unusual growth 
characteristics prompted Ozanne and coheagues to characterize the growth promoting 
factors produced by the cehs. They identified two activities, one which enhances the 
growth of SMS-SB cells plated at low ceh density in serum-fr ee media, and another, now 
teimed transforming growth factor - leukaemia-derived (TGF-LD) which promotes the 
growth of mouse and human fibroblasts but does not act on hematopoietic cehs. TGF-LD 
is secreted by various other B and T ceh precursor ALL ceh lines but at a lower level than 
secreted by SMS-SB cehs (Zack et al., 1987). From proliferation assay data it seems 
unlikely that TGF-LD has an autocrine function for SMS-SB.
1.9 Research aims
The original aim of this thesis was to investigate the growth characteristics of SMS-SB 
cehs, identify the autocrine growth factor, and determine its exact role in SMS-SB and 
normal B ceh growth and development. It was hoped to purify and chai’acterise the 
autocrine growth factor (SB-AF), since preliminary studies performed by the Genetics 
Institute, Cambridge, Massachussets, had determined that SMS-SB cehs do not produce 
any of the currently characterised interleukins; SB-AF appears to be a novel pre-B ceh 
cytokine.
Numerous cytokines were tested for the ability to substitute for the SB-AF activity, and 
these studies have identified PDGF as a candidate autocrine growth factor. PDGF, and
PDGF receptors, are known to be expressed by SMS-SB cells. Unfortunately, further 
investigations will be required to fully understand the role of PDGF in SMS-SB ceU 
growth, and whether PDGF has a role in normal B cell development.
Another interesting discovery made during preliminary attempts to identify the SB-AF 
components, was that sCD23 dramatically promotes thymidine incorporation by SMS-SB 
cells, although an autocrine role for this cytokine has subsequently been ruled out. The 
main focus of the research presented in this thesis was to identify the biological effects of 
sCD23 interaction with SMS-SB cells, and to determine exactly how this interaction takes 
place, after a demonstration that SMS-SB cells do not express any known CD23 
receptors. SMS-SB cells appear to express a novel receptor for CD23.
SMS-SB cells provide an extremely interesting model to study autocrine factor activity 
and characterise the novel CD23 receptor. Future studies should help to clarify the role of 
autocrine growth factors and CD23 in both early B cell development and malignant 
hansformation.
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Materials and Methods
Chapter 2 
Materials and Methods
2.1 Materials
2.1.1 Chemicals
The chemicals were of 'AnalaR' grade, and, with the exception of those listed 
below, were obtained from BDH Chemicals Ltd. or Sigma Chemical Co. Ltd., both of 
Poole, Dorset, England.
SUPPLIER CHEMICAL
Amersham International Pic., Aylesbury, 
Bucks, UK.
a-[32p]-dCTP (3000Ci/mmol)
(Methyl-[%]) -Thymidine (20-30Ci/mmol)
Avanti Polar Lipids, Inc., Alabaster, 
Alabama, USA.
l-palmitoyl-2-oleoyl-phosphatidyl-choline
(POPC)
BRL (UK), Gibco Ltd., Paisley, 
Scotland.
Restriction enzymes / buffer concentrates. 
Select agar
Biogenesis Ltd., Bournemouth, England. RNAzolB
Biorad Laboratories Affigel-15
Affigel-10
Boehringer Mannheim UK Ltd., Lewes, 
East Sussex, England.
Caesium chloride
DNA molecular weight markers IV and VI
Proteinase K
Neuraminidase
J. Burrough (FAD) Ltd., Witham, 
Essex, England.
Ethanol
Central Services, Beatson Institute. Sterile distilled water and PBS 
L-broth
Difco Labs., Detroit, Michigan, USA. Bacto-agar
Gibco (Life Technologies), Paisley, 
Scotland.
Uncut Lambda DNA
Molecular Probes Ltd. 3,3'-Dioctadecyloxacarbocyanine 
percholate (DiOCig(3))
Oxoid Ltd., Basingstoke, England. PBS tablets
Pfansteihl Europe Ltd., Davenham, 
England.
n-Octyl- (3-D-glucopyranoside (analytical 
grade)
Pharmacia Biotech Ltd., Milton Keynes, 
England.
NICK™ columns 
Sephadex G50
50
2.1.2 Kits,
SUPPLIER KIT
Amersham International PLC., Amersham, 
Bucks, England.
ECL Western Blotting analysis 
system.
Bio 101 Inc., Stratech Scientific, Luton, 
England.
Geneclean kit
Cruachem Ltd., Glasgow, Scotland. Cruachem oligonucleotide purification 
cartridges.
Perkin Elmer Cetus Ltd., Beaconsfield, England. GeneAmp RNA PCR kit.
Pharmacia Biotech Ltd., Milton Keynes, Bucks, 
England.
Oligo-labelling kit.
Promega Ltd., Southampton, England. PolyATract mRNA Isolation System 
IV
Magic Minipreps DNA Purification 
system
2.1.3 Equipm ent and Plasticware
Main pieces of equipment are referred to in the appropriate sections. The following 
companies provided the most commonly used items:
SUPPLIER EQUIPMENT
Becton Dickinson Labware, Plymouth, Devon, 
England,
Falcon tubes ( 15 and 50 ml) 
Polystyrene round bottom tubes 
(12x75mm and 17x100mm)
Bibby-Steiilin Ltd., Stoney, Staffs., England. Bacteriological dishes (90mm)
Chance Propper Ltd., Warley, England. Gold star microshdes (76x26mm) 
Glass coverslips (22x50mm)
Costar, Cambridge, Massachusetts, USA. 96 well plates 
Disposable ceh scrapers
Eastman Kodak Co., Rochester, N.Y., USA. X-ray film (XAR-5)
Fuii Photo Co. Ltd., Japan X-ray film (RX)
NUNC, Gibco, Life Technologies Ltd., Paisley, 
Scotland.
Tissue culture flasks (25, 80 and 
175 cm3)
Cryotubes (1 and 1.5 ml)
Griener Labortechnik Ltd., Dursley, England. Eppendorf tubes
Labsystems, Basingstoke, England. Pipette tips (200 and 500|o.l)
Whatman International Ltd., Maidstone, 
England.
3mm chromatography paper.
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2.1.4 Plasmids
pBSCD21 Contains an Xhol-Clal subfragment of CD21 recloned in 
pBluescriptllSK-. A gift from Dr. J-Y. Bonnefoy.
pCDL SRa296CD23 The full length CD23 cDNA in expression vector pCDL 
SRa. A gift from Dr. J-Y. Bonnefoy.
Sp65 The full length c-fos cDNA in a pBR322 expression vector . 
A gift from Mr Joseph Winnie.
2.1.5 cDNA Probes
CD21 Approximately lOOObp Xho-1/Not-1 fragment of pBSCD21
CD23 A 1.6kbp BamHI fragment of human CD23 from pCDL 
SRa296CD23.
c-fos A 2.1kbp HINDIII - EcoRI fragment of pSp65.
GAPDH 0.7kb PCR fragment of rat GAPDH
2.1.6 Water
Distilled water for solutions was obtained from a Millipore MilHRO 15 system and for 
nucleic acid procedures it was further purified on a Millipore MilliQ system.
2.1.7 Cell Culture Materials
SUPPLIER MATERIAL
Biological Industries (Kibbutz Beth 
Heamek Israel).
RPMI-1640 medium
Life Technologies Ltd (Gibco Europe), 
Paisley, Scotland.
2.5% (w/v) Trypsin
Protein free hybridoma medium II
Penicillin / streptomycin
Glutamine
Northumbria Biologicals. Foetal calf serum
Seromed, Biochrom KG, HAM's F-12 Medium 
Iscove medium
Sigma Chemical Co., St Louis, USA. Trypan blue
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2.1.8 Cytokines
SUPPLIER H u m a n  Re c o m b in a n t  C y to bo n es
Glaxo Institute for Molecular Biology, 
Geneva, Switzerland.
IL-la, IL-lp, IL-2, IL-3, IL-4, IL-5, 
IL-6, IL-8, IL-13, GM-CSF
British Biotechnology Ltd., Abingdon, 
UK
IL-1(3, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, 
TNF-a, TNF-(3, PDGF-aa
Genetics Institute, IL-11
Pepro Tech Inc., Rocky Hill, NJ, USA. IL-15
R&D Systems, Abingdon, UK. IL -la
2.1.9 Recombinant CD23
Full length 45kDa CD23 and affinity-purified 25, 29 and 37 kDa forms of sCD23 were 
produced in baculovirus-infected Sf9 cells and in E.Coli, as described previously (Jansen 
et a l ,  1991; Pochon et a l, 1992; Flores-Romo et a l, 1993). All forms were a gift from 
Glaxo IMB in Geneva, courtesy of Dr. Pierre Graber.
Gel filtration-purifed 25kDa sCD23 was produced from baculovirus-infected Sf9 cell 
supernatant using an AcA44 column, and then SDS-PAGE/westem blotting with anti- 
CD23 antibodies to detect the CD23-containing fractions. These fractions were then 
pooled and dialysed against PBS for 48 hrs, before the protein concentration was 
calculated.
2.1.10 Antibodies
SUPPLIER a n t ib o d y
Alexis Corporation, (Ancell Ltd.), 
Nottingham, UK.
Mouse monoclonal anti-85kD (Human 
BCell)/R-PE
Glaxo IMB, Geneva, Switzerland (gifts 
from Dr. J-Y. Bonnefoy)
Anti-CD23 antibodies: Mab25 (mouse 
IgG monoclonal), EBVCS4 (mouse IgM 
monoclonal), Rb55 (rabbit polyclonal)
Monosan Biologicals, Bradsure 
Biologicals Ltd., Loughborough, UK.
Mouse anti-CD6, -CD16, -CD18, - 
CD43, -CDw49d, -CD54, -CD71, - 
CD76, -CD105
Pharmingen, San Diego, CA, USA. Mouse anti-human bcl-2 monoclonal Ab.
R&D Systems Europe Ltd., Abingdon, 
UK.
Mouse anti-human platelet derived 
growth factor (PDGF), neutralising 
antibody
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Serotec Ltd., Kidlington, Oxford, UK. Fluorescein-isothiocyanate (FITC) - 
conjugated mouse anti-CDlla, -CDllb, 
-CDllc, -CD19, -CD20, -CD21, - 
CD22, -CD23, -CD25, -CD45 and anti- 
CD72
Psnïi-c-myc (mouse monoclonal)
F(ab)2 ' Rabbit anti-mouse IgG : FITC 
Sheep anti-mouse IgG : FITC 
Normal rabbit IgG
The Binding Site, Birmingham, UK. Biotinylated anti-CD23
Scottish Antibody Production Unit 
(SAPU)
Normal rabbit serum
2.2 Methods
2.2.1 Cell Culture of Human B Lymphocyte CeU Lines
SMS-SB cells were maintained in Protein Free Hybridoma Medium II (PFHMII) and also 
in RPMI-1640 medium supplemented with 10% (v/v) foetal calf serum and 2mM L- 
glutamine. All other cell lines (described below) were maintained in RPMI-1640 
supplemented with 10% (v/v) foetal calf serum and 2mM L-glutamine. Cells were 
routinely sub-cultured every 3 days unless otherwise described in the text or figure 
legends. The cells were cultured in 75cm^ Costar flasks at 37°C in a 7% CO2 atmosphere. 
Maintenance of the cells was carried out in a Laminar-flow-hood,
All of the cell lines were routinely examined for mycoplasma infection (Mr. Joseph 
Winnie, Beatson Institute) and were consistently negative.
2.2.1a Cell lines
Daudi -
DOK-
Jijoye -
Raji-
Ramos - 
RPMI-8226
Human thyroid Burkitts lymphoma (gift from Dr. M.M. 
Harnett, Dept. Biochemistry and Molecular Biology, Univ. of 
Glasgow).
Pre-malignant human keratinocyte (gift from Dr. K. Parkinson, 
Beatson Institute).
Human B lymphoblastoid cell line (gift from Prof. CM Steel, 
Dept, of Medical Biology, University of St.Andrews).
Human, EBV-negative, Burkitts lymphoma (gift from 
Dr. J-Y. Bonnefoy, Glaxo IMB, Geneva).
Human Burkitts lymphoma (gift from Dr. M.M. Harnett) 
Human EBV-transformed multiple myeloma (gift from 
Dr. J-Y. Bonnefoy)
" ' I
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SKW - IgM-secreting human B-lymphobiastoid line (gift from Prof.
C.M. Steel)
SMS-SB- Human Pre-B acute lymphoblastic leukaemia (gift from
Dr. B. Ozanne, Beatson Institute).
2.2.1b Frozen Cell Stocks
A frozen stock of each cell line was maintained in liquid nitrogen. From a logarithmically 
growing culture, cells were centrifuged and resuspended in 90% PCS with 10% DMSO at 
approximately 1x10^ cells/ml. The cells were rapidly aliquoted into 1ml Nunc cryotubes 
and frozen at -VO'^ C overnight. The tubes were then placed into liquid nitrogen for long 
term storage.
2.2.1c Large Scale Culture o f  Cell Lines
To obtain sufficient cells for preparation of large scale cell lysates, cells were grown in 
spinner-fermenters until at least 10  ^ cells were available for harvest. This process was 
carried out for Raji, RPMI 8226 and SMS-SB cells to provide a negative, positive and 
test sample, respectively. Numerous test cultures were carried out until it was decided 
that, in spinners, SMS-SB cells grow optimally in a mixture of 3 parts Iscoves plus 1 part 
Ham's F-12 medium (Raji and RPMI-8226 cells grow equally well in most media tested). 
The cultures were grown in successively larger spinners until at least 4 Htres of cells at 
approximately 10^ cells per ml were available for harvest. The cells were incubated at 
37®C and approximately 2 weeks elapsed before the cells were ready to harvest. Prior to 
harvest, an aliquot of each cell type was removed and tested in a Hposome binding assay 
to ensure that no alteration in liposome binding ability had occurred during culture under 
the new conditions. After centrifugation and two washes with ice-cold PBS, aliquots of 
cells were biotinylated (see section 2.2.8a) and then kept at -70°C until required.
2.2. Id Determination o f  cell viability
Cell viability was determined by mixing 25[ul of cell suspension with 75 p,l of 0.05% (w/v) 
trypan blue in PBS. The membranes of dead cells lose their integrity and so allow trypan 
blue to enter the cell. The numbers of live and dead cells were counted using a Neubauer 
haemocytometer. The total number of cells in 4 x 16 square grids was multiplied by 10"^  to 
estimate the number of cells per ml of culture.
% viability = number of live cells xlOO 
total number of cells
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2.2.1e Preparation o f  Conditioned Medium
To prepare conditioned medium, SMS-SB cells were grown for 2 days at an initial 
concentration of 5x10^ per ml in PFHMII medium. The cells were then removed by 
centrifugation at 3000 rpm for 10 minutes, and the media was collected and sterile filtered 
through a 0,22\xm filter before being aliquoted and stored at -20®C.
2.2.2 Proliferation Assay
Tritiated-thymidine uptake assays were performed to assay for SB-AF activity and to 
assess the response of SMS-SB cells to various recombinant human cytokines.
The appropriate number of SMS-SB cells (2500 cells, unless otherwise stated) harvested 
from log phase cultures (without centrifugation), were dispensed as 80 \xl aliquots (in 
PFHMII) to individual wells of 96 well flat-bottomed tissue culture plates. A further 2Q\x\ 
of PFHMII supplemented with the appropriate concentration of cytokine or conditioned 
medium (as described in the figure legends) was then added. The plates were incubated at 
37°C for 24 or 48 hrs (see individual experiments) in a humidified 5% COg atmosphere. 
After this time, each culture was pulsed with 0.33 qCi of tritiated methyl thymidine ([^H]- 
TdR) for 6 hrs at 37°C. The cells were harvested onto glass fibre mats using a LKB 
Wallac 1295-001 Cell Harvester. The mats were air-dried and counted using an LKB 
1205 Betaplate Liquid Scintillation Counter. All determinations were made in triplicate 
and at least 3 repeats were performed for each experiment.
2.2.3 Flow Cytometric Analysis 
2.2.3a Cellphenotyping '
Flow cytometric techniques were used to analyse the surface expression of various cluster 
of differentiation (CD) antigens by SMS-SB cells. Aliquots of between 5x10^ and 1x10^ 
cells were removed from cultures, centrifuged and then washed twice with ice-cold PBS. 
The cells were resuspended at a concentration of 10^ cells per ml in PBS, Ipg of the 
appropriate mouse anti-human MAb was added to a lOOp.1 sample of cells (see text and 
figure legends for details). Samples where the antibodies were directly conjugated to a 
fluorescent marker were incubated for 30 min on ice and protected from light. After 
incubation, the cells were centrifuged, washed twice with ice-cold PBS and finally 
resuspended in 0.5 ml of PBS for analysis by flow cytometry. In cases where the primary 
antibody was unconjugated, a secondary conjugated antibody was employed to allow 
detection. Staining with the primary Ab was as described for the directly conjugated Ab, 
but after the final wash step, Ipg of the secondary Ab (e.g. FITC anti-mouse IgG) was 
added to the cells for 30 min. After incubation, the cells were washed twice in ice-cold 
PBS and resuspended in 0.5 ml of PBS for analysis.
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In each experiment, a control was included where no antibody was added, to correct for 
autofluorescence of the cells. Where a secondary antibody was used, a control of cells 
stained with only the second Ab was included to account for any non-specific binding of 
the antibody.
Propidium iodide (PI) was added to each sample at a final concentration of 5pg/ml, 
immediately prior to data collection. Ab staining was analysed using a FACScan flow 
cytometer (Becton-Dickinson, Mountain View, Ca,, USA) with an argon laser tuned at 
488 nm. Cells were gated on forward and side light scatter, as well as for the PI emitted 
fluorescence to facilitate exclusion of non-viable cells from the acquisition. All histograms 
represent data from 10“^ viable cells for each sample.
2.2.3b Flow cytometric determination o f  apoptosis
Flow cytometric discrimination and quantification of viable, early and late apoptotic and 
necrotic cells is based on their differential permeability and fluorescence following staining 
with the DNA-binding fluorochromes Hoechst 33342 and propidium iodide (Dive et a i ,
1992).
Preparation of the cells was the same as in section 2.2.3a but instead of adding an Ab, the 
cells were stained with 20 pi of propidium iodide (50 pg/ml in PBS, stock) and 100 pi of 
Hoechst 33342 (lOpg/ml in PBS, stock). Both fluorochrome solutions were freshly 
prepared for each experiment. An unstained population of cells was analysed initially to 
allow settings to be adjusted for forward and side scatter then both dyes were added 
individually to give an estimate of which populations were being stained. For the dual 
staining, cell suspensions were incubated with the dyes for 1 min. before 10^ cells were 
analysed by a dual laser Coulter Elite flow cytometer. The laser excitation frequency for 
propidium iodide was 488nm and the ultraviolet emitting laser (351.l-363.8nm) was used 
to excite Hoechst 33342. Both fluorescence signals were subjected to logarithmic 
amplification - propidium iodide fluorescence (red) was detected with a 575 nm band pass 
and Hoechst fluorescence (blue) between 420 and 470 nm. In aU experiments cell debris 
was excluded by electronic gating.
2.2.3c Flow cytometric analysis o f  cell cycle and intracellular proteins
Flow cytometry was used to examine expression of the intracellular proteins bcl-2 and c- 
myc during the cell cycle and apoptosis of SMS-SB cells. Saponin was used to 
permeabilise the cells and allow entry of the antibodies.
For each stain, 10^ cells were washed in 0.5% (w/v) BSA / 0,1% (w/v) saponin/PBS 
(SBP buffer) and then incubated in SB? supplemented with 10% (v/v) normal rabbit 
serum for 15 minutes at 4°C. The cells were then washed twice with SBP buffer before 
addition of Ipg of the primary antibody (mouse anti-human bcl'-2 or anti-human c~myc) in
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SBP buffer to a final volume of 100 jul, and incubation at 4^C for 20 min. After another 2 
washes in SBP buffer, lOpl of a 1/100 dilution of the secondary antibody (sheep anti­
mouse IgG - FITC) were added in SBP buffer for 20 min at 4^C. The cells were washed, 
as before, and fixed in 2% paraformaldehyde / 0.5% BSA in PBS for 15 minutes, washed 
another twice with PBS, and kept at 4^0 until analysis.
To analyse the cell cycle position of the cells after various culture treatments (see 
individual experiments), propidium iodide was used to stain the DNA. After the cells were 
stained with antibody, fixed and washed, they were suspended in a solution of 0 .1 % 
Triton X-100 / 0.1% sodium citrate (citrate buffer) plus lOOqg/ml propidium iodide, prior 
to analysis on a Coulter Elite flow cytometer. Cells were incubated with SBP buffer alone 
to control for any change in forward or side scatter or in autofluorescence due to the 
saponin. Cells incubated with saponin plus secondary antibody were used to control for 
fluorescence due to non-specific binding of the secondary antibody.
2.2.3d Fluorescent liposome FACS
The cells were prepared as before (section 2.2.3a) but instead of adding fluorescent Ab to 
stain the cells, 50pl of CD23-containing fluorescent liposomes (see section 2.2,4) were 
added and the cells incubated at 4°C for 2 hrs. After incubation, the cells were washed 
three times with hposome buffer (20mM HEPES pH7 / 140mM NaCl / 200mM CaCl2  / 
0.5% BSA /  0.1% Na Azide) before being resuspended in 100 pi of hposome buffer and 
analysed. The tubes were kept at 4®C at all times prior to analysis.
i) For antibody inhibition assays, either the liposomes or the cells (see individual 
experiments) were pre-incubated with the given antibody (at lOpg/ml, unless otherwise 
stated) for 1 hr at 4°C before the liposomes were added.
In ah cases, glycophorin A-containing hposomes were used as a negative control and 
normal rabbit IgG or mouse IgG (as detailed in the figure legends) were used as controls 
in the antibody blocking experiments.
ii) To investigate the nature of the ceh-liposome interaction, various sugars were tested 
for their abihty to inhibit the binding of CD23-liposomes to SMS-SB cells. Glucose-1- 
phosphate and fucose-l-phosphate (from Sigma Chemical Co.) were pre-incubated with 
the hposomes for 1 hour, at final concentrations between 0.02 and 50 mM in hposome 
buffer, before the liposomes were added to the cehs.
hi) To assess the sensitivity of the novel receptor to neuraminidase treatment, cells at 10^ 
cells per ml were washed in PBS and incubated in PBS containing 0.1 U/ml of one of the 
following bacterial neuraminidase : 
a- Vibrio cholerae
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b- Clostridium perfringens 
c- Arthrobacter ureafaciens.
The cells were incubated for 1 hr at 37^C then washed with ice-cold PBS before being 
incubated with the liposomes as before.
iv) To investigate whether the CD23 / novel receptor interaction was calcium-dependent, 
a liposome FACS assay was performed as before but 5mM EDTA / PBS was added to the 
incubation of cells plus liposomes.
2.2.4 Liposome Preparation
Preparation of fluorescent liposomes containing 45kDa CD23 or Glycophorin-A was 
carried out as follows : 200 pi (50mM in chloroform stock) of POPC (10 pmoles) and 
100 pi (0.5 mM in Dimethylformamide stock) of DiOlS (50 nmoles) were vortexed in a 
glass tube at room temperature to give a lipid ratio of 1/200, Di018/P0PC. The solvent 
was evaporated by flushing with N2 followed by 30 min drying with a Speedivac, After 
drying, 50pl of Ix PBS/ 800 mM n-Octyl-[3-D-glucopyranoside (OGP) (analytical grade) 
was added and the solution vortexed until clear (15-30 min). 150 pi of Ix PBS were then 
added to make the volume 200pl and the final concentration of OGP 200 mM. The ideal 
ratio of detergent to lipid is 100 mM OGP to lOmM lipids or 1/10.
At this point, the protein was added to the lipids - either CD23 or glycophorin A. The 
protein was dissolved in Ix PBS/50mM OGP at 20-25pg/ml. All the work was carried out 
at 4^C. Approximately 15pg of protein was added to the tube and 50mM OGP / PBS was 
added to give a final volume of 800pl. The tube was protected from the light, vortexed for 
10 seconds and then incubated on ice for 1 hr with occasional vortexing. The ratio of 
protein to lipid should be 1 / 50000 moles (1/25000 minimum). The final volume was 1 ml 
and OGP concentration was 50 mM.
12-14 kD cut off, 0.0011", 1 cm dialysis tubing was use to dialyse the liposomes against 4 
X IL of 20mM HEPES pH 7.0 / 140 mM NaCl (liposome buffer base) Firstly, the tubing 
was boiled in ImM EDTA, rinsed well with dH2 0 , and dried with a paper towel. The 
fresh liposomes were filtered through a 0.22 qm filter and then loaded into 25 cm long 
dialysis tubing using a 0.8 x 80mm needle (Socochim).
After dialysis, 0.1% Na Azide was added to the solution and 100 pi of the concentrated 
liposomes were kept at 4°C without protease inhibitors to test for binding. The remaining 
concentrated liposomes were diluted 1/10 with liposome buffer containing ImM Na-/?- 
tosyl-L-lysine chloromethyl ketone (TLCK), lOmM iodoacetamide and stored at 4®C in 5 
ml aliquots.
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2.2.5 Nucleic acid preparation  
2.2.5a Transformation o f  competent cells
To grow up sufficient plasmid and extract fragments for use as nucleic acid probes, 7
competent Exoli DH5a cells were thawed on ice and to each 20 pi aliquot, lOOng of 
appropriate plasmid DNA were added. Following a 20 minute incubation on ice, the cells 
were heat-shocked for 2 min at 42°C, placed on ice for 2 minutes and finally incubated m %
SOC medium (2% bacto-tryptone, 0.5% bacto-yeast extract, lOmM NaCl, 2.5mM KCl, 
lOmM MgCl2 , lOmM MgSO^ and 20 mM glucose) for 1 hr at 37°C with constant 
shaking at 225rpm to allow expression of antibiotic resistance markers. The transformed 
cells were micro centrifuged for 5 minutes and the pellet resuspended in 100 pi of L- 
broth. Dilutions of 1:10 and 1:100 (in L-broth) of the resuspended cells were spread onto 
separate agar plates (1.5% agar in L-broth containing lOOpg/ml ampicdhn). The plates 
were incubated overnight at 37°C. Representative colonies were inoculated into 12ml of 
L-broth containing lOOmg/ml ampiciUin to be incubated overnight at 37®C with constant 
shaking. For expansion of the cultures and DNA extraction, see below.
2,2.5b Small scale preparation o f  plasm id DNA
Modification of the alkali lysis method, proposed by Sambrook et al, 1989, was used to 
extract plasmid DNA from small bacterial cultures. Following on from section 2.2.5a, 1.5 
ml aliquots of a confluent overnight culture were spun in eppendorf tubes at 14000rpm for 
5 minutes, the pellet was resuspended in 200pl of 2 mg/ml lysozyme in 50 mM glucose,
25 mM Tris and 10 mM EDTA pH 8.0 and left at room temperature for 5 minutes. Cell 
lysis was continued by the addition of 400pl of 0.2M NaOH, 1% (v/v) SDS and 
incubation on ice for 10 minutes. Lysis was terminated by the addition of 300ml of 3M 
NaOAc pH 4.8, vortexing and incubation on ice for 10-15 minutes. The tubes were 
centrifuged at 14000 rpm for 5 min, 800pl of the supernatant was mixed with 480pl of 
isopropanol to induce DNA precipitation and the samples kept at -20^C overnight. The 
precipitated DNA was pelleted by centrifugation for 20 minutes at 4°C, washed with ice- 
cold 70% ethanol and finally lyophihsed under vacuum and resuspended in 50pl of TE 
(lOmM Tris, pH7.4, O.lmM EDTA). Before gel electrophoresis, RNase treatment was 
performed by incubating the sample with 50|xg/ml RNase for 30 minutes at 37^0.
Aliquots of l|ul were subjected to the appropriate restriction enzyme digestion (section 
2.2.5d) and electrophoretic analysis (section 2.2.7a) while the DNA concentration was 
determined by spectrophotometry. The DNA was stored at -20°C.
2.2.5 c Large scale preparation o f  plasm id DNA.
To obtain large amounts of plasmid DNA, the alkali lysis method proposed by Sambrook 
et at., 1989 was used, after analysis of mini-prep samples to ensure the correct plasmid 
and fragment were being cultured. Overnight cultures (1 litre) were collected by 
centrifugation (6000 i*pm) for 5 minutes at 4^C. The pellets were washed in 100ml of
60
bugwash solution (150mM NaCl, lOmM TrisHCl and ImM EDTA pH 8.0), respun and 
then resuspended in 20 ml of solution 1 (50mM glucose, 25mM TrisHCl pHS.O and 
lOmM EDTA pH8.0). After a 5 minute incubation on ice, 80 ml of solution II (0.2M 
NaOH and 1% (w/v) SDS) were added and mixed by gentle inversion. The samples were 
left at room temperature for 5-10 minutes and then the lysis terminated by addition of 30 
ml of cold solution III (3M Na acetate, 11.5% (v/v) glacial acetic acid). The samples were 
shaken vigorously, left on ice for 10 minutes followed by centrifugation at 4000 rpm, 4^C 
for 15 minutes; at the end of the run, the centrifuge was allowed to stop without braking. 
The supernatant was filtered through a gauze and then 0.6 volumes of ice-cold 
isopropanol were added, the sample mixed well and the DNA precipitated at room 
temperature for 15 minutes. The DNA was pelleted at 5000 rpm, 15 minutes at room 
temperature, the supernatant removed and the pellet washed with ice-cold 70% ethanol. 
The pellet was dried a room temperature, resuspended in 12 mis of TE buffer and then the 
plasmid DNA separated out by a CSCI2 gradient as follows:
12ml of resuspended DNA were mixed with 12.9g CSCI2 and 0.8ml of ethidium bromide 
(stock solution lOmg/ml). The refractive index was adjusted to 1.39 with CSCI2 or TE 
buffer and the solutions transferred to centrifuge tubes. After centrifugation at 40,000rpm 
for 48 hours at 20®C in an ultracentrifuge, the closed, circular plasmid DNA was removed 
using a UV lamp and a blunt ended needle. The ethidium bromide was removed by 
vigorously mixing equal volumes of sample and CSCI2 saturated isopropanol, removing 
the top red layer and repeating the process until the top layer was clear. Plasmid DNA 
was precipitated in glass Corex tubes by adding 3M NaOAc - 1/10 the volume, 100% 
ethanol - 2.5 volumes and leaving the samples overnight at -20°C. The precipitates were 
pelleted by centrifugation at 8000 rpm for 30 min, washed with 70% ethanol, vacuum 
dried and resuspended in 0.5ml TE buffer to be stored at -20^ >C.
2.2.5d Restriction endonuclease digestion o f  DNA.
For every Iqg of plasmid DNA to be digested, 1 unit of the appropriate restriction 
enzyme was added in the presence of reaction buffers supplied by the manufacturers. The 
total reaction volume did not exceed lOp.1 and the ratio of enzyme to volume was 1:10. 
The samples were incubated for 1 hr at 37^C before the reaction was terminated by 
addition of DNA loading buffer and the samples run on an agarose gel (see section 
2.2.7a).
Genomic DNA (25-50qg) was digested in the same way but in a proportionally larger 
volume to a maximum of lOOql, and incubation was at 37°C overnight.
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2.2.5 e Extraction o f  Genomic DNA from  cell lines.
Genomic DNA was extracted using a method described by Laird et ai, 1991. Briefly, 10^ 
cells were washed with PBS and then digested with 0.5 ml of lysis buffer at 37^0 for 2 hrs 
with agitation.
Lvsis buffer: lOOmM Tris HCl (pH8.5)
5mM EDTA (pH8 )
0.2% SDS 
200mM NaCl 
lOOqg Proteinase K per ml 
One volume of isopropanol was added to the lysate and the sample swirled until 
precipitation was complete. The aggregated precipitate was lifted from the solution and 
washed with ethanol before being dissolved in TE by agitation at 55®C for 2 hrs. The 
concentration was determined by spectrophotometer and the samples stored at -20^C.
2.2.5f Total and Poly A RNA extraction from  cell lines.
Total RNA was isolated using the RNAzol B method, according to the manufacturer's 
instructions. Briefly, 10^ - lO'^  cells were pelleted, washed in ice-cold PBS, lysed with 0.2- 
2 ml RNAzol B and the RNA solubilised by passing the lysate through a pipette a few 
times. Chloroform was added to 1/10 the volume, the tube was shaken vigorously for 15 
seconds, left on ice for 5 minutes and then centrifuged at 12,000g / 4^C for 15 minutes. 
The colourless upper aqueous phase (where the RNA is found) was removed from the 
blue phenol-chloroform phase. To precipitate the RNA, the aqueous phase was added to a 
tube containing an equal volume of ice-cold isopropanol and the sample was stored at - 
20^C overnight. The RNA was then pelleted, washed with 70% ethanol, air-dried and 
resuspended in 20-50ql of DEPC-treated dH2 0 . Sample concentrations were determined 
by spectrophotometer readings on 1 /2 0 0  dilutions with samples having a 260/280 ratio 
greater than 1.9.
PolyA mRNA obtained using the PolyATract mRNA Isolation System TV according to 
manufacturer's instructions. Briefly, 0.1 -l.Omg of total RNA were brought to a final 
volume of 500ql in RNase-Free water. The RNA was denatured at 65^C before the 
biotinylated-oligo(dT) probe and 20xSSC were added. The annealing mixture was cooled 
at room temperature while the streptavidin-paramagnetic beads were washed with 
O.SxSSC. The contents of the annealing reaction were added to the beads and incubated 
for 10 minutes. After several washes with O.lxSSC, the mRNA was eluted with a total of 
250ql of RNase-free water and the concentration and purity determined by 
spectrophotometer.
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2.2.6 Polymerase chain reaction (PCR)
2.2.6a Oligonucleotide preparation
Designed oligonucleotides were synthesised on an Applied Biosystems mode 381A DNA 
synthesiser. After incorporation of the final nucleotide, the 5' methoxy-trytil group was 
left in place to allow efficient purification of the oligonucleotides on trytil affinity columns. 
Elution from the synthesis resin and removal of side chain protective groups was achieved 
by overnight incubation in 2ml of concentrated ammonia solution (29%) at 55°C. The 
Cruachem trytil affinity columns were washed with 2ml of concentrated acetonitrile and 
then 2ml of 2M triethylamine acetate pH7.0 before the oligonucleotide samples were 
added. The sample was passed through the column twice to ensure efficient capture. 3ml 
of dilute ammonium hydroxide in water (1:10), 2ml of MiUiQ water, 2ml of 2% 
trifluoroacetic acid and then 2ml of MilUQ water were flushed through the column to 
remove any unbound material. The purified oligonucleotides were eluted with 1ml of 20% 
acetonitrile and the DNA lyophilised in a Speedivac before being resuspended in 50|ul of 
MilliQ water and stored at -20^C.
The following oligonucleotides were designed, produced and used as primers in PCR 
reactions to examine the appropriate gene expression in various cell lines:
CD21a 5’-CCT ATG ATC CAO AAT GGA CAT CAC-3'
CD21b 5’-AGA TTT ACA GCG TGC CTC TTC ACA-3'
CD23a 5'-GCA GCT GAA CAG CAG AGA TTG AAA-3’
CD23b 5’-TGC CCT TGC CGA AGT AGT AGC ACT-3’
c-fos a 5'-TCC AAC CGC ATC TGC AGC GAG CA-3'
c-fos b 5’-GAC AGG CGA GCC CAT GCT GGA GAA-3’
2.2.6 c Reverse‘■transcriptase PCR Amplification
The Perkin-Elmer Cetus GeneAmp RNA PCR kit was used to detect and analyse gene 
expression at the RNA level. This involved reverse transcription of total RNA to cDNA 
with subsequent amplification of the cDNA by PCR with AmpllTaq DNA Polymerase.
For the reverse transcription step, a master mix was prepared as follows : 5mM MgCl2 , 
IxPCR buffer II, ImM of dCTP, dGTP, dATP and dTTP, IqM  RNase inhibitor, 1 unit/ml 
of reverse transcriptase, and 2.5p.M random hexamers. To 18jul of this mix was added lp.g 
of the appropriate total RNA in a volume of 2\x\. To reduce evaporation, the mix was 
overlaid with lOOpl of mineral oil and to allow extension of the hexameric primers by 
reverse transcriptase, they were incubated at room temperature for 10 minutes. The tubes 
were incubated at 42^C for 15 minutes, 99°C for 5 minutes and 5°C for 5 minutes to 
achieve reverse transcription. To each reaction tube, 78p.l of a prepared PCR master mix
63
(2mM MgCl2 , IxPCR bufferll, 2.5 units/lOOpl of Amplitaq DNA polymerase and water 
to a final volume of 78p.l per sample) was added along with the appropriate "upstream" 
and "downstream" primers (as detailed on figures) each at a final concentration of 0.15|uM 
and sterile dH2 0  was added to make the total reaction volume lOOpl The tubes were 
spun briefly in a microcentrifuge and then PCR ampHfication was carried out in a Perkin 
Elmer Cetus DNA Thermal Cycler as follows:
2  minutes at 94°C for 1 cycle
1 minute at 94®C,1 minute at 55®C and 1 minute at 72®C for 35 cycles 
10 minutes at 72°C for 1 cycle 
storage at 5®C until retrieval
The samples were examined by gel electrophoresis (section 2.2.7a), purified (section 
2,2.7b) and then probed in a Southern blot (section 2.2.7c) to demonstrate the presence or 
absence of specific products.
2.2.7 Nucleic acids - separation, purification and hybridisation.
2.2.7a Agarose ge l electrophoresis.
Non-denaturing 0.8% (w/v) agarose gels were used to visualise DNA fragments of 
>200bp. Agarose was dissolved in 50ml (mini-gel) or 200ml (maxi-gel) of IxTBE buffer 
(lOx stock contains 108g Tris HCl, 55g boric acid and 9.5g of EDTA in 1 litre of dH2 0 ) 
for fragment resolution or IxTAE (lOx stock contains 48.8g Tris, 11.4ml glacial acetic 
acid and 40ml of 0.25M H9TA pH8.0 in 1 litre of dH2 0 ) for DNA purification, in the 
case of restriction fragments. Ethidium bromide was added to a final concentration of
0.4jug/ml. TAE gels were set at 4°C and TBE gels at room temperature. Electrophoresis 
buffer was the same as that used in gel formation. Prior to loading, the DNA samples were 
mixed with 3|ul of DNA loading buffer (0.25% bromophenol blue and 30% glycerol in 
dH2 0 ) and then electrophoresed at l-5V/cm with the appropriate sized DNA markers. 
The DNA was visualised on a 312nm transiUuminator.
2.2.7b Purification o f  DNA restriction fragm ents
To purify DNA fragments from low melting point TAE agarose gels, a Promega Magic 
Miniprep DNA purification system was used. The fragment of DNA was cut out with the 
gel and the agarose melted in an Eppendorf tube before the addition of 1ml of DNA 
purification resin. After vortexing for 1 minute, the resin with the bound DNA was drawn 
slowly through a mini-column with a syringe. The column was washed with 2ml of 70% 
isopropanol, the tube microfuged for a few seconds to remove residual wash solution, and 
then left at room temperature for 10 minutes to allow evaporation of isopropanol. Bound 
DNA was eluted with 50|ul of dH2 0  at room temperature for 1 minute and the eluate
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collected by microcentrifuge for 20 seconds. The purified fragments were analysed by gel 
electrophoresis and stored at -20^C.
2.2.7c Southern Blot Analysis
Genomic DNA was digested with either BamHI, HIND III or ECoRI restriction enzymes 
(see section 2.2.5d). After digestion, samples of 20pg per well were size fractionated by 
electrophoresis on 1% agarose / TBE gels at a constant 30V (see section 2.2.7a). Transfer 
of the DNA onto Hybond N+ membrane was achieved under vacuum (50-60 mbar 
pressure). Once the gel was on the vacuum blotter and the edges sealed with agarose to 
ensure a vacuum, it was treated to depurinate and denature the DNA and allow transfer to 
the nylon. After each step, the solution was removed from the blotter before addition of 
the next one. The steps used were as follows :
1. 0.25M HCl for 30-45 min (until bromophenol blue of the dye front turned yellow).
2. 0.5M NaOH / 1.5M NaCl for 30-45 min.
3. 3M NaCl / 0.5M Tris pH8  for 30-45 mins.
At this point the gel was completely covered with 20xSSC (3M NaCl, 0.3M sodium 
citrate, pH 7.0) and transfer was continued for 1.5 - 2 hrs. After the transfer, the 
membrane was UV cross-linked in a Stratalinker 1800.
2.2.7d Northern blot analysis
Total RNA was loaded at 20-30|ug/well and polyA RNA loaded at 3-6[ug/well. Before 
loading, volumes of approximately 5 pi were mixed with 3 volumes (15 pi) of RNA loading 
buffer (350pl formaldehyde, Ipl formamide, 150pl DNA loading buffer, lOpl ethidium 
bromide [stock lOmg/ml] and 200pi 5x MOPS buffer containing O.IM MOPS, 40mM 
CHgCOONa and 5mM EDTA, pH7.0) and heated for 15 minutes at 65°C. The samples 
were then loaded onto a 150ml flat-bed 1% (w/v) agarose gel containing 30ml of 5x 
MOPS buffer and 26.3ml of formaldehyde. The electrophoresis buffer was Ix MOPS 
buffer and this was recirculated during an overnight run at 30V. The gel was washed in 
dH2 0  for 15 minutes prior to blotting to remove the formaldehyde. RNA was transferred 
to nylon membrane (Hybond N-t) either by traditional overnight capillary blotting 
(described by Sambrook et al. , 1989) or by 1V2 hours of vacuum blotting, both methods 
using 20xSSC buffer. The RNA was UV-crosslinked using a UV Stratalinker 1800 and 
the positions of 18S and 28S ribosomal RNA were marked. Hybridisation to specific 
probes was carried out as described in section 2.2.7.
65
2.2.7e Pulse Field Gel Electrophoresis
The method for nmnmg pulse field gels was adapted from the LKB 2015 Instruction 
Manual from Pharmacia.
i) Preparation of agarose blocks- DNA was prepared from cells suspended in agarose 
blocks to prevent shearing. 10^-10^ cells (approximately 0.6-6pg of DNA) were added to 
each block (ensuring same number of cells in all samples) after they had been washed with 
ice-cold PBS to remove any traces of serum. Cells were resuspended in approximately 
50pl of L-buffer (O.IM EDTA pH8.0, O.OIM Tris Cl pH7.6, 0.02M NaCl) and then 50pl 
of 1 .2 % low melting point agarose in PBS (equilibrated to 45°C) were added. The lOOpl 
sample was pipetted into the plastic block mould provided and allowed to solidify for 2 0  
minutes. Once solidified, the blocks were pushed out into a universal containing 1ml of 
Proteinase K digestion buffer (lOOmM EDTA pH8.0, 0.2% (w/v) sodium deoxycholate, 
1% (w/v) sodium lauryl sarcosime, 2mg/ml Proteinase K) and incubated at 55°C for 24- 
48 hrs. After incubation, the blocks were stored at 4^C for 1 hour to firm the agarose and 
then they were washed 4x30 minutes in Wash buffer (20mM Tris pH8.0, 50mM EDTA) 
on a shaker.
ii) Pulse field gels- A 200ml 0.8% agarose / TBE solution was prepared and equilibrated 
to 42°C. To load the gel, the DNA blocks were placed onto the teeth of the comb and 
then the comb placed in position in the 20x20 cm gel mould. The cooled agarose was 
slowly poured into the gel mould to cover the blocks. After the gel had set, the comb was 
removed and the blocks sealed with the remainder of the agarose. 2 litres of 0,25x TBE 
were prepared, poured into the pulse field tank and the thermostatic circulator was run for 
30 minutes to cool the buffer to 14®C before initiating the run. The gel was removed from 
the frame, clipped into the tank and then the apparatus programmed with the desired 
settings - 16 hr run with 30 second pulses of 6 V/cm. After the run, the gel was removed 
and stained in 0.4qg/ml ethidium bromide in 0.25x TBE for 20-30 minutes and then 
washed for 2 0  minutes (or as long as necessary) in dH20  before being photographed under 
UV light.
2.2.7f Radiolabelling o f  cDNA probes.
For Southern and Northern blot analyses, a[^^P]dCTP labelled DNA fragments were 
produced using the random priming technique. An Oligo-labelling kit (Pharmacia) was 
used to synthesise new cDNA strands in the presence of radio actively labelled dCTP. For 
each probe, 50-100ng of appropriate DNA, in a volume of 34ql with dH2 0 , was linearised 
by boiling, cooled on ice and then lOql of reaction buffer (containing random primer 
sequences, dATP, dGTP and dTTP, at the required salt concentrations) were added along 
with 5ql of oc[^^P]dCTP and Ipl of Klenow fragment. The reaction was incubated at 
37®C for 1 hour. After incubation was complete, the unincorporated nucleotides were
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37®C for 1 hour. After incubation was complete, the unincorporated nucleotides were 
removed by centrifugation at 2500 rpm for 4 min through a column made of Sephadex 
G50/TE (pHS.O), supported by glass wool, in an Eppendorf tube. The unincorporated 
nucleotides remained in the beads while the labelled probe was collected in a clean 
Eppendorf. The degree of cd^^P]dCTP incorporation was determined by analysis of Ipl 
aliquots in a Beckman LS5000CE counter and was 1-2 x 10^ dpm/pg for each probe. The 
probe was boiled for 10 mins, placed on ice for 5 min and then added to the hybridisation 
solution,
2.2.7g Hybridisation with ^^P~Labelled cDNA
2.2.7g-l Southern blots were hybridised using 10 - 20ml of Rapid-Hyb buffer 
{Amersham\ used as per manufacturer’s instructions), in Hybaid bottles. Pre-hybridisation 
was performed at 42®C for 30 minutes, in a Hybaid oven, prior to addition of the ^^P- 
labeUed cDNA probe (see section 2.2.7f) for 1.5 hours.
2.2.7g-2 Northern blots:- the nylon membranes were pre-hybridised at 42®C in Hybaid 
bottles or in plastic bags for 6-16 hrs in hybridisation buffer (5x SSPE, lOx Denhardt's, 
2% SDS, 50% deionised formamide and Img/ml yeast RNA). Fresh hybridisation buffer 
was then added and the blot hybridised for 16 hrs with the relevant ^^P-labelled cDNA 
probe (see section 2.2.7f) at 42®C.
Denhardt's solution (50X) 5g Ficoll, 5g polyvinyl pyrrolidone, 5g 
BSA plus H?0 to final volume 500ml
SSPE (20X) 174g NaCl, 27.6g NaH2P0 ^-2 H2 0 , 7.4g 
EDTA plus HpO to 1 litre, pH7.4 |
After hybridisation, both Southern and Northern blot membranes were washed as 
follows:-
2 X SSC / 0.1% SDS 4 washes of 15 min. each at room temperature
1 X SSC / 0.1% SDS 1 wash of 20 min at 65®C
0.1 X SSC / 0.1% SDS 1 wash of 15 min at 65®C
The membranes were then exposed to Kodak XAR-5 füm for 1 to 7 days at -70®C, with
an intensifying screen.
After hybridisation, the membranes were stripped by placing them into a solution of 0.1% 
SDS at 100®C and leaving the solution shaking until it had cooled to room temperature. 
The membranes were reprobed with GAPDH cDNA, as a loading control.
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2.2.8. Isolation and Purification o f  novel receptor
The approach chosen to purify the novel CD 23 receptor was to biotinylate the surface 3
proteins of SMS-SB cells, prepare a cell lysate, and then run the lysate over a pre­
adsorption column (to reduce non-specific binding) followed by a CD23 affinity column. |
Any bound material was eluted, dialysed, run on an SDS-PAGE gel. Western blotted to 
nylon membrane and probed with streptavidin-peroxidase to be detected by ECL.
■ 4I2.2.%2l Biotinylation o f  cell surface proteins
10^ cells were harvested and washed with 50ml of PBS. The cells were resuspended at 
10^ cells/ml in 5mM sulfosucctnimidyl-6 - (biotinamido) hexanoate (NHS-LC-Biotin) / PBS 
and incubated on a roller for 30 - 60 minutes at room temperature, in the dark. The cells
' Iwere then washed three times with 50ml of ice-cold PBS before a cell extract was made.
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2.2.8b Preparation o f  cell lysate
2.2.8 b-1 Small scale cell lysate
After biotinylation, the cells were resuspended in 15ml of Extraction buffer (50mM 
HEPES, 5mM CaCl2 , 140mM NaCl, 1% n-Octyl-^-D-glucopyranoside (OGP), ImM 
PMSF, ImM TLCK). The mixture was vortexed for approximately 4 minutes before being 
ground m a glass homogeniser twenty times, to break up the cells. The extract was left on 
ice for 30 - 60 minutes then centrifuged at 100,000g for 30 minutes at 4®C, before the 
supernatant was added to the pre-adsorption column.
2.2.8b-2 Large scale cell lysate
After biotinylation, the 10^ biotinylated cells were mixed with 1-5x10^ non-biotinylated 
cells, produced in large scale spinner cultures (see section 2.2.1c). The cells were 
resuspended in 50-100ml (depending on the viscosity of the mixture) of Extraction buffer 
before being homogenised using a Polytron homogeniser, passaged twice through a |
French Pressure Cell, sonicated and then left on a roller, at 4°C, for 2 - 1 8  hours. Before %
the extract was loaded onto the pre-adsorption column it was centrifuged at 45K, 4®C, 
for 45 minutes and the supernatant was collected.
2.2.8c Preparation o f  affinity columns
Since 25 kD CD23 is an acidic protein (pi = 5.3), Affigel-15 was used to produce an 
affinity column. The protein was dialysed overnight with 6 - 8  kD cut-off tubing, against 2 
litres of coupling buffer (O.IM MOPS pH7.5). The reaction volume for the coupling was
1.5 - 4.5 mi of protein per ml of resin and the ratio was 3mg protein per ml resin. The 
resin was mixed and then added to a scintered glass funnel to remove the liquid phase.
Taking care to avoid drying out the resin, it was washed with 3 volumes of ice-cold dH2 0  
and transferred to a polypropylene tube where the prepared protein was added. After
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overnight incubation on a roller, the unbound protein was removed with coupling buffer 
on a scintered glass funnel - the eluate was retained. The remaining active sites of the resin 
were blocked by incubation for 1 hour at room temperature with O.IM Ethanolamine 
pH8.0 ( five X column volumes) and then the resin was washed in IxPBS. Pre-elution was 
performed with two x column volumes of 3M NH4SCN followed by a wash with PBS. 
The unbound protein, eluted material and all the washes were pooled and dialysed 
overnight against 5 litres of PBS before spectrophotometer readings were taken to 
determine the coupling efficiency. BSA / IgG or BSA alone columns were used as pre­
affinity columns to remove proteins which would bind non-specifically to the CD23 
column (as detailed in figure legends). These were made with Affigel-10 resin and BSA / 
IgG (3:1) to give 3mg protein per ml of resin.
2.2.8d CD23 affinity chromatography
2.2.8d-l Small scale affinity columns
Pre-adsorption affinity column - to remove a 0.5ml sample of BSA/IgG or BSA column 
resin from the tube, 2ml of PBS were added and the tube was tapped untd a 'slurry' had 
formed. An approximately 1ml sample (depending on the initial amount of resin) was 
transferred to a clean 15ml Falcon tube, centrifuged at lOOOrpm for 2 minutes and the 
PBS removed. 2ml of Extraction buffer were added and mixed with the resin before it was 
centrifuged, as before, and the process with extraction buffer was repeated; the 2 ml of 
extraction buffer was removed after centrifugation. The pre-adsorption column was now 
equilibrated and ready for use.
The supernatant from the ceU extract preparation (section 2.2.8b-1) was loaded onto the 
resin and the tube was sealed, put onto a roller at 4°C, and left overnight.
After incubation, the resin was centrifuged, as before, and the unbound material removed 
with a pipette. The final fraction of extract was removed with a needle, taking care not to 
aspirate any resin. The unbound material was retained to load onto the CD23-affinity 
column resin.
C023 affinity column - the column resin was equilibrated, as described for the pre­
adsorption column, and the unbound material from the pre-adsorption was added to the 
CD23 column. The column was incubated overnight at 4°C, as described for the pre­
adsorption column. Again, after centrifugation, the unbound material was collected and 
retained to load onto the gel.
Elution of bound material - the resin was washed at 4°C, on a roller, as follows: 1 x 1 5  
minutes with 14ml of Extraction buffer; Ix 20 minutes and 2 x 10 minutes with Wash 
Buffer 1; 1 x 10 minutes with Wash Buffer 2.
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Wash buffer 1:50mM HEPES
5mM CaCl2 
0.5M NaCl
plus 0.1% Triton X 100 (for pre-adsorption columns) 
or 30mM OGP (for CD23~affinity columns).
Wash Buffer 2: 5 OmM HEPES
5mM CaCl2 
0.5M Urea
plus 0.1% Triton X 100 (for pre-adsorption columns) 
or 30mM OGP (for CD23-affinity columns).
After the washes, the bound material was eluted by resuspending the 0.5ml of resin in 
0.5ml of SDS-PAGE sample buffer (as described in 2.2.8e-l). The sample was boiled for 
5 minutes, centrifuged at 1000 rpm for 3 minutes, and then the 0.5ml sample was removed 
to be run on the gel.
Since the same pre-adsorption and CD23 columns were used for each cell line sample, a 
small sample of the resin was removed after each elution, and boiled in SDS sample 
buffer. This sample was run on a Phastgel and a silver stain was performed, using the 
automated PhastGel system, by Pharmacia. From the silver stain it could be determined 
that the resin was clean before addition of the next cell sample.
2.2.8d-2 Large scale
Pre-adsorption affinity column - 5ml of IgG/BSA resin were equilibrated with 
Extraction buffer, as described in section 2.2.8d-l, but in a Pharmacia XK26 column. The 
prepared cell extract (50ml) (section 2.2.8b-2) was added to the column, and the column 
connected to a pump to allow recirculation of the extract. The recirculation was carried 
out at 4°C, overnight, before the unbound material was collected a measuring cylinder to 
add to the CD23-affinity column.
CD23 affinity column - 5ml of CD23-affmity resm were equilibrated, as described above. 
The unbound material from the pre-adsorption column was added to the CD23-column 
and recirculated overnight, at 4°C, as described above. After recirculation, a measuring 
cylinder was used to collect the unbound material as it was pumped through the column.
Elution - for both columns, the resin was washed whilst in the column:- 100ml of 
Extraction buffer (20 x column volume) were pumped through the column for 30 minutes; 
100ml of Wash buffer 1, flowed through for Ihour; 100ml of Wash buffer 2, flowed
through for 1 hour. The progress of the washes was followed with a Pharmacia, UVl 
Single Path Monitor.
To elute the bound material, five x column volumes (15 ml) of elution buffer were added 
to the column, and the elution followed using the UV single path monitor.
Elution buffer:- lOOmM Tris pH8.5 
20% Ethyleneglycol 
0.5M NaCl 
3M NPI4SCN 
plus 0.1% Triton X 100 (pre-adsorption column)
or 30mM OGP (CD23-affinity column)
The fractions which contained protein were collected and dialysed (8-12kDa cut-off) 
overnight against 500ml of the following buffer:-50mM HEPES, 2mM CaCl2 , plus either 
0.1% Triton X 100 (pre-adsorption columns) or 30mM OGP (CD23 columns). After 
dialysis, the sample was concentrated from 50ml to approximately 1ml with a Filtricon 
centrifuge concentrator. The concentrators were filled with O.IM NaOH for 10 minutes 
then washed with H2O, before the samples were loaded and centrifuged at 6 K until the 
volume was sufficiently reduced. 40pl of each sample was removed and mixed with lOpl 
of SDS-PAGE non-reducing sample buffer (see section 2.2.8e-l).
2.2.8e SDS-PAGE gel electrophoresis, Western blotting and ECL
detection system
2.2.8e-l SDS-PAGE sample buffer (non-reducing) - 25mM Tris pH 6 .8 , 20%
glycerol, 10% SDS, 5mM EDTA, bromophenol blue - 1 part sample buffer was added to
four parts sample, before it was loaded onto the gel. A 7.5% acrylamide gel was prepared 
using a Biorad mini-gel gel rig; the gel was made as follows:- 25% acrylamide (30% 
acrylamide / 0.8% bis-acrylamide, therefore final percentage is 7.5%), 0.375M Tris pH8 .8 , 
0.1% SDS, 0.5% ammonium persulphate and 0.05% Temed, made up to 10ml with 
dH2 0 . The gel was set with a methanol overlay before a stacking gel (0.125M Tris, 
pH6 .8 , 0.1% SDS, 17% acrylamide (as above), 1% ammonium persulphate, 0.13% 
TEMED) was poured. After 40pi of each sample was loaded, the gel was run at 200V, 
maximum mA for 45 minutes in running buffer (1% SDS, 30g/l Tris, pH 6 .8 , 144g/l 
Glycine).
2.2.8e-2 Western blot; the protein was transferred from the gel to nitrocellulose
(Biorad, Transblot, 0.45pm), in transfer buffer (lOmM 3-(cyclohexylamino)-l-propane 
sulphonic acid (CAPS), 10% methanol) at 90V, 300mA for 25 minutes. After transfer, the 
nitrocellulose was incubated for 1 hour in blocking buffer (IxPBS, 0.1% Triton xlOO, 1% 
caesin, 1% gelatine), then washed for 15 minutes in PBS/0.05% Tween.
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For the CD21 Western, 10ml of a cocktail of primary anti-CD21 MAbs (loBla (8 pg/ml), 
CR2 (8 pg/ml), MCA664 (8 pg/ml), THB5 (20pg/ml) and BU33 (lOpg/ml) in PBS / 
0.05% Tween 20) were added to the blot for 4 hours at room temperature, on a shaker. 
The blot was then washed 3 times with blocking buffer (over 1 hour) before 20ml of 
4pg/ml goat anti-mouse peroxidase IgG (in PBS/0.05% Tween 20) was added for 1 hour, 
at room temperature, on a shaker. The blot was washed three times with blocking buffer 
over 1 hour and then washed twice with PBS / 0.05% Tween 20 for 10 then 5 minutes.
For Western blots of biotinylated proteins, the blot was blocked (as described for the 
CD21 Western) and then put into a bag with 10ml of 2pg/ml streptavidin-peroxidase in 
PBS /  0.05% Tween 20 for 1 hour, at 37°C, on a shaker. Excess streptavidin-peroxidase 
was kept to be re-used, and the blot was washed three times with blocking buffer (over 1 
hour) and then twice with PBS / 0.05% Tween 20 for 10 then 5 minutes.
2.2.8e-3 ECL detection system- To develop the blots, an Amersham, Enhanced 
chemilluminescence (ECL) kit was used, according to manufacturers instructions. 10ml of 
Solutions 1 and 2 were mixed in a dish, and the blot submerged for 1 minute before excess 
hquid was removed with a tissue and the blot wrapped in Saran wrap. The blot was 
exposed to Fuji RX füm for between 1 second and 20 minutes, depending on the strength 
of the signal, to detect antibody binding.
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Chapters 3, 4 and 5 
Results
Results 
Chapter 3
Autocrine growth factor production by SMS-SB cells 
3.1 Introduction
The proliferation and differentiation of B lymphocytes is under the control of numerous 
growth factors; most act in a paracrine fashion but some are known to be produced by the 
B cells themselves and to have autocrine effects. Most examples of B cell autocrine 
growth factors come from EBV-transformed or neoplastic B-cell lines, although it is now 
apparent that normal cells, if appropriately activated and cycling, produce cytokines which 
act in an autocrine fashion to promote their growth {Blazar et aL, 1983; Gordon, 1985; 
Jurgensen et a i, 1986). Autocrine factor production has been implicated in the 
development of tumours, allowing cells to grow autonomously and avoid normal growth 
regulation, but it is apparent that production of an autocrine factor is not sufficient for 
transformation (Young et al., 1991), Most of the information regarding autocrine growth 
factors comes from studies of mature B cells and there is very little evidence of a role for 
autocrine growth regulation m the early stages of B cell development.
The data presented in this chapter demonstrate a role for autocrine factor production by a 
pre-B cell line, SMS-SB, and attempt to identify the cytokine responsible.
The cells are derived from a patient, SB, whose acute leukaemia had the very unusual 
characteristic that the leukocytes were actively dividing in her blood and, when leukaemic 
cells were taken from the patient, they grew spontaneously in culture without going 
through a crisis phase. These cells are routinely cultured in serum-containing and protein- 
free media without the addition of exogenous mitogens. The results demonstrate that 
SMS-SB cells are density-dependent for growth, and that conditioned media from SMS- 
SB cultures can promote the growth of those cells cultured at low cell density - data 
which demonstrate the production of an autocrine growth factor by SMS-SB cells.
3.2 Results
3.2.1 Phenotype o f  SM S-SB  cells
SMS-SB cells express the following B cell antigens: CD5, CD19, CD22, CD45; and are 
MHC (HLA-DR) class II positive. The cells are CDIO- and CD20-negative with only low 
expression of the enzyme TdT. They have cytoplasmic \x chains but no surface 
immunoglobulin and, as such, have a phenotype similar to that of most normal pre-B cells 
(see table 5.1),
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3.2.2 SM S-SB  cells proliferate in protein-free media
SMS-SB cells proliferate under conditions of low serum and so it was decided to 
investigate the growth characteristics of SMS-SB cells in a medium completely devoid of 
protein - PFHMII. The graphs of figure 3.1 compare cell number (in cells/ml x 10^) 
against days of incubation, from initial seeding densities of 1 0 ,^ 5x10^ and 1 0 ^ cells per 
ml, in 10% FCS/DMEM (panel A) and protein-free (panel B) grown cultures. The 
doubling time of the cells is approximately 48 hours, at all seeding densities and, initially, 
the cells appear to grow at approximately the same rate in serum-containing and protein- 
free conditions. At an initial seeding density of 10^ cells, the number of cells doubles after 
48 hrs but the growth for the subsequent 3 days is slower than that of cells seeded at 
higher density. The main difference between SMS-SB cell growth in protein-free and 10% 
ECS medium is the final concentration to which the cells grow. In protein-free medium, 
the cells grow to a maximum of 2.9 x 10^ cells/ml whereas in 10% FCS medium they 
reach 4.3 x 10^ cells/ml, suggesting that essential nutrients in protein-free medium are 
depleted more quickly than in 10% FCS medium. However, the growth of SMS-SB cells 
is not adversely affected by culture in protein-free medium and this medium was chosen 
for further experiments because it eliminates the possibility of synergistic reactions 
between serum proteins and cytokines being tested.
3.2.3 SM S-SB  cells are density-dependent fo r  growth
SMS-SB cells were seeded at various initial densities to examine their ability to proliferate 
in protein-free media. The data in figure 3.2 represent incorporation of [^H]-thymidine 
([^H]-TdR) by cells seeded at 1 0 ,^ 10^, 10^ and 10  ^ cells per well and incubated for 1, 2 
or 3 days. SMS-SB cells seeded at 10^ and 10^ cells per well continue to grow at the 
characteristic rate, with a two-fold increase in incorporated [^Hj-TdR after 2 days. Cehs 
seeded at 1 0 0 0  cells/well show a lag period of 2  days and then begin to proliferate; cells 
seeded at 100 cells/well do not proliferate and actually show decreased [^H]-TdR 
incorporation, suggesting that they are dying. Thus, SMS-SB cells are density-dependent 
for growth. The most likely explanation for these observations is that SMS-SB cells 
produce an autocrine growth factor which is required at a minimum concentration to 
maintain growth of the cehs. The presence of 10^, lO'^  cells per well appears sufficient to 
maintain the concentration of the autocrine factor, whereas the lag phase seen with 1 0 0 0  
ceUs/weU may be explained by the time taken for the cells to produce a sufficient quantity 
of the autocrine factor to allow proliferation. Apparently, at 100 ceUs/weU, there is not 
enough autocrine factor produced to 'condition' the media and the cells lose the abihty to 
grow autonomously.
3.2.4 SM S-SB  cells produce an autocrine growth fa c to r
To test the hypothesis that SMS-SB cells produce an autocrine growth factor, medium 
from cultures of SMS-SB cehs grown at the 'normal' ceh density of 5x10^ cells/ml (known
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Fig. 3.1. SMS-SB cells grow in protein-free medium.
For each of the experiments illustrated in figure 3.1., SMS-SB cells were harvested from 
log-phase cultures in either 10% FCS/DMEM (panel A) or PFHMII (panel B) and seeded 
at 10^ (□), 5x10^ (#) and 10^ (O) cells per ml in the same medium. The number of cells 
per ml in each culture was counted every day for 5 days of incubation, using trypan blue 
to determine the viability of the cells. The graphs compare cell number against days oi 
incubation, for the different initial seeding densities.
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Fig. 3.2 SMS-SB cells are density dependent for growth
SMS-SB cells were harvested from log-phase cultures in PFHMII and seeded at 10^, 10^, 
10^ and 10^ cells per well, as shown in the legend, in the same medium. Cultures were 
pulsed with 0.3p,Ci/well [^H]-TdR for six hours prior to harvest, on days 1,2 and 3. Au| 
cultures were established in triplicate and the error bars represent the standard deviation 
of the triplicate data. This is a single experiment, representative of four independent 
repeats. I
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Fig.3.3 SMS-SB cells produce an autocrine growth factor
SMS-SB cells were seeded at 2500 cells per well in PFHMII; PFHMII conditioned 
medium (as described in materials and methods) was included at 1 , 5 , 1 0 , 15 and 2 0 % of 
the final culture volume of 100[xl. The cultures were incubated at 37°C for 48hrs and 
pulsed with 0.3pCi/weU [^H]-TdR for six hours prior to harvest. All cultures were 
established in triplicate, and the experiment is representative of more than five 
independent repeats. The error bars represent the standard deviation of triplicate data.
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Pig,3.4 Growth of SMS-SB cells in the presence and absence of 
conditioned medium.
The cells were prepared as described for figure 3.3; however, they were seeded in the 
culture wells at 1000, 2500 and 5000 cells/well, in a final volume of lOOpl. Cells were 
cultured in the presence and absence of conditioned medium (CM) at 20% of the final 
culture volume. The data legend illustrates which bar on the chart represents each seeding 
density (cells per well), and whether or not conditioned medium was present in the culture 
(+ CM). The cultures were incubated for 24, 48 and 72 hours, and pulsed with 
0.3pCi/well [^H]-TdR for six hours prior to harvest. All cultures were established in 
triplicate, and the experiment is representative of more than five independent repeats. The 
error bars represent the standard deviation of triplicate data.
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Fîg.3.5 [^H]-TdR incorporation by SMS-SB cells cultured at low cell 
density in the presence and absence of conditioned medium.
The experiment was performed as described in figure 3.4, but the cells were seeded at 
1Q2, 5x102,1 0  ^5x10^ and 10"^  cells per well. The cultures were harvested after a) 24 hrs 
and b) 72hrs, only. The graphs represent incorporation of [^Hj-TdR for various seeding 
densities of cells (in cells per well), with and without conditioned medium. The data 
legend illustrates which bar represents each initial seeding density (cell number per weU) 
and whether the cells were cultured in the presence of conditioned medium (+ CM). The 
cultures were pulsed with 0.3pCi/weU [^Hj-TdR for six hours prior to harvest. All 
cultures were established in triplicate, and the experiment is representative of four 
independent repeats. The error bars represent the standard deviation of triplicate data.
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as conditioned medium (CM), was added back to cells propagated at lower cell density 
and growth was compared in the presence and absence of conditioned medium. Figure 3.3 
shows a graph of [^Hj-TdR incorporation by 2500 cells, versus the final percentage of 
CM in the culture well, after an incubation period of 48 hours. CM augments the growth 
of the cells in a dose-dependent manner - in wells where the cells were cultured in fresh 
medium alone, there was a mean [^Hj-TdR incorporation of approximately 500 cpm 
compared with a maximum mean of 4500 cpm in wells where 20% CM was present. The 
data of figure 3.4 are from experiments where different numbers of SMS-SB cells were 
incubated in the presence or absence of conditioned medium for 1,2 or 3 days. The results 
demonstrate that CM promotes the growth of SMS-SB cells at 2500 and 5000 cells/well, 
although, at these densities, the cells can grow in media alone. At 1000 cells per weU, 
conditioned media appears to promote growth of the cells for 48 hours and then the [^H]- 
TdR incorporation decreases at 72 hours suggesting that the CM effect is short-lived. It is 
possible that the exogenous conditioned media has been depleted and the cells are unable 
to produce enough of the factor to condition their own media. At 2500 and 5000 cells per 
well, the exogenous conditioned media may have sustained cell growth long enough for 
the cells to produce the necessary concentration of CM and continue growth. If there is a 
lag when cells are unable to proliferate, between the initial seeding and the time when the 
minimum required concentration of CM is reached, it could explain why the addition of 
CM produces higher incorporation; it would remove the lag phase of growth and allow 
continued proliferation.
Conditioned media appears'to promote the growth of SMS-SB cells cultured at densities 
as low as 500 cells per well but if only 100 cells are seeded per well then even addition of 
CM cannot promote their growth (figure 3.5). It is likely that the exogenous CM is acting 
to ’save' the cells until they can produce sufficient autocrine factor to condition their own 
media. Presumably, cultures of 100 ceUs/well are unable to attain the required 
concentration of CM in 72 hours, before the exogenous CM is depleted and the cells can 
no longer proliferate.
Thus, SMS-SB are density-dependent for growth due to the production of an autocrine 
growth factor which, if present at a high enough concentration, allows them to grow 
autonomously under protein-free conditions.
3.2.5 Preliminary identification and characterisation o f  the autocrine grow th
factor
Initial studies to characterise the SMS-SB autocrine growth factor (SB-AF) involved the 
use of Centricon filters which allow concentration of molecules above a specific molecular i
weight. The autocrine activity can be concentrated over lOkDa, 30kDa and lOOkDa filters 
(figures 3.6, 3.7 and 3.8 respectively), suggesting that SB-AF is either a large protein of
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over lOOkDa in size or that it is a 'sticky' molecule which can bind to other proteins 
produced by SMS-SB cells and thus be concentrated above the lOOkDa filter. The data of 
figures 3.6-8 demonstrate the growth promoting effect of normal CM and how this effect 
is removed once the media is passed through various sized filters. If the material retained 
above the filters is added to the cells then it greatly enhances proliferation of the cells - 
above that seen with normal CM - presumably because the SB-AF has been concentrated. 
That SB-AF is actually removed from CM by the filters is shown by the graph 
representing the material contained in the filtrate. The material which has passed through 
the filters does not promote SMS-SB cell growth, indicating that the autocrine factor has 
been removed. To demonstrate that the filters themselves have no effect on the SB-AF, 
samples of the retentate and filtrate were mixed to reconstitute the CM. From the graphs 
it can be seen that reconstituted CM gives results almost identical to those of normal CM, 
showing that the activity is not altered by concentration/separation over the filters. 
Therefore, the SB-AF can be concentrated above an lOOkDa filter but gel filtration 
chromatography will be required to determine the native molecular weight of SB-AF.
One problem encountered during proliferation assays performed with SMS-SB cells in 
PFHMII is that addition of protein, for example BSA or HSA, promotes growth of the 
cells. As can be seen from figure 3.9, the protein effect does not occur until addition of 
approximately lOpg/ml of BSA and seems to plateau at 40-100pg/ml. It is possible that 
this effect contributes to the enhanced proliferation seen on addition of the Centricon 
retentâtes to SMS-SB cells, although the filters do appear to remove SB-AF, since 
filtrates alone have no growth promoting effect compared to normal CM.
In an effort to identify candidates for the SB-AF, a range of recombinant human cytokines 
were analysed for the capacity to promote the proliferation of SMS-SB cells cultured at 
low cell density in PFHMII (figure 3.10). The majority of cytokines tested had no ability 
to promote SMS-SB cell growth and gave a stimulation index of approximately 1, 
suggesting that they do not represent the SB-AF. IL-5 gave a stimulation index of 2.4, 
sCD23 gave a stimulation index of 5.6, and PDGF-aa, an index of 2.2. However, data 
from experiments performed by the Genetics Institute, Cambridge, Massachusetts, using 
cytokine bioassays and analysis of SMS-SB RNA, have shown that none of IL -la  to IL-7, 
or TNFa or |3, are actually produced by SMS-SB cells (data not shown); thus, IL-5 does 
not represent the SB-AF. The effect of sCD23 on SMS-SB cells will be discussed in 
chapter 4A. No analysis has been made for production of IL-10, IL-11, IL-13 or IL-15, 
although the recombinant forms of IL-11, IL-13 and IL-15 do not promote SMS-SB cell 
proliferation, in the range of concentrations tested (figure 3.10). The growth promoting 
effect of IL-10 on SMS-SB cells remains to be tested.
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Fig. 3.6 SMS-SB cell autocrine activity can be concentrated over a 
lOkDa filter.
Centricon, lOkDa molecular weight cut-off filters were used to concentrate the SMS-SE 
cell conditioned medium (as described in materials and methods). 48 hour proliferatior 
assays were set up with 2500 cells per well in a volume of lOOpl PFHMII (as described ir 
materials and methods) in the presence of 0, 1, 5, 10, 15 and 20% conditioned mediurr 
either: normal CM (O); retentate CM- material concentrated above the lOkDa filter-(#): 
filtrate CM-material which had passed through the filter-(open triangles); CM which had 
been reconstituted by mixing the retentate and the filtrate together (closed triangles). The 
cultures were pulsed with 0.3pCi/well [^Hj-TdR for six hours prior to harvest. AH 
cultures were established in triplicate, and the e>q)eriment is representative of three 
independent repeats. The error bars represent the standard deviation of triplicate data.
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F1g.3.7. SMS-SB cell autocrine activity can be concentrated over a 30kDa 
filter.
The experiment was performed exactly as described in the figure legend of figure 3.6 but a 
SOkDa cut-off Centricon filter was used to concentrate the conditioned medium.
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Fig.3.8 SMS-SB cell autocrine activity can be concentrated over a
lOOkDa filter.
The experiment was performed exactly as described in the figure legend of figure 3.6 but 
an lOOkDa cut-off Centricon filter was used to concentrate the conditioned medium.
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Fîg.3.9. Effect of protein upon [^Hj-TdR uptake by SMS-SB cells
A proliferation assay was performed using 2500 cells per well in PFHMII supplemented 
with increasing concentrations of bovine serum albumin (BSA). The graph represents the 
[^H]-TdR incorporation recorded after the cells were incubated for 48hrs in eithei 
medium alone or in PFHMII supplemented with increasing concentrations of BSA, from 
lOOpg/ml up to lOOpg/ml BSA (shown on a log scale). All cultures were established in 
triplicate, and the experiment is representative of three independent repeats. The error 
bars represent the standard deviation of triplicate data.
10000
I. 80003-co
?
S-8C
, i  6000-g
EtXpo.
4000
oood
ood
od o s ooo
Concentration of BSA (micrograms per ml)
85
Fîg.3.10. Effect of recombinant cytokines upon [^Hj-TdR uptake by SMS- 
SB cells
Proliferation assays were performed, using 2500 cells per well, in PFHMII supplementec 
with recombinant cytokines, as detailed on the bar chart. The individual cytokines were 
included at several concentrations, however, the data presented represents the effect ol 
50U/ml of each cytokine, in a final culture volume of lOOp^ l. The cultures were pulsec 
with [^H]-TdR for six hours prior to harvest at 24hrs and each culture was established ir 
triplicate. A stimulation index was calculated for each cytokine according to the 
equation:-
Mean cpm incorporated in presence of cytokine
Stimulation Index = ____________________________________
Mean cpm incorporated in absence of cytokine
Each experiment illustrated for an individual cytokine is representative of at least three 
independent repeats.
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3.2.6 PDGF- a candidate fo r  SB-AF
PDGF-aa is able to promote the growth of SMS-SB cells cultured at low cell density, 
and gives a stimulation index of approximately 2 (figure 3.10). This stimulation index is 
quite low, compared to the effect of soluble CD23 (discussed in chapter 4A), but the 
result is of great interest because SMS-SB cells are known to release PDGF-a chains and 
they also express PDGF-(3 receptors (Tsai et al., 1994). Thus, PDGF-aa is implicated as 
a candidate for the SB-AF. Figure 3.11 shows a dose-response titration of PDGF-aa 
action on the proliferation of 2500 SMS-SB cells/well after a 48 hour incubation. The 
cells grew at the characteristic rate after addition of PDGF-aa, with incorporation of 
[lH]-TdR at 48 hrs being twice the level recorded for cells in medium alone. The 
maximum response was seen on addition of Ing/ml PDGF-aa, which is within the normal 
concentration range for PDGF activity. Expression, at the RNA level, of the PDGF-A 
chain gene has also been demonstrated in another pre-B cell line, NALM-6 , which 
expresses the PDGF-A receptor and can bind PDGF-j3p, but the cells do not secrete 
PDGF-aa into the media (Tsai et at., 1994). Unfortunately, the action of recombinant 
PDGF, or SMS-SB cell conditioned medium, upon Nalm-6  cell proliferation (or vice 
versa) could not be examined because Nalm-6  cells do not grow in protein-free media are 
not density-dependent for growth.
To investigate whether PDGF is responsible for the autocrine activity present in SMS-SB 
cell conditioned media, samples of CM were pre-incubated with a neutralising anti-human 
PDGF at 4°C for 3 hours (with gentle agitation) before addition to 1000 cells/well in a 48 
hr proliferation assay (figure 3.12). Unfortunately, attempts to perform subtraction 
experiments by removing the antibodies, and any bound PDGF, from the CM prior to 
addition to the cells - using Dyna-beads with bound protein G - were unsuccessful 
because treatment of normal PFHMII with the beads made the media inhibitory for SMS- 
SB ceU growth (data not shown). It is possible that residual azide was present in the 
beads, although thorough washing did not rectify the situation.
The results of titrating anti-PDGF (which is able to neutralise human PDGF-a(3, -a a , and
-(3(3 forms) with a constant, sub-optimal amount (10% final concentration) of CM, in a {
proliferation assay, are shown in figure 3.12. If the mean [^H]-TdR incorporation due to
addition of antibody alone, is subtracted from the mean [^H]-TdR incorporation recorded
for a constant 10% CM plus anti-PDGF, the results suggest that anti-PDGF does remove
some of the SB-AF activity (see figure legend for calculation used). However, the results
are not significantly different to those observed on addition of 10% CM alone. The
protein-effect caused by addition of the antibody at concentrations of over lOpg/ml may
have affected the results, however, it is possible that the small inhibition of autocrine
activity is real but PDGF represents one of several molecules which comprise SB-AF. It is
also possible that PDGF has no real role to play, although the fact that the cells express
..i
Fig.3.11. Effect of PD G F-aa on [^H]-TdR incorporation by SMS-SB cells
Proliferation assays were performed, as described previously, to examine the effect o: 
PDGF-aa on the growth of SMS-SB cells. 2500 cells were seeded per wells in PFHMI 
supplemented with increasing concentrations of PDGF-aa (ng/ml), and incubated for At 
hrs; for the last 6 hrs prior to harvest, the cells were pulsed with [^Hj-TdR. Each culture 
was established in triplicate and the experiment is representative of four independen 
repeats.
I
I01Ç
0)C3IX
CO
1600
1400
1200
1000
800
600
400
0 0.01 0.02 0.05 0.2 1.0
Final concentration of PDGF-aa (ng/ml)
88
Fig. 3.12. Effect of anti-PDGF on SMS-SB cell autocrine growth factor
Proliferation assays were performed (as described previously) using 2500 cells per wel 
and incubated for 48hrs. A comparison was made of [^H]-TdR incorporation when ceUj 
were cultured in: 10% conditioned medium (CM) (#); increasing concentrations o: 
neutralising anti-PDGF-aa/PFHMll from 0 to 20p.g/ml (O); a constant 10% CM pluj 
increasing concentrations of neutralising anti-PDGF-aa/PFHMll from 0 to 20(ug/ml (□) 
The fourth line (■) represents the incorporated cpm for 10% CM plus anti-PDGF-ac 
after the data has been corrected for the protein effect due to addition of antibody alone 
(O). This correction was made by calculating the stimulation (cpm) due to antibody alone 
(cpm in the presence of antibody - cpm in PFHMII alone) and subtracting this value fron 
the incorporated cpm in the presence of both 10% CM and anti-PDGF-aa. The standarc 
error of the corrected data was calculated using the equation:-
Sc = -V((Si)2 + (S2)2)/2 )
Where Sc represents the standard deviation (S.D.) of the corrected mean; S% represents 
the S.D.of mean 1; and Sg represents the S.D. of mean 2.
Each culture was established in triplicate and the experiment is representative of three 
independent repeats.
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PDGF receptors and secrete PDGF-a chains suggests that it may contribute to the ability 
of SMS-SB cells to grow autonomously.
3.3 Discussion
The results detailed in this chapter demonstrate that the pre-B cell Hne, SMS-SB, can 
grow autonomously in protein-free medium and maintain the same growth rate as when 
cultured in serum-containing medium. The use of PFHMII allows the growth promoting 
effects of various cytokines to be examined without synergistic or inhibitory effects from 
growth factors present in serum. SMS-SB cells are density-dependent for growth and die 
when cultured at densities of less than 1000 cells per well in PFHMII (figure 3.2). The 
density of 1 0 0 0  cells per well may be 'on the cusp' for cell survival since in some 
experiments the cells die at this density and, in others, the cells begin to proliferate after a ^
lag phase of approximately 2 days (figure 3.5). This density-dependence for growth 
suggests that SMS-SB cells produce an autocrine factor to sustain and promote their 
growth. If the cells are seeded at low density, i.e. less than 1000 cells per well, then they 
may be unable to produce enough of this factor to condition the medium for growth. This 
hypothesis is supported by data which show that conditioned media from high density 
cultures of cells can augment the growth of SMS-SB cells cultured at densities where they 
would usually die. This augmentation of cell growth occurs even in cultures where cells 
can survive in the absence of CM (figure 3.4), but the exogenous SB-AF prevents the lag 
in growth seen when cells are initially seeded and are attempting to produce a sufficient J
concentration of autocrine factor. It is probable that some cells die in the low cell density 
cultures, which could account for the observed lag in growth; cells given CM would 
continue to grow at the normal rate and so cell numbers would be higher when the 
cultures were finally pulsed with pH]-TdR, compared to cultures where there had been a t
lag in growth.
Several cytokines are known to be involved in pre-B cell growth and development, J
including IL-3, IL-4, IL-5 and IL-7 (Dorshkind & Landreth, 1992); these are normally i:
produced by stromal cells, not by the B cells themselves. However, since SMS-SB is a 
leukaemic cell line, it is possible that deregulated transcription of one of these cytokine 
genes has lead to autocrine production of the growth factor. Experiments performed hy 
the Genetics Institute have shown that none of IL-la to IL-7 or TNFa or-p, are 
produced by SMS-SB cells, and IL-11, IL-13 and IL-15 do not significantly promote 
SMS-SB cell growth (figure 3.10). The only cytokines tested which are candidates for 
SB-AF are PDGF and sCD23. The effects of sCD23 will be discussed in chapter 4A.
Initial experiments to determine the molecular weight of the SB-AF, using Centricon 
filters, suggest that it is over lOOkDa in size. This sizing does not correspond with 
identification of PDGF as a candidate for SB-AF, since the molecular weight of PDGF
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heterodimers is approximately 30kDa. However, PDGF is a very 'sticky' protein and it 
could attach to larger proteins produced by SMS-SB cells; PDGF-aa would, therefore, 
be concentrated with them over the lOOkDa filter.
PDGF-aa is a candidate for SB-AF because SMS-SB cells release PDGF-a chains into 
the medium and also express the PDGF-B receptor. The PDGF-B receptor does not bind 
PDGF-aa with very high affinity but the cells were shown to express low levels of 
PDGF-A receptor RNA, so it is possible that an autocrine system could exist (Tsai et al., 
1994). Experiments where neutralising anti-PDGF antibodies were added to conditioned 
media did not show a significant inhibition of SMS-SB cell growth; thus, the antibodies 
did not appear to affect the autocrine activity present in CM. Unfortunately, interpretation 
of these experiments is severely hampered by the protein-effect caused by addition of 
microgram amounts of protein to SMS-SB cells in PFHMII. Several investigators have 
demonstrated an autocrine growth mechanism for v-^is-transformed cells (the viral 
homologue of human PDGF-p chain) (Waterfield et al., 1983; Doolittle et al., 1983) but 
in some cases the mitogenic effect of the v-sis product (p28^"‘^ ^ ) is only partially 
inhibited by anti-PDGF antibodies. There are several reports that PDGF may act as an 
internal autocrine factor by binding to, and activating, the PDGF-R inside the cell, but 
requiring surface expression of the receptor to couple with intracellular signalling 
pathways and have a mitogenic effect (Huang et al., 1984; Fleming et al., 1989 & 1992).
Thus, it is possible that PDGF-aa does play a role in SMS-SB cell growth but that it 
binds to the PDGF receptors internally. That the receptors require to be expressed on the 
cell surface to be involved in the signalling pathways, could explain why some stimulation 
of growth is seen with recombinant PDGF. It is probable that some of the receptors 
expressed on the cell surface would not have bound PDGF internally and, therefore, 
would be free to bind exogenous PDGF and augment the growth of the cells. Although 
the other PDGF autocrine models are from non-haematopoietic tumours, there is a report 
of an internal autocrine factor effect in murine haematopoietic stem cells which produce 
erythropoietin (EPO) and express EPO receptors (Goldwasser et al., 1991). Experiments 
which must be performed to establish the autocrine effect of PDGF include: addition of 
anti-sense for PDGF; examinination of PDGF-receptor tyrosine phosphorylation; and the 
effect of suramin on cell growth. The theory that PDGF acts as an internal autocrine 
factor for SMS-SB cells remains purely hypothetical.
It is possible that PDGF has no real role to play in SMS-SB cell growth, although it is 
unusual to find its expression in B cells. It is equally possible, if not probable, that PDGF 
plays only a minor role in SMS-SB cell growth with the majority of the activity being due 
to an, as yet unidentified, molecule. This would explain why the cells are density- 
dependent for growth; an internal autocrine system might suggest independent growth.
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Normal pre-B cells are under the control of multiple growth factors, some of which may 
be produced in an autocrine fashion. Synergistic effects between several autocrine factors 
have been described for non-EBV-transformed B cell lines (Abken et al., 1992), so it is 
possible that SMS-SB cells produce numerous factors to promote their own growth.
Another candidate for SB-AF activity, possibly in synergy with PDGF, is soluble CD23 
(sCD23). Data from proliferation assays (figure 3.10) shows a stimulation index of 5.6 for 
sCD23 - nearly twice that of PDGF or IL-5. Soluble CD23 has been shown to act as an 
autocrine factor for several EBV-transformed mature B cell lines but no effects have been 
described during early B cell development. It is of interest to note that SMS-SB cells do 
not express EBVNA2 and, as pre-B cells, would not yet be expected to express CD23 - a 
mature B cell marker.
The focus of the next chapter is the effect of sCD23 on SMS-SB cell growth and death.
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Chapter 4A 
Proliferative effects of sCD23 on SMS-SB cells
4a. 1 Introduction
The 25kDa soluble form of CD23, sCD23, has been ascribed numerous cytokine 
functions. Most of these functions involve synergy with XL-la for the effects to be seen: 
hence, pro-thymocyte differentiation (Mossalayi et al., 1990a), proliferation and 
maturation of myeloid progenitors (Mossalayi et al., 1990b), and centrocyte survival and 
differentiation (Liu et al„ 1991) are all promoted by a combination of IL -la  and sCD23.
CD23 has also been implicated in B cell growth and activation. The expression of CD23 is 
a requirement for transformation of B cells by EBV, and it appears to be involved in 
growth stimulation of the cells (Kitner & Sugden, 1981). Normal, JgM"^/IgD+ B cells also 
express CD23 when appropriately activated (Walker et al., 1986), but transformation ty 
EBV appears to cause super-induction and constitutive expression of CD23 (Thorley- 
Lawson et a i, 1985). The sCD23 which is released into the supernatant of EBV- 
transformed cells, acts in an autocrine fashion to promote proliferation of the cells 
(Swendeman & Thorley-Lawson, 1987). It is also a growth factor for normal, receptor- 
stimulated, B cell blasts (Swendeman & Thorley-Lawson, 1987; Gordon et al,, 1988), 
although this role is disputed by some investigators (Uchibayashi et a l, 1989). It is 
possible that the discrepancy in results is due to the state of activation of the B cells used 
in the proliferation assays; the growth of B cells triggered with sub-mitogenic amounts of 
anti-Ig is not stimulated by sCD23 (Uchibayashi e ta l,  1989); sCD23 may act to promote 
the growth of appropriately activated or transformed B cells.
However, these growth-promoting effects of sCD23 on B cells have only been seen with 
mature cells and there are no reports of sCD23 affecting early B cell growth or 
differentiation. The data presented in this chapter demonstrate a potential role for sCD23 
in promoting the growth of the pre-B cell line, SMS-SB, and indicate that this effect does 
not require synergy with IL-la.
4a.2 Results
4a.2.1 sCD23 promotes proliferation o f SMS-SB cells, in the absence oflL-lou
The data in figure 3.10 demonstrate that sCD23 can promote the growth of SMS-SB 
cells, with a stimulation index of 5,6 - almost twice that seen with PDGF-aa or IL-5. The 
graph of figure 4.1 represents [^H]-TdR incorporation by 2500 SMS-SB cells, after a 48 
hr incubation with the range of concentrations of sCD23 indicated. The graph shows a 
bell-shaped, dose-response curve for gel filtration-purified recombinant sCD23, with the 
maximum growth stimulation seen on addition of approximately 200-500 ng/ml. The
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concentration of sCD23 required is quite high, compared to the effects of sCD23 
observed in other systems, where a concentration of approximately 100-200 ng/ml sCD23 
is usually sufficient. However, the specific activity of the gel filtration-purified sCD23 was 
not determined due to its inherent instability; the material may contain other proteins. The 
protein concentration calculated for the gel filtration sample will also account for the other 
proteins, so the actual concentration of sCD23 added in the assays was probably 
somewhat lower than the values shown in figure 4.1.
To ensure that the effect of the gel-filtration purified material was, in fact, due to sCD23 
and not to some other protein which had been co-eluted from the column, antibody- 
inhibition experiments were performed with a polyclonal anti-CD23 antibody, Rb55. 
Figure 4.2 shows [^H]-TdR incorporation by 2500 SMS-SB cells/well incubated for 48 
hrs. SMS-SB cells (panel A) were incubated with either; a sub-optimal, concentration of 
gel-filtration purified sCD23 (lOOng/ml); Rb55, anti-CD23, alone; or constant, lOOng/ml 
concentration of sCD23, which had been pre-incubated for 1 hr at 4^0 with an increasing 
concentration of anti-CD23, as described in the figure legend. Due to the obvious protein 
effect caused by the addition of antibody alone, the difference in [^H]-TdR incorporation 
due to antibody alone was subtracted from the values obtained for sCD23 plus anti-CD23. 
These values are recorded as the 'corrected' result for sCD23 plus anti-CD23 and 
demonstrate that anti-CD23 inhibits, by approximately 30%, the growth promoting effects 
of gel filtration purified sCD23. The error bars drawn for these corrected values were 
calculated from the standard deviations of the two mean [^Hj-TdR incorporation values 
which represent each antibody concentration. The formula used in the calculation is:
Se = ■n/((S,)2 +(S 2)2)/2 ).
Where = Standard deviation (S.D.) of the corrected mean; Sj = S.D. mean 1; S2 = S.D. 
mean 2 .
To ensure that the observed inhibition was CD23-specific, a control experiment was 
performed using purified rabbit IgG in place of anti-CD23. The experiment was performed 
exactly as before and the results are shown in panel B of figure 4.2. From the graph, it is 
evident that even after correction for the protein effect due to antibody addition, IgG did 
not inhibit the growth stimulation due to sCD23. Therefore, it can be concluded that the 
effect of Rb55, anti-CD23 is truly CD23-specific, and that at least 30% of the growth 
stimulation by gel-filtration purified sCD23 is actually due to sCD23. It is likely that most, 
if not all, of this response is actually due to sCD23 because in later FACS experiments 
(figure 5.10), the maximum inhibition of CD23~binding observed with Rb55 was only 
approximately 50%. Experiments to further inhibit the stimulatory effect, by using higher 
amounts of anti-CD23, were hindered by an enhanced protein effect.
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Fîg.4.1 Effect of sCD23 on [^HJ-TdR incorporation by SMS-SB cells
A proliferation assay was performed with 2500 cells per well in PFHMII supplemented* 
with increasing concentrations of gel-filtration purified 25kDa sCD23 from 20ng/ml to 
lOpg/ml, and incubated for 48 hrs. The dose response curve represents the mean" 
incorporation of [^H]-TdR stimulated by each concentration of sCD23; the error bars 
indicate the standard deviation of the data for each triplicate culture. The experiment is 
representative of more than five independent repeats.
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Fîg.4.2 Effect of anti-CD23 on the ability of sCD23 to promote SMS-SB 
cell growth.
The experiment in panel A was performed as described in Fig.4.1 but the cells were- 
cultured in either: lOOng/ml of gel-filtration purified sCD23 (sCD23) (•); an increasing"' 
concentration of Rb55 anti-CD23 (pg/ml) (O'); or a constant lOOng/ml sCD23 plus an 
increasing concentration of Rb55 anti-CD23 (pg/ml) (p). The fourth line (■) represents 
data for anti-CD23 plus sCD23 (P) corrected for the protein effect due to antibody alone, 
(O . The corrected data (■) was calculated by subtracting the stimulation (cpm) due to  
antibody alone (mean cpm of cells in the presence of antibody - background mean cpm of- 
cells with PFHMII alone), from the values (mean cpm) obtained for sCD23 plus anti- 
CD 23 (O). The errors for the corrected data were calculated by the equation:-
Sc = V((Si)2 + (S2)2)/2)
Where Sc represents the standard deviation (S.D.) of the corrected mean; Sj represents' 
the S.D.of mean 1; and S2 represents the S.D. of mean 2.
Panel B demonstrates the results obtained when this experiment was repeated but with the 
substitution of purified normal rabbit IgG for the anti-CD23 antibody.
Each culture was established in triplicate and the graph shows the mean incorporated cpm;  ^
the error bars represent the standard deviation of the data or, in the case of the corrected, 
data, the standard error of the difference. The experiment is representative of three* 
independent repeats.
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Fig.4.3 Effect of affinity-purified sCD23 fragments upon growth of SMS- 
SB cells.
Proliferation assays were performed as previously described (Fig.4.1) but the cultures- 
were supplemented with either 25kDa (panel A), 29kDa (panel B) or 37kDa (panel C)‘ 
baculovirus-produced affinity-purified sCD23 (ng/ml). The results represent the mean 
[^H]-TdR incorporation of triplicate cultures with the standard deviation of the data 
shown as error bars.
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Fig.4.4 IL -la  does not enhance the growth-promoting effect of sCD23 
with SMS-SB cells.
Proliferation assays were performed rising 2500 cells per well in PFHMII supplemented^ 
with either increasing concentrations of affinity-purified 25kDa sCD23, from 20ng/ml to 
2 0 0 ng/ml (•) , or increasing sCD23 concentrations plus a constant Ing/ml IL -la  (O) or 
lOng/ml IL -la  (□). The cultures were established in triplicate and incubated for 48hrs^ 
with a pulse of [^H]-TdR for 6 hrs prior to harvest. The data represent the mean [^H]-TdR 
incorporation for each condition, with error bars showing the standard deviation of the" 
data.
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Fîg.4.5. additive effect of sCD23 and conditioned medium on SMS-SB 
cell growth.
A proliferation assay was performed using 1000 cells per weU in PFHMII supplemented" 
with either: increasing amounts of conditioned medium (CM) (O); or a constant lOOng/ml 
gel-filtration purified 25kDa sCD23 plus increasing amounts of CM (•). The cultures 
were set up in triplicate, incubated for 48hrs, and pulsed with [^H]-TdR for the last 6 hrs^  
prior to harvest. The results represent the mean [^H]-TdR incorporation for each, 
condition, with the standard deviation of the data shown as error bars. This is a single- 
experiment, representative of three independent repeats.
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Due to the possibility that some of the other proteins in the gel filtration material might 
contribute, in a synergistic fashion, to the growth promoting effect of sCD23 on SMS-SB 
cells, affinity-purified sCD23 was also tested. The results of experiments using the 25, 29 
and 37kDa fragments of CD23 are illustrated in figure 4.3, panels A, B and C, which 
represent [^H]-TdR incorporation by 2500 cells/well, after a 48 hour incubation in the 
presence or absence of sCD23. All three, affinity-purified, fragments of CD23 stimulate 
the proliferation of SMS-SB cells, and the magnitude of the effect is similar to that seen 
with the gel filtration purified material, at equivalent concentrations. Affinity-purified 
sCD23 is able to promote the growth of SMS-SB cells, and this occurs in the absence of 
IL-la. Neither pre-treatment of cells with recombinant IL-la, nor addition of 
recombinant IL -la  to cells in the proliferation assays enhanced the effect of either gel- 
filtration or affinity-purified sCD23 - Figure 4.4 is representative of data obtained for all 
these various conditions. The graph represents [^H]-TdR incorporation by 2500 SMS-SB 
cells per well, after 48 hour incubation with either affmity-purified sCD23, sCD23 plus 
Ing/ml IL-la or sCD23 plus lOng/ml IL-la, as indicated in the figure legend. It is clear 
that IL -la does not act in synergy with sCD23 to promote the growth of SMS-SB cells 
since the mean [^H]-TdR incorporation for cells incubated with a combination of sCD23 
and IL -la was not higher than the mean pH]-TdR incorporation recorded for cells with 
sCD23 alone. IL -la alone added to SMS-SB cells has no effect, either positive or 
negative, on SMS-SB cell growth (refer to figure 3.10).
Figure 4.5 demonstrates that sCD23 and CM have an additive effect on SMS-SB cell 
growth. A constant, sub-optimal concentration of gel fütration-purified sCD23 (lODng/ml) 
was added to the cells, along with an increasing amount of CM (as described in the figure 
legend); the effect of both stimulants on SMS-SB cell growth was greater than either 
added alone.
4a.2,2 SM S-SB Cells Do Not Express CD23
Since sCD23 can promote the growth of SMS-SB cells, it was identified as a candidate 
for the SMS-SB autocrine activity and experiments were performed to determine whether 
SMS-SB cells actually express CD23. Southern blot analysis, using a CD23-specific 
probe, was performed on DNA from SMS-SB and SKW cells, digested with the 
restriction enzymes; BamHI, HINDIII and EcoRl (figure 4.6). A sample of 25 pg of 
uncut CD23 plasmid was run on the gel to test the hybridisation capacity of the probe. 
The results of restriction digest and the hybridisation demonstrate that the CD23 gene is 
present in SMS-SB cells, as expected, and the restriction digest pattern is the same as that 
seen with SKW cells: the restriction enzymes utilised suggest that the CD23 gene in SMS- 
SB cells has no deletions or insertions.
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Pîg.4.6. Southern blot analysis of the CD23 gene in SMS-SB cells
Southern blots were carried out as described in materials and methods. The first lane., 
contained 25pg of uncut CD23 plasmid, pCDL SRa296CD23, as a positive control for 
probe hybridisation. Lanes 2 and 3 were loaded with 20p,g samples of BamHI-digested ' 
SMS-SB and SKW genomic DNA, respectively. The SMS-SB and SKW samples of each 
digest were loaded beside each other to allow comparison of the digest patterns. Lanes 4. 
& 5, and lanes 6  & 7, represent HINDIII and EcoRI digests of the two cell lines,- 
respectively. After the digests were separated by agarose gel electrophoresis and blotted " 
onto nylon-membrane, the blot was hybridised with a -labelled, 1.6kbp, BamHI insert '  
of human CD23 from the pCDL SRa296CD23 plasmid. Hybridisation was visualised ty  " 
autoradiography.
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Fig.4.7 Northern blot analysis of CD23 expression in SMS-SB cells and 
other B lymphoid cell lines.
Total cellular RNA was prepared (as described in materials and methods) from a range of- 
B lymphoid cell lines and from SMS-SB cells cultured in either PFHMII or in 10% FCSj* 
RPMI 1640 medium. From total RNA, the polyA mRNA fraction was isolated using the^ 
PolyATmct mRNA Isolation System TV. 5pg of each cell line mRNA were loaded per lane,^  
on an agarose / formaldehyde gel. Lanes 1 & 2 contained mRNA from SMS-SB cells- 
grown in PFHMII and serum-containing medium, respectively. Lane 3, 4 and 5 contained^ 
mRNA from the B cell lines SKW, Jijoye and Ramos, respectively. After separation by* 
electrophoresis, the RNA was blotted onto nylon membrane and hybridised with a 
labelled, 1.6kbp, BamHI insert from the pCDL SRa296CD23 plasmid. Hybridisation, " 
demonstrating the existence of the 1503bp CD23 RNA, was visualised ly  - 
autoradiography. The experiment is representative of five independent repeats.
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Fig.4.8 GaPDH loading control for CD23 Northern analysis
The Northern blots from the experiments described in Fig.4.7 were stripped (as described 
in methods) and re-hybridised with a [^^P]-labelled, 0.7kb GAPDH probe. Hybridisation 
was visualised by autoradiography.
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Flg.4.9 PCR analysis of CD23 expression in SMS-SB and other B 
lymphoid cell lines.
Total cellular RNA was prepared (as described in materials and methods) from a range of, 
B lymphoid cell lines, a keratinocyte cell line, and from SMS-SB cells cutured in either" 
PFHMII or in 10% FCS/ RPMI 1640 medium. The total cellular RNA was used as a 
template for reverse-transcriptase (RT)-PCR using the primers, CD23a and CD23b, > 
indicated on the figure. After the PCR reactions were complete, the products (256bp)’‘ 
were separated by agarose gel electrophoresis, Southern blotted onto nylon membranes,, 
and probed with a [^^P]-labelled, 1.6kbp insert from the plasmid pCDL SRot296CD23, " 
The gel was loaded as shown on the figure: lanes 1 & 2 were PCR products from SMS- 
SB cells cultured in PFHMII and in serum-containing medium; lanes 3, 4 and 5 contained, 
PCR products from SKW, Jijoye and Ramos B cell lines, respectively; lanes 6  & 7 were ' 
negative controls of keratinocyte cells (DOK) and a PCR reaction performed with no, 
template RNA, respectively. Hybridisation was visualised by autoradiography. The" 
experiment is representative of four independent repeats.
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Fig.4.10. PCR analysis of c-fos expression - an RNA quality control.
The RNA samples used in the experiments described in Fig.4.9. were also used as' 
templates for an RT-PCR reaction with primers specific for c-fos (as detailed on the, 
figure). The products of PCR reactions (1020 bp) using RNA from SMS-SB cells cultured" 
in PFHMII and in serum-containing medium, SKW, Jijoye, Ramos and keratinocyte cells^ 
were loaded onto an agarose gel as described above. After electrophoresis, the DNA was * 
Southern blotted onto nylon membranes, and probed with a [^^P]-labelled c-fos inserF 
from the plasmid Sp65. Hybridisation was visualised by autoradiography.
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After the discovery that SMS-SB cells are negative, by flow cytometry, for surface 
expression of CD23 (data not shown), the next stage was to examine the expression of 
CD23 RNA. After numerous attempts, it was realised that the amount of CD23 RNA 
present in B cells, even in cell lines known to be CD23-positive by flow cytometry, is too 
low to be detected by a Northern blot of total RNA (data not shown). Therefore, 
messenger RNA (mRNA) was prepared from total RNA using the PolyATmct mRNA 
Isolation System IV, from Promega. The results of the Northern blot of mRNA (figure 
4.7) demonstrate that the cell line SKW, known to be CD23-positive by FACS analysis, 
express large quantities of CD23 mRNA and the Burkitt's lymphoma cell line, Ramos, 
which appears to be negative for CD23 expression by FACS, contains a small amount of 
CD23 mRNA. The cell lines Jijoye and SMS-SB cells, both negative for surface CD23 
expression by FACS, do not express any CD23 mRNA. The Northern blot was stripped of 
radioactivity and reprobed with a GAPDH probe (figure 4.8) demonstrating that loading 
of the mRNA was approximately equal and that the mRNA of the negative cell lines 
could, in fact, be hybridised with a probe. That the loading of mRNA from SMS-SB 
cultured in serum-containing medium was quite low, compared with SKW cells, is not a 
concern because approximately the same level of Ramos mRNA was loaded and CD23 
message could be detected.
Although it appears that neither SMS-SB cells cultured in 10% FCS/DMEM, nor 
PFHMII, express any CD23 mRNA, it was decided to perform reverse transcriptase - 
polymerase chain reaction (RT-PCR) with CD23-specific oligonucleotide primers to allow 
the most sensitive detection of CD23 RNA (figure 4.9), RNA was isolated from SMS-SB 
cells and from SKW, Ramos and Jijoye B cell lines and a keratinocyte line, as a negative 
control. A line drawing (not to scale) of the human CD23 cDNA is given, showing the 
positions of the two CD23 oligonucleotides, CD23a and CD23b; the sequences of which 
are shown on the figure. After reverse-transcription and 35 cycles of PCR amplification, 
products of the individual reactions were electrophoresed and detected by Southern 
blotting and hybridisation with a CD23-specific probe (figure 4.9). SKW and Ramos both 
generated a strong signal of the expected 256bp; results analogous to those obtained from 
the Northern blot analysis. No signals were detected using SMS-SB, Jijoye or 
keratinocyte RNA and there was no product from a reaction performed without template 
RNA, demonstrating that no contamination of reagents had occurred. As a positive 
control for the condition of the RNA and the reverse transcriptase reaction, an RT-PCR 
reaction was performed using c-/05-specific oligonucleotide primers, as illustrated in 
figure 4.10. It is clear that the RNA from all cell lines tested had been successfully 
reverse-transcribed giving clear bands of c-fos product. These data demonstrate that 
SMS-SB cells do not contain detectable levels of CD23-RNA and, thus, that they do not 
express CD23, thereby negating the hypothesis that SMS-SB cells utilise sCD23 as an 
autocrine growth factor.
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Fig,4.11 The effect of recombinant IL-4 on CD23 expression by SMS-SB ‘ 
cells.
SMS-SB cells were cultured in 25cm^ flasks at 5x10^ cells per ml in PFHMII, either in the, 
presence or absence of recombinant human IL-4 at 10, 50 and lOOU/ml. A culture of- 
SKW cells was also prepared as a positive control for CD23 expression. After IShrs, thej 
cells were harvested, washed in ice-cold PBS and stained with FlTC-conjugated anti-> 
CD23 plus PE-conjugated anti-CD 19, for 45 minutes. The cells were then washed and" 
subjected to two-colour flow cytometric analysis - each graph represents data from lO ,^ 
cells.
Panel A represents untreated SMS-SB cells without antibody; panel B represents- 
untreated SMS-SB cells with both anti-CD23 and anti-CD19; panel C represents SMS-SB 
cells treated with 50U/ml IL-4 and then stained with both anti-CD23 and anti-CD19 (this- 
panel also represents results obtained from cells treated with 10 and lOOU/ml IL-4); panel' 
D represents SKW cells stained with both anti-CD23 and anti-CD 19 antibodies.
In the dot-plots illustrated, the x-axis shows staining with anti-CD 19 (fluorescence 2), and- 
the y-axis shows staining with anti-CD23 (fluorescence 1). The experiment is', 
representative of three independent repeats.
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4a.2.3 CD23 expression^ by SMS-SB cells  ^is not induced by IL-4
Normal, peripheral B cells express a small amount of the CD23a isofoim but addition of 
IL-4 to these cells induces expression of substantial amounts of CD23a and, especially, 
CD23b. (Yokota et al., 1988). IL-4 can induce expression of CD23b on several cell types, 
including normal human T cells (Delespesse et al., 1992), and macrophages (Yokota et 
al., 1988). In human B cells, the expression of CD23 appears to be associated with that of 
IgD, and most reports suggest that IL-4 cannot induce CD23 expression on IgD-negative 
cells (Kikutani et al, 1986). However, malignant pre-B cells, from ALL patients, have 
been shown to express CD23 after stimulation with IL-4 (Law et al., 1991), so it was 
decided to investigate whether CD23 expression could be induced on SMS-SB cells.
To examine the effect of IL-4 on CD23 expression, SMS-SB cells were cultured in the 
presence of vai'ying concentrations of IL-4, for 18 hours before being washed, incubated 
with FTTC-labelled anti-CD23 and PE-labelled anti-CD 19 MAbs and analysed by flow 
cytometry. The results of figure 4,11 demonstrate that IL-4 does not induce surface CD23 
expression on SMS-SB cells at 10, 50 or lOOU/ml, although the cells stain with anti- 
CD 19 antibody; levels of CD23 RNA were not examined. SKW cells were used as a 
positive control for staining of cells by the FITC-labelled anti-CD23 antibody.
Ligation of CD40 also induces expression of CD23 on normal human pre-B cells (Saeland 
et al., 1993). SMS-SB cells were analysed, by flow cytometry, for expression of CD40 
antigen but it was discovered that SMS-SB cells do not express CD40 (data not shown) 
and so experiments attempting to induce CD23 expression by hgation of CD40, were not 
performed.
4a.3 Discussion
The data presented in this chapter illustrate the ability of sCD23 to promote the growth of 
SMS-SB cells but demonstrate that it is a paracrine, not autocrine, response since the cells 
do not express CD23.
Gel filtration (GF) pui’ified sCD23 augments the growth of SMS-SB cells and to test the 
specificity of this effect it would have been useful to use a control insect cell supernatant 
and collect the same fractions for testing, but, unfortunately, this was not available. 
However, the growth promoting effect of the gel filtration-purified sCD23 was partially 
inhibited by a polyclonal anti-CD23 antibody, but not by control rabbit IgG. Due to the 
protein effect seen on addition of antibodies to the cultures, the results had to be corrected 
but, after the correction, it was shown that there was a significant difference between 
values obtained on addition of sCD23 and those obtained when the anti-CD23 was 
present. The dose-response curve obtained during proliferation assays with GF-purified 
sCD23 was bell-shaped, suggesting that the growth promoting effect was lost at higher
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concenti-ations of sCD23. There was evidence of some precipitated material in those 
culture wells during proliferation assays and it is possible that precipitation of sCD23, due 
to formation of oligomers in solution (Beavil et aL, 1995), had occurred. Precipitation of 
oligomeric complexes would reduce the available sCD23 and could account for the 
decreased growth-promoting activity observed in the cultur es.
Affinity-purified sCD23 was capable of promoting SMS-SB cell growth, although 
difficulty was encountered due to its apparent instability; often a repeat of the same 
experiment showed no enhancement of SMS-SB ceU growth. Several batches of sCD23, 
provided by GIMB, were tested, with some batches never showing any growth-promoting 
activity and others showing activity for a few weeks and then becoming inactive.
However, the 25, 29 and 37kDa forms of affinity-purified sCD23 have the abihty to 
promote SMS-SB cell growth, suggesting that the stalk region, which is absent from the 
25kDa form, is not involved in binding to SMS-SB cells. These fragments have all been 
shown to exist as trimers, after chemical cross-linking, and the 25kDa form may also foim 
dimers of trimers which aid in binding to CD23 receptors (Beavil et aL, 1995). There is no 
obvious difference in the abihty of the three forms of sCD23 to promote SMS-SB cell 
growth. The affinity-purified material promotes SMS-SB cell growth to a level equivalent 
with GF-pmffied sCD23 which also suggests that there were no synergistic effects due to 
contaminating proteins found in the GF material. One concern had been that IL -la  (the 
cytokine most frequently described to synergise with sCD23), or an EL-l-hke molecule, 
were contaminants in the gel filtration sCD23. Although inhibition experiments with a 
neutralising anti-IL-la antibody were not performed, this explanation appears unlikely 
since affinity-purified sCD23 alone augments SMS-SB cell growth, and no synergy was 
observed on addition of recombinant IL-la. Thus, sCD23 alone promotes the growth of 
SMS-SB cells.
Analysis of CD23 expression by Northern blot and RT-PCR demonstrates that SMS-SB 
cells do not express CD23, although CD23 message could be detected in several other B 
cell hues which were examined. Also, CD23 expression could not be induced by culture of 
the cells with IL-4, as has been noted for some pre-B cells from ALL patients (Law et aL, 
1991).
There is a negative regulatory element near the muiine CD23 transcription start site 
(Dierks et aL, 1994), and CD23 gene expression may be controlled by the presence or 
absence of a factor able to bind to this site, thus, some pre-B ALL cells may have lost this 
negative signal, or, alternatively express transcription factors which override the negative 
signals - possibly in the same way that a signal through CD40 can induce CD23 
expression on normal pre-B cells (Saeland et aL, 1993), That IL-4 alone does not induce
109
CD23 expression by SMS-SB cells suggests that regulation of CD23 expression may be 
similar to that seen in normal pre-B cells; however, the lack of CD40 expression by SMS- 
SB cells makes it difficult to compare the two regulatory mechanisms directly.
CD23 is not produced by SMS-SB cells so it cannot account for the autocrine growth 
activity present in conditioned media from SMS-SB cells; sCD23 is not the SB-AF. 
Unfortunately, no fuither work has been carried out to characterise the SB-AF. The 
remaining section of chapter 4 describes experiments which attempt to determine the 
mechanism of action whereby sCD23 promotes SMS-SB cell growth; the data 
demonstrate that sCD23 prevents apoptosis of SMS-SB cells.
'
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Chapter 4B 
Anti-apoptotic effect of sCD23 on SMS-SB cells 
4b. 1 Introduction
Haematopoietic precursor cells are strictly dependent upon the presence of 
haematopoietic growth factors for growth, survival and differentiation (Askew et aL, 
1990). IL-3 is one such factor, and its abihty to enhance the survival of haematopoietic 
precursors is thought to be accomphshed by the suppression of apoptosis (Askew et aL, 
1990). Thus, myeloid precursor cehs, deprived of IL-3, wih undergo apoptosis. There are 
several genes which may be involved in promotion or suppression of apoptosis. The 
normal response of most IL-3-dependent cells, to cytokine withdrawal, is down-regulation 
of c-myc expression, followed by cell cycle arrest in Gj, and eventually apoptosis. 
However, over-expression of c-myc accelerates apoptosis of IL-3-dependent cells upon 
growth factor withdrawal (Askew et aL, 1990), possibly by forcing' the cells into cycle 
but providing only a pai’tial proliferative signal which fails to replace those provided by 
IL-3. An imbalanced mitogenic signal, induced by inappropriate expression of ceU cycle 
genes, such as c-myc, appears to induce apoptosis (Evan et al., 1992; Chemey et aL, 
1994); this mechanism may aid in the elimination of cells which sustain mutations that 
perturb their proliferative potential.
Bcl-2 has properties of an anti-apoptotic gene and, for example, when transfected into an 
IL-3-dependent B cell Une, on factor deprivation, the cells do not undergo apoptosis but 
aiTest in Gq/Gi (Marvel et al., 1994). Even in cells which over-express c-myc, the co- 
expression of bcl-2 allows resistance to apoptosis (Merino et al., 1994), suggesting that 
bcl-2 may substitute for a 'survival' signal, normally provided by the growth factor, to 
allow the cell cycle to proceed.
Thus, in the absence of necessai'y growth factors, many cells wiU undergo growth arrest 
and/or apoptosis. With respect to SMS-SB cehs, the data from proliferation assays show 
that cells cultured in the absence of CM have very low [^H]-TdR incoiporation which 
suggests that the cells die at low ceU density. The density-dependence of SMS-SB cehs 
could be explained if the inability to condition theu own medium leads to factor 
deprivation and consequently to apoptosis of the cehs. In this respect, the increased [^H]- 
TdR incorporation observed on addition of sCD23 to the cultures may reflect the abihty 
of sCD23 to save the cells fr om apoptosis and allow thefr continued growth, rather than a 
role for sCD23 as an overt mitogen.
A role for sCD23 in the prevention of apoptosis has aheady been demonstrated, since 
addition of sCD23 and IL -la  to centrocytes prevents apoptosis and drives the cehs 
towards a plasmacytoid phenotype (Liu et al., 1991). Therefore, experiments were
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performed to examine whether SMS-SB cells undergo apoptosis when plated at low cell 
density, and whether sCD23 acts to prevent apoptosis and promote survival of the cells,
4b.2 Results
4b.2,l SMS-SB cells undergo apoptosis at low cell density
One of the biochemical hallmarks of apoptosis is DNA cleavage in the linker regions 
between nucleosomes, which results in a characteristic pattern of fragmentation into 
ISObp (or multiples thereof) oligonucleosomes (a DNA 'ladder') when the DNA is subject 
to conventional gel electrophoresis (Wyhie, 1980).
To investigate whether SMS-SB cells undergo apoptosis at low cell density, the cells were 
plated at 2x10^ cells per ml and incubated for 24 hrs before preparation of DNA and gel 
electrophoresis with ethidium bromide to visualise the DNA. Unfortunately, clear DNA 
laddering was not visible with SMS-SB cells at low cell density, and only a smear of DNA 
was present on the gel (data not shown). There are reports which suggest that 
intemucleosomal cleavage of DNA is not an essential step in apoptosis, but in cell lines 
which do not show DNA laddering, there are distinctive fragments of 50kbp generated. 
These fragments appear to be caused by endonucleolytic activity dining apoptosis which 
releases loops of chromatin (Oberhammer et al., 1993).
To examine SMS-SB cells_for the presence of the 50kbp band, indicative of apoptosis, the 
cells were cultured at 2x10^ ceUs/ml in PFHMII and at various time points, 10  ^cells were 
harvested and washed before being embedded in agarose blocks and the DNA released by 
a 48 hr digestion with proteinase K solution. The blocks were then subjected to pulse-field 
gel electrophoresis and the gel stained with ethidium bromide. A 46kbp fi'agment of 
lambda DNA, generated by heating to 65®C, was used as a size marker. The visible 50kbp 
band (figure 4.12) demonstrates that SMS-SB cells do undergo apoptosis at low cell 
density, with the maximum DNA cleavage apparent between 18 and 24 hours. The 
disappearance of the 50kbp band after 24 hours may be due to further DNA degradation, 
although DNA laddering was not observed.
The time course experiment suggests that, in future experiments, incubation for between 
18 and 24 hours should allow examination of the cells m the process of undergoing 
apoptosis.
112
Fig 4.12 Pulse-field gel electrophoresis - to examine apoptosis of SMS-SB - 
cells after culture at low cell density,
SMS-SB cells were cultured at 2x10^ cells/ml in PFHMII and, at times of 0, 4, 6 , 8 , 12,. 
18, 24, 36 and 48 hours, 10  ^cells were harvested (using trypsin, if necessary, to remove- 
the cells), washed and embedded in agarose blocks, before being subjected to digestion 
with a proteinase K solution. A block containing lambda DNA (previously heated to^ 
65®C) was run in lane one of the pulse-field gel as a size marker of 46kbp. The SMS-SB 
cell sample blocks were loaded in chronological order. After 16 hours of pulse-field gel, 
electrophoresis, the gel was stained with a 0.4p,g/ml solution of ethidium bromide and- 
then washed in dH^O before being photographed under UV Hght. The experiment is 
representative of two independent repeats.
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Fîg.4.13 Photomicrographs of SMS-SB cells.
Cultures of SMS-SB cells were established in PFHMII at normal cell density (5x10^' 
cells/ml; Panel A), or at low cell density (2.5x10'  ^ cells/ml) in the absence (Panel B) or, 
presence of lOng/ml (Panel C) or lOOng/ml (Panel D) gel-filtration purified 25kDa- 
sCD23. After 24 hours of culture, the cells were examined by phase-contrast hght 
microscopy using a 40X magnification lens.
. û  n
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4b.2.2 sCD23 prevents apoptosis in low cell density cultures o f SMS-SB cells
To test the hypothesis that sCD23 inhibits apoptosis of SMS-SB ceils, cells were cultured 
at normal and low cell density (2 x ICri cells per ml) in PFHMII for 24 hr in the presence 
and absence of sCD23 and then examined by hght microscopy (figure 4.13).
Cehs cultured at normal ceh density (5 x 10^  cehs per ml) showed few apoptotic 
characteristics and grew in suspension (figure 4.13, panel A), whereas cehs cultured at 
low cell density (panel B) exhibited a more spread morphology and became so adherent to 
the tissue culture flask that trypsinisation was required to remove them. The ceh 
membranes were blebbed and the cytoplasm was vacuolated, ah features chai'acteristic of 
apoptotic cells (Cohen, 1993), in contrast with the few, remaining viable cells which 
appear smaher and are sthl spherical (compare ceh morphology in panel B). In several 
instances, apoptotic bodies were visible (data not shown), representing the final stage of 
apoptosis; in vivo these would probably have been phagocytosed by macrophages. 
Addition of sCD23 produced cells with a morphology indistinguishable from that of 
normal ceh density cultures; fewer apoptotic cehs were evident as the concentration of 
sCD23 was increased from lOng/ml to lOOng/ml (panels C & D), and the cehs grew in 
suspension. Incubation of SMS-SB cehs in the presence of lOOng/ml sCD23 was sufficient 
to maintain the morphology of the cells exactly as those in culture at normal ceh density.
4b.2.3 Flow cytometric analysis o f  apoptotic cells
A two-colour flow cytometric technique has been described which discrkninates and 
quantifies viable, apoptotic and necrotic cells via measurement of forward and side Hght 
scatter (proportional to ceh diameter and granularity, respectively), and the DNA-binding 
flurochromes Hoechst 33342 and propidium iodide (Dive et al., 1992; Daizynkiewicz et 
at., 1992). Cehs in the early stages of apoptosis have changes in membrane permeability 
such that propidium iodide is excluded from the cells (as normal), but the Hoechst 
fluorochrome begins to stain the cehs. The increase in Hoechst 33342 fluorescence seen in 
apoptotic, compared with viable, cells may reflect a decreased abhity of apoptotic cehs to 
 ^ actively pump out the dye. Viable cehs exclude propidium iodide and efflux Hoechst
33342, therefore are stained with neither fluorochrome but, in contrast, late stage 
apoptotic or necrotic cehs stain with both dyes (Dive et ai, 1992).
This method was employed to confirm the morphological criteria which suggest that 
SMS-SB cehs undergo apoptosis when cultui'ed at low ceh density but addition of sCD23 
can prevent the apoptosis. Light scatter measurements were used initiahy to gate out 
debris from the analysis. Two sub-populations were apparent - one with high forward 
scatter/ low side scatter (viable cehs) and the second with low forward scatter and high 
side scatter (apoptotic cehs). That these populations represent viable and apoptotic cehs 
was confirmed by analysis of the fluorochrome binding patterns of the cehs (figure 4.14).
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Cells were analysed after a 24hr incubation at normal or low cell density either alone or in 
the presence of sCD23 or IL-4. The cells were stained with propidium iodide and Hoechst 
33342 and, after gating on the basis of scatter parameters, analysed by two-laser flow 
cytometry. In cultures propagated at normal ceh density (figure 4.14, panel A and Table 
4.1), >90% of the cells were routinely located in the lower left quadi'ant of the dot-plots - 
the quadrant which represents viable cehs, not stained by either dye. In the experiment 
presented, 91.5% of cells cultured at normal ceh density were viable with very few 
dead/necrotic cells evident (lower right quadrant). There were a total of 8.9% apoptotic 
cells in the normal ceh density cultures; 2,8% were stained only with Hoechst 33342 
(upper left quadrant) and represent early apoptotic cells whereas 6 .1% of the cehs stained 
with both fluorochromes and were scored as late apoptotic cells (upper right quadrant).
These values contrast sharply with values obtained for cells cultured at low ceh density 
(panel B) where 68.3% of the cells were viable, 3.3% early apoptotic, and 25.1% late 
apoptotic. The inclusion of IL-4 in these cultures (panel D) results in a smah decrease in 
late apoptotic cehs, with a shght increase in the number of dead cells present, but the 
percentage of viable cells remains low and comparable with that seen in cultures of cells at 
low ceh density alone. In striking contrast, the presence of sCD23 in the low ceh density 
cultures (Figuie 4.14, panel C) restores the percentage of viable cells in the culture to 
89.1%, and reduces the percentage of late apoptotic cehs to 6.3%; values which are 
essentially identical to those obtained for normal ceh density cultures.
Table 4.1 Flow cytometric analysis of apoptosis in SMS-SB cells
Cu l t u r e
CONDITIONS
% o f  cehs: 
VIABLE
% o f  cehs:
EaRLY APOPTOTIC
% o f cehs:
LATE APOPTOTIC
% o f cehs: 
DEAD
NCD 91.5 2 .8 6 .1 0.3
LCD 68.3 3.3 25.1 4 .3
LCD + sCD23 89.1 0.9 6.3 3.9
LCD + IL-4 64.5 0 .8 17.5 2 0 .0
Where, NCD = normal ceh density, LCD = low ceh density. For experimental detah see 
legend to figure 4.14
In individual experiments, the actual percentages of viable and apoptotic cells varied in 
both normal and low ceh density cultures but the restoration of values to those observed 
with normal ceh density cultures, on addition of sCD23, was consistent. Figure 4.15 
describes the results of an individual experiment, representative of 3 others, demonstrating 
that the capacity of sCD23 to block apoptosis in low ceh density cultui es is concentration 
dependent. Addition of 20ng/ml gel fhtration purified sCD23 reduces the late apoptotic 
population to 5.9%, from the 97% present in low ceh density cultures, and lOOng/ml 
sCD23 reduces the percentage of late apoptotic cells to only 1.6% - comparable with the
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Fig.4.14 Flow cytometric analysis of apoptosis in SMS-SB cells.
Cultures of SMS-SB cells were established in PFHMII at normal ceU density (5x10^, 
cells/ml; Panel A), or at low cell density (2.5x10"  ^ cells/ml) in the absence (Panel B) or. 
presence of lOOng/ml gel filtration-purified 25kDa sCD23 (Panel C), or 20U/ml IL-4 
(Panel D). After 24 hours of culture, the cells were harvested (using trypsin, if necessary,'  ^
to remove the cells), washed with ice-cold PBS and then stained simultaneously with 
propidium iodide and Hoechst 33342; to detect apoptotic and dead cells. CeU debris was- 
gated out on forward and 90° scatter parameters, and the cells analysed by two-laser flow 
cytometry.
On the individual dot-plots, the percentage figures shown on the lower left quadrant 
represent viable cells and those on the lower right represent dead cells. The values in the* 
upper left quadrant refer to early apoptotic ceUs, whUe those in the upper right quadrant, 
represent late apoptotic ceUs. The experiment shown is representative of more than five 
independent repeats.
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Fig.4.15 apoptosis of SMS-SB cells - effect of sCD23 and anti-CD23.
The experiments were performed exactly as described in the legend to figure 4.14, but, 
different concentrations and forms of sCD23 were used. The bar chart represents the. 
percentage of apoptotic cells (early plus late apoptotic cells), as measured by the two-laser* 
flow cytometric technique. From the first bar downwards, the chart demonstrates the  ^
percentage of apoptotic cells in SMS-SB cells cultured at:- low cell density (LCD), 
(2.5x1 O'* cells/ml); LCD plus 200ng/ml affinity purified, Kcoli produced, 25kDa sCD23r 
LCD plus 200ng/ml affinity purified, E.coli produced, 25kDa sCD23, plus lOng/ml IL -laf 
LCD plus 20ng/ml gel-filtration purified 25kDa sCD23, plus 40|.ig/ml Rb55, polyclonal,  ^
anti-CD23; LCD plus 20ng/ml gel-filtration purified 25kDa sCD23; LCD plus lOOng/mh 
gel-filtration purified 25kDa sCD23; and finally, normal cell density (5x10^ cells/ml).
The data presented is from a single experiment, representative of at least four independent, 
repeats.
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Fig.4.16 apoptosis of SMS-SB cells - the effect of various cytokines.
The experiments were performed exactly as described in the legend to figure 4.14, but, 
several cytokines were tested for the ability to prevent apoptosis of SMS-SB cells at low, 
cell density. The column chart (A) demonstrates the percentage of viable cells and* 
apoptotic cells (as calculated by two-laser flow cytometry) present in a culture at normal" 
cell density, compared with low cell density cultures in the presence of various cytokines.. 
The data legend demonstrates which column represents viable versus apoptotic cells. The* 
effect of addition of 10 ng/ml IL-la, IL-2, IL-3, IL-4 (50U/ml), IL-7 or IL-13 (both Id 
ng/ml) only, to the LCD cultures is shown, and compared to the effect of addition of 
lOOng/ml gel-filtration purified 25kDa sCD23.
The bottom panel represents the same data but shown as the ratio of % viable : %* 
apoptotic cells. The results demonstrated are from a single experiment but are, 
representative of three independent repeats.
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1.3% seen in cultures propagated at normal cell density. The ability of 20 ng/ml sCD23 to 
prevent apoptosis of SMS-SB cells was partially inhibited by the addition of 40p.g/ml 
Rb55 anii-CD23 to the cultures. The anti-CD23 increased the percentage of apoptotic 
cells to 16.2% - approximately a three fold increase. The data of figure 4.15 also 
demonstrate the ability of affinity purified sCD23 to prevent apoptosis of SMS-SB cells 
and show that there is no synergistic effect on addition of IL -la in combination with 
affinity-purified sCD23. Addition of IL-la, in combination with a sub-optimal 
concentration of gel filtration purified sCD23 (data not shown), did not decrease the 
percentage of apoptotic cells obtained, thus sCD23 does not appear to synergise with IL- 
l a  for prevention of apoptosis of SMS-SB cells.
Several other cytokines were tested for the ability to prevent apoptosis of SMS-SB cells 
at low cell density (figure 4.16). The data are presented both as absolute percentages 
obtained (panel A) and as a ratio of the percentage viable cells divided by the percentage 
apoptotic cells (panel B). None of IL-la, IL-2, IL-3, IL-4, IL-7 or IL-13 were able to 
prevent apoptosis of SMS-SB cells, at the concentrations tested. The results obtained on 
addition of these cytokines were almost exactly the same as those for cells cultured at low 
cell density alone, as is apparent from the ratio bar chart (figure 4.16, panel B).
Other than IL-la, these cytokines have not been tested for synergistic effects with sCD23, 
but the fact that sCD23 alone can reduce the percentage of apoptotic cells to the values 
obtained from cultures at normal cell density, suggests that sCD23 alone is sufficient to 
prevent entry of SMS-SB cells into apoptosis.
4b.2.4 sCD23 promotes bcl~2 expression in SMS-SB cells
In several models of apoptosis, the proto-oncogenes c-myc and bcl-2 are implicated in
regulating the induction of apoptosis - in a positive and negative fashion, resepctively.
Normal B cells appear to down-regulate c-myc, after growth factor deprivation, and 
undergo growth arrest but, in BBV-immortalised B cells, over-expression of c-myc seems 
to force cells into the cell cycle and in the absence of a second signal they undergo 
apoptosis (Chemey et a l, 1994). SMS-SB cells were examined, by flow cytometry, for 
the expression of c-myc protein, after culture at normal and low cell density, m the 
presence and absence of sCD23. No fluorescence was observed, suggesting that the cells 
contain extremely low levels of c-myc protein, and there was no increase of c-myc 
observed in cells cultured at low cell density. Due to the short half life of c-myc protein, 
there was concern that the protein was being degraded before antibody staining was 
achieved. However, fixing the cells after initial permeabilisation with saponin did not allow 
detection of any c-myc. Another concern was that the anti-c-myc antibody may not have 
been binding effectively to the c-myc protein. This explanation was also eliminated after
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the B cell lines Raji and RPMI 8226 were tested with anti-c-myc. Although Raji cells did 
not have detectable c-myc protein, RPMI 8226 cells showed strong binding of the anti-c- 
myc antibody, demonstrating that the flow cytometric technique did allow detection of the 
intracellular protein (data not shown). Thus, SMS-SB cells do not appear to overexpress 
c-myc, and there was no visible increase in the level of c-myc in the cells after culture at 
low cell density. However, to further investigate the role of c-myc in apoptosis of SMS- 
SB cells, Northern blots would have to be perfoimed.
As mentioned previously, in the mature B lymphoid system the induction (or maintenance) 
of bcl-2 appears to be critical for the survival of germinal centre cells, and sCD23 is one 
of a number of stimuli which have been shown to induce bcl-2 expression in centrocytes in 
in vitro studies (Liu et al., 1991). Thus, SMS-SB cells were examined for expression of 
bcl-2 under a variety of culture conditions. A flow cytometric technique was employed, 
which allows analysis of bcl-2 expression and cell cycle parameters of the cell populations. 
After culture, the cells were gently permeabüised with saponin, stained with anti-Z?c/-2 
antibody (and FTTC-labelled sheep anti-mouse IgG), fixed with 1% paraformaldehyde, 
and then stained with propidium iodide, to visualise cell cycle parameters. In noimai cell 
density cultures (figui'e 4.17, panel A), the cells show a strong G1 peak, with a significant 
proportion of cells in or G2/M phases; i.e., the cells are still cycling. There is strong 
staining for bcl-2 expression in all phases of the cell cycle, and the level may increase 
slightly in the G2/M population; over 97% of cells scored positive for bcl-2 expression. 
Approximately 2% of the cells were present m the far left area, which represents apoptotic 
cells. The cells were aU in the lower half of this area, demonstrating that they have low 
levels of bcl-2.
After culture at low cell density (figure 4.17, panel B), the majority of the cells are in a 
pre-Gl peak (far' left area) - known to represent the late apoptotic population - and show 
weak staining for bcl-2, with only 2 2 % of the cells scoring positive for bcl-2 expression. 
However, in the presence of sCD23 (figure 3.2.20, panel C), there is a restoration of the 
cell cycle profile - characteristic of asynchi'onously growing cells - and strong bcl-2 
expression occurs in aU phases of the cell cycle, with 92% of the cells scoring as bcl-2- 
positive. Figure 4.18 is an example from a separate experiment showing bcl-2 expression 
during cell cycle phases, after culture of the cells for 12 hours at low cell density. The dot- 
plot clearly shows the pre-Gl, apoptotic population (far left area) but, in this example, 
some cells appear to be in earlier stages of apoptosis and are sttQ expressing bcl-2 (upper 
left section). There is an obvious downwards trend in bcl-2 expression as the cells proceed 
through apoptosis until, at the late apoptotic stage (lower left section) they are bcl-2- 
negative.
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Fig.4.17 Flow cytometric analysis of expression in SMS-SB cells.
SMS-SB cells were cultured as described in the legend to figure 4.14, harvested (using, 
trypsin, if necessary, to remove the cells) and washed. The cells were gently permeabüised. 
in 0 .1% saponin-containing buffer, blocked with normal rabbit serum and then treated- 
with monoclonal MiXi-bcl-2 antibody. After a 20 minute incubation on ice, the cells were" 
washed and an aliquot of FITC-conjugated, sheep anti-mouse IgG added to visualise the. 
primary MAb. After further incubation and washing, the cells were fixed in 2%' 
paraformaldehyde, treated with lOOpg/ml propidium iodide in citrate buffer and then 
analysed by flow cytometry. In the dot-plots illustrated, the x-axis shows propidium iodide, 
staining in linear units of fluorescence, whüe the y-axis represents bcl-2 staining on a* 
logarithmic scale. The three panels represent the foUowing culture conditions: Panel A 
normal cell density; Panel B - low cell density; Panel C - low ceU density + lOOng/ml gel-* 
fütration purified sCD23. The experiment shown is representative of four independent 
repeats.
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Fig.4.18 Flow cytometric analysis of bcl-2 expression throughout the cell .
cycle and apoptosis.
SMS-SB cells were cultured at low ceU density for 12 hours, stained and treated exactly, 
as described in figure 4.17. In the dot-plot illustrated, the x-axis shows propidium iodide- 
staining in linear units of fluorescence, while the y-axis represents bcl-2 staining on a"^  
logarithmic scale. The dot-plot demonstrates that levels of bcl-2 expression fall as cells, 
enter apoptosis (the pre-Gl peak) but are relatively constant throughout the rest of the" 
cell cycle (Go/Gl, S and G2/M phases). The cell cycle phases were determined as" 
compared with a population of cells growing at normal cell density. The experiment^ 
shown is representative of four independent repeats.
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4b.3 Discussion
The results presented in this section demonstrate that SMS-SB cells do, indeed, undergo 
apoptosis when they aie cultured at low cell density; this effect is possibly due to 
deprivation of the SB-autocrine factor, and provides an explanation for the initial lag 
phase seen during growth of the cells (refer figure 3.2), and also for the low [^HJ-TdR 
incorporation achieved when SMS-SB cells are cultured at low cell density in the absence 
of CM (refer figure 3.3). Entry into apoptosis appears to begin at approximately 12 hours 
after initial seeding at low cell denisty, and continues until approximately 24 hours. Both 
morphological and flow cytometric results indicate that SMS-SB cells do undergo 
apoptosis at low cell density and that sCD23 is able to prevent entry of the cells into 
apoptosis. IL-la, the cytokine which has numerous synergistic effects with sCD23, 
including the prevention of apoptosis of germinal centre B cells, does not synergise with 
sCD23 in the prevention of SMS-SB cell apoptosis. None of the other cytokines tested 
were able to promote the survival of SMS-SB cells. In fact, sCD23 alone appears 
sufficient to maintain the low ceU density population at the viability of noimal cell density 
cultures.
The precise role of c-myc in the apoptotic process is not known, although, by flow 
cytometry, SMS-SB cells do not appear to over-express c-myc and the levels do not 
appear to increase as the cells enter apoptosis. However, a role for c-myc in the apoptosis 
of SMS-SB cells cannot be ruled out until more sensitive analysis of expression is 
performed by Western or Northern blots.
One proto-oncgene which appears to be involved in prevention of SMS-SB cell apoptosis 
is bcl-2. The conclusion reached, from the FACS experiments, is that sCD23 either 
sustains, or actively promotes, the expression of bcl-2 in SMS-SB cells cultured at low 
cell density, and this event may provide a molecular explanation for the ability of sCD23 
to rescue the cells from apoptosis. It is possible that bcl-2 substitutes for the signal 
provided by the SB-AF, and provides a 'survival' signal to allow the cells to continue 
proliferation under the control of other cell cycle genes.
SMS-SB cells, as pre-B cells, may be expected to undergo apoptosis since at the pre-B 
cell stage rearrangement of Ig genes occurs and there is a considerable chance that they 
will rearrange in a non-productive fashion. The productive rearrangement of Ig genes is 
essential for further differentiation of B cells and, to ensure that only cells with a normal 
phenotype are released into the periphery, cells with non-productive rerrangements die in 
the bone marrow - probably by apoptosis (Cohen & Duke, 1992). It has become apparent 
that at the pre-B stage of B cell development the cells are 'susceptible' to apoptosis, and 
levels of bcl-2 present in the cells appear to correlate with this susceptibility. Merino et 
a i, 1994, demonstrated developmental regulation of bcl-2 levels with high levels present
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in pro-B and mature B cells, but low levels in pre-B, immature B and germinal centre cells 
- the stages where cells are prone to apoptosis.
Some human, and murine, malignant pre-B cell lines have been reported to express higher 
levels of bcl-2, compared with mature B cell lines, although normally the opposite is seen 
(Graninger et a i, 1987; Gurfînkel et ai, 1987). When SMS-SB cells are compared with 
Raji and RPMI8226 ceils (both mature B cell stages), the levels of bcl-2 detected by flow 
cytometry are almost exactly the same (data not shown). Unfortunately, without analysis 
of bcl-2 levels in other pre-B and mature B cell lines it is difficult to conclude whether 
SMS-SB cells do over-express bcl-2. It will also be important to investigate the possible 
involvement of other members of the bcl-2 family, such as bcl-x and box, since they may 
act to regulate bcl-2 function.
However, assuming that bcl-2 does have a direct effect on prevention of apoptosis, it will 
be interesting to discover what causes the down-regulation of bcl-2 when SMS-SB cells 
ai'e cultured at low cell density. A recent report has identified two pre-B cell-specific 
enhancer sites (tcI sites) in the 5' negative regulatory region of the bcl-2 gene which have 
no significant function in mature B cells. The protein(s) which binds to these regions are 
thought to be a members of the Ets family of proteins, several of which are expressed at a 
higher levels in pre-B cells than in mature B cells (Chen & Boxer, 1995). It is possible 
that, as pre-B cells, SMS-SB cells stUl express the negative regulatory protein(s) but that 
a positive regulatory signd normally over-rides the negative signal. If SB-AF provides a 
positive regulatory signal for bcl-2 transcription, then removal of SB-AF, by culture of the 
cells at low cell density, may remove this signal and allow the negative regulatory protein 
to act, or there may be a signal which induces transcription of the negative factor. The 
level of bcl-2 would, therefore, decrease and the cell would undergo apoptosis.
Another interesting feature of the bcl-2 gene is the identification of a negative regulatory 
element (NRE) in the 5’ untranslated region which contains a p5J-dependent element. 
Thus, p53 may act to down-regulate bcl-2 expression and promote apoptosis of SMS-SB 
cells. Investigation into the induction of p53 in low cell density cultures of SMS-SB cells 
would also be interesting.
From the data presented, it is apparent that sCD23 can prevent the down-regulation of 
bcl-2 expression in SMS-SB cells and so it wÜl be interesting to examine the signals 
transduced by the CD23-receptor. In germinal centre B cells, sCD23 is thought to prevent 
apoptosis by signalling through CD21, the B cell-expressed, non-IgE ligand for CD23 
(Aubry et a i, 1992). Since CD21 is not normally expressed on pre-B cells, it was decided 
to investigate which CD23-receptor mediates the biological effects of sCD23 on SMS-SB 
cells. The finding of these experiments are presented in chapter 5.
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Chapter 5
SMS-SB ceils express a novel CD23-receptor
5.1 Introduction
The reported receptors for CD23 are CD21 (Aubry et ai, 1992) and GDI lb & CD 11c 
(Lecoanet-Henchoz et al., 1995). CD21, also a receptor for C3d, C3g and iC3b 
complement proteins, interferon~a and EBV, is an approximately 140kDa glycoprotein 
expressed on B lymphocytes, some T lymphocytes, foUiculai' dendritic cells and 
pharyngeal epithelial cells (Weis et al., 1984; Delcayi'e et al., 1991; Tanner et at., 1987). 
The CD23/CD21 interaction appears to involve the C-type lectin activity of CD23 since 
binding can be inhibited by fucose- 1 -phosphate, and by timicamydn treatment of the 
RPMI 8226 cell hne (Pochon et al., 1992). CD21 and CD23 appeal' to function as 
adhesion molecules (Aubry et al, 1992; Bjorck et al, 1993; Aubry et al, 1994), and the 
interaction is thought to have a role in enhancing antigen presentation, possibly because 
CD23 also associates with MHC class II antigens (Bonnefoy et al, 1988; Flores-Romo et 
al, 1990). Since CD21 is expressed by follicular dendritic cells, the ability of sCD23 to 
prevent apoptosis in germinal centre cells (Liu et al, 1991) has been postulated to occur 
via CD21, a hypothesis somewhat supported by data ft'om Bonnefoy et al. (1993) that a 
subset of anti“CD21 antibodies are able to prevent apoptosis of germinal centre B cells, in 
vitro. However, CD21 is not expressed until the late pre-B cell stage of differentiation, 
raising the possibility that other, as yet unidentified, receptors for CD23 might exist within 
the B cell compartment.
CDllb-CDlS and CDllc-CD18 are members of the (32-integrin family of adhesion 
proteins, and act as CD23-receptors on monocytic cells (Lecoanet-Henchoz et al. 1995). 
Binding of CD23 to CD 1 Ib-CD 18/CD 1 Ic-CD 18 is also inhibited by tunicamycin 
treatment of the cells, suggesting that sugars are involved in the interaction. Addition of 
sCD23 to activated monocytes results in production of inflammatory cytokines including 
IL-ip, IL- 6  and TNF-a, indicating a possible role for CD23 in inflammatory responses. 
The only member of the p2-integrin family normally found on B ceils is LFA-1 (CDlla- 
CD18), although activated B cells may express GDI lb and/or CDllc; expression of 
LFA-1 is not usually noted on pre-B cells and it does not bind CD23 (Lecoanet-Henchoz 
et a l  1995).
This chapter of results describes experiments performed to investigate the CD23-receptor 
on SMS-SB cells which is responsible for the biological effects of sCD23. The data 
demonstrate that none of CD21, CD lib  or CD llc are expressed by SMS-SB cells yet the 
cells can bind CD23-containing hposomes in a CD23-specific fashion. Initial results from 
CD23 affinity-columns, used in an attempt to isolate the novel CD23-receptor, are also 
presented.
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5.2 Results
5.2.1 SMS-SB cells do not express known CD23-receptors
The expression of known CD23 receptors was assessed by flow cytometry as shown in 
figure 5.1. SMS-SB cells and SKW cells were stained with FTTC-labelled MAb to each of 
the p2-integrins, CD 11 a, CD 11b and CDllc, represented by the data of panels A-C 
respectively. The data clearly illusti'ate that while SKW cells express high levels of all 
three CD 11 species (solid line), the level of staining of SMS-SB cells (closely spaced 
dotted line) was the same as the autofluorescence profile of SMS-SB cells (widely spaced 
dotted line). Thus, SMS-SB cells do not express any of CDlla, CD 11b or CD llc 
antigens on their surface, and staining with FITC-anti-CD18 (figuie 5.1, panel D) 
illustrates that SMS-SB cells also lack this component of the P2~integrin complex. Panel 
E, shows flow cytometric analysis of CD21 expression by SMS-SB cells compared with 
the mature B cell lines, Daudi and Ramos. Daudi cells are strongly positive for CD21 
expression while Ramos are either negative, or very weakly positive. SMS-SB cells are 
negative for surface expression of CD21.
Southern blot analysis of the CD21 gene in SMS-SB cells, compared to SKW cells, was 
performed on DNA digested with the restriction enzymes BamHI, HINDEI and EcoRI 
(figure 5.2). A sample of 25pg of uncut plasmid was run on the gel to test the 
hybridisation capacity of the probe. The results of the restriction digest hybridisation 
demonstrate that the CD21 gene in SMS-SB cells has no deletions or insertions, 
compared with SKW cells.
More sensitive techniques, to detect expression of the CD23 receptors, were only 
performed for CD21 since the data on CD 11b and CDllc was published quite recently 
(Lecoanet-Henchoz et al. 1995). As for detection of CD23 RNA (Figuie 4.7), no 
transcripts for CD21 were detected by Northern blots of total RNA and preparation of 
mRNA was necessary. The results of Northern blots of mRNA (Figure 5.3) demonstrate 
that the cell lines Daudi and Ramos both express transcripts for CD21 but none of SMS- 
SB cells (cultured either in protein-free or serum-containing medium), SKW or Jijoye cells 
have detectable levels of CD21 mRNA. That Ramos cells express CD21 mRNA is 
interesting due to the very low, almost undetectable, staining seen by FACS (figure 5.1, 
panel E). The Northern blot was stripped of radioactivity and reprobed with a GAPDH 
probe (Figure 5.4) to demonstrate that loading of the mRNA was approximately equal and 
that the mRNA of the cell lines which were negative could be hybridised with a probe.
To ensure that there was no transcription of CD21 in SMS-SB cells, RT-PCR was 
performed with CD21-specific oligonucleotide primers (Figure 5.5). RNA was isolated 
ft'om SMS-SB cells and from SKW, Ramos and Jijoye B cell lines and a keratinocyte line,
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Fig.5.1 Expression of CD21, GDI 8 and GDI 1 antigens by SMS-SB
cells.
Aliquots (5x10^ cells) of SMS-SB cells and Ramos, SKW and Daudi B lymphoid cell Hnes. 
were harvested, washed in ice-cold PBS and stained with FlTC-conjugated MAbs specific- 
for the CDlla, CDllb, CDllc, CD 18, CD19 and CD21 antigens. After a 45 minute 
incubation, the cells were washed and analysed by flow cytometry; non-viable cells were, 
excluded from acquisition by propidium iodide counter-staining. On each graph, FITC- 
staining is shown along the x-axis on a logarithmic scale (fluorescence 1 ), with the number 
of events recorded per channel shown on a linear scale along the y-axis. For each plot,^ 
data was collected from 10"^  live-gated cells. The line styles, which represent each MAb * 
staining, are indicated on the individual panels; ’auto' refers to the autofluorescence of 
unstained cells.
Panel A - CD lla expression on SKW and SMS-SB cells
Panel B - CD llb expression on SKW and SMS-SB cells
Panel C - CD llc expression on SKW and SMS-SB cells
Panel D - CD18 and CD19 expression on SMS-SB cells
Panel E - CD21 expression on Daudi, Ramos and SMS-SB cells
The experiment is representative of three independent repeats.
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Fîg.5.2 Southern blot analysis of the CD21 gene in SMS-SB cells
Southern blots were carried out as described in materials and methods. The first lane* 
contained 25pg of uncut CD21 plasmid, pBSCD21, as a positive control for probe 
hybridisation. Lanes 2 and 3 were loaded with 20j^g samples of BamHI-digested SMS-SB- 
and SKW genomic DNA, respectively. The SMS-SB and SKW samples of each digest 
were loaded beside each other to allow comparison of the digest patterns. Lanes 4 & 5,~ 
and lanes 6  & 7, represent HINDIII and EcoRI digests of the two cell lines, respectively.- 
After the digests were separated by agarose gel electrophoresis and blotted onto nylon- 
membrane, the blot was hybridised with a [^^P]-labelled, l.Okbp, Xho-l/Not-1 insert of 
human CD21 from the pBSCD21 plasmid. Hybridisation was visualised by 
autoradiography. The experiment is representative of three independent repeats.
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Flg.5.3 Northern blot analysis of CD21 expression in SMS-SB cells and ' 
other B lymphoid cell lines.
Total cellular RNA was prepared (as described in materials and methods) from a range of, 
B lymphoid cell lines and from SMS-SB cells cutured in PFHMII and in 10% PCS/ RPMI 
1640 medium. From total RNA, the polyA mRNA fraction was isolated using the" 
PolyATract mRNA Isolation System IV. 5p,g of each ceU hne mRNA were loaded per lane, 
on a formaldehyde gel. Lanes 1 & 2 contained mRNA from SMS-SB cells grown in, 
PFHMII and serum-containing medium, respectively. Lane 3, 4^<T^6 contained mRNA 
from the B cell lines SKW, Jijoye, Ramos, and Daudi respectively. After separation by, 
electrophoresis, the RNA was blotted onto nylon membrane and hybridised with a 
labelled, l.Okbp, Xho-1/Not-1 insert of human CD21 from the pBSCD21 plasmid.- 
Hybridisation, demonstrating the existence of the 3934bp CD21 RNA, was visuahsed by 
autoradiography. The experiment is representative of five independent repeats.
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Fig.5.4 GaPDH loading control for CD21 Northern analysis
The Northern blots from the experiments described in Fig.5.3 were stripped (as described' 
in methods) and re-hybridised with a -labelled, 0.7kb GAPDH probe. The lane, 
which represented Daudi cells was removed from the blot before it was exposed to the 
film, since the strength of the signal obtained interfered the other lanes. Hybridisation was' 
visualised by autoradiography.
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Fig. 5,5 PCR analysis of CD21 expression in SMS-SB and other B
lymphoid cell lines.
Total cellular RNA was prepared (as described in materials and methods) from a range of, 
B lymphoid cell lines, a keratinocyte cell line, and from SMS-SB cells cultured in PFHMII 
and in 10% FCS/ RPMI 1640 medium. The total cellular RNA was used as a template for’ 
reverse-transcriptase (RT)-PCR using the primers, CD21a and CD21b, indicated on the, 
figure. After the PCR reactions were complete, the products (240bp) were separated by 
agarose gel electrophoresis, Southern blotted onto nylon membranes, and probed with a^  
l.Okbp, Xho-1/Not-1 insert from the pBSCD21 plasmid. The gel was loaded as shown on, 
the figure: lanes 1 & 2 were PCR products from SMS-SB cells cultured in PFHMII and in' 
serum-containing medium; lanes 3, 4 and 5 contained PCR products from SKW, Jijoye 
and Ramos B ceU Hnes, respectively; lanes 6  & 7 were negative controls of keratinocyte’ 
cells (DOK) and a PCR reaction performed with no template RNA, respectively.- 
Hybridisation was visualised by autoradiography. The experiment is representative of four- 
independent repeats. }
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DOK, as a negative control. A line drawing of the human CD21 cDNA is given, showing 
the position of the two CD21 oligonucleotide primers, CD21a and CD21b; the sequences 
of these primers are given on the figure. After reverse-transcription and 35 cycles of PCR 
amplification, products of the individual reactions were electrophoresed and detected by 
Southern blotting with a CD21-specific probe. Ramos, Jijoye and SKW cells all gave a 
product of 240bp, demonstrating that they do contain transcripts for CD21. This shows 
that the RT-PCR technique is much more sensitive than mRNA Northern analysis, since 
both Jijoye and SKW had no detectable signal by Northern blot (figure 5.3). Figure 5.5 
illustrates that SMS-SB cells do not express CD21, although in 2 out of five experiments, 
one of the duplicate reactions gave a product of similar (but not identical) size to the 
products from the other cell lines. That this product could hybridise with the CD21- 
specific probe suggests that it is CD21, although the amount of product, after 35 cycles of 
PCR, was very small. Developmental regulation of gene expression is unlikely to be an 'all 
or nothing' process so very low levels of CD21 transcript may be expected since 
expression of CD21 begins at the late pre-B cell stage.
The keratinocyte RNA and reaction performed with no RNA, both gave negative results 
demonstrating that the reagents were not contaminated. As a positive control for the 
reverse-transcriptase reaction, c-/05-specific oligonucleotides were used (refer to figure 
4.10).
5.2.2 Specific binding o f CD23-containing Hposomes to SMS-SB cells
SMS-SB cell do not express any of the currently characterised receptors for CD23 and so 
a formal demonstration of CD23 binding to SMS-SB cells was sought. Liposomes 
containing full-length (45kDa) CD23, and contr ol liposomes containing glycophorin A, 
were prepared and incubated with SMS-SB cells before the cells were examined by 
confocal microscopy. Propidium iodide was added prior to the examination, to allow 
detection of dead cells; the nuclei of dead cells appear red under the confocal microscope. 
CD23-containing liposomes bind to SMS-SB cells, with an apparently random distribution 
on the surface of the cells (figure 5.6, panel A); control glycophorin-A containing 
liposomes do not bind to the cells (panel B). Binding of CD23-liposomes to the cell hne 
RPMI 8226, which binds CD23 via CD21 (Aubry et al., 1992), is shown in figure 5.7. 
Liposome binding to RPMI 8226 cells does not appear to be evenly distributed on the ceU 
surface; a possible reason for this is that the cells had been left for approximately two 
hours before analysis and some 'capping' or clustering of the receptor/liposomes may have 
occurred. This effect was observed with SMS-SB cells if the cells were left with the 
liposomes for over an hour before analysis (data not shown).
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Flg.5.6 CD23-contaîning liposomes bind to SMS-SB cells.
Fluorescent liposomes containing either full length (45kDa) CD23 or glycophorin-A were" 
prepared as described (materials and methods), and 50pl were added to each washed, 
aliquot of 10  ^SMS-SB cells, at 4®C. After a 2hr incubation, the cells were washed three- 
times in ice-cold liposome buffer and the suspensions analysed by confocal microscopy. ' 
Propidium iodide was included to identify dead cells which stain red in the analysis (for an 
example, see panel A). Panel A illustrates binding of CD23-containing liposomes, and, 
panel B the binding of control, glycophorin-containing liposomes, to SMS-SB cells. A- 
photomicrograph was taken at a magnification of 160X.
SMS-SB ♦ CDZ3-LIPOSOMES
B
SMS-SB ♦ GLVCO A - LIPOSOMES
'1
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Fig.5.7 CD23-containing liposomes bind to RPMI 8226 cells.
This experiment was performed exactly as described in the legend of figure 5.6. but with' 
the B cell line RPMI 8226, and the stained cells were left on ice for approximately 1.5 hrs 
prior to examination under the confocal microscope. The confocal photomicrograph was 
kindly provided by Dr. J-P. Aubry, Glaxo 1MB, Geneva.
RPMI BZZfc ♦ CDZ3-LIP0S0MES
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To quantitate liposome binding, the cells were stained with the liposomes, as before, and 
analysed by flow cytometry. Figure 5.8 demonstrates that CD23-containing liposomes 
bind strongly to both SMS-SB (panel B) and RPMI 8226 (panel C) cells but not to Raji 
cells (panel A); glycophorin-A-containing hposomes failed to bind to any of the cell hnes. 
Liposome binding to SMS-SB ceUs, via the novel CD23 receptor, is of a level similar to 
that observed for RPMI 8226 cells which bind CD23 via CD21.
Several cytokines were tested for the abihty to modulate the level of CD23-liposome 
binding to SMS-SB cells. None of IL-la to IL-8 , or GM-CSF have any effect on CD23- 
hposome binding to SMS-SB cells (figure 5.9), suggesting that they do not affect the 
expression of the novel CD23 receptor. IL-la has previously been shown to increase the 
binding of CD23-liposomes to monocytes, which bind CD23 via CDllb and/or CD llc 
(Lecoanet-Henchoz et a l, 1995), suggesting that it increases either the number, or 
affinity, of receptors on the surface of the cehs.
One interesting result obtained duihng these experiments is that culture of SMS-SB cehs in 
PFHMII supplemented with 50U/ml IL-4 increases the size of SMS-SB cells from 
approximately 17pm diameter to approximately 24pm, as determined by confocal 
microscopy (figure 5.10); IL-4 has no effect on the level of CD23-liposome binding 
(figure 5.9 & 5.10). This result demonstrates that SMS-SB cells do express functional IL- 
4 receptors but IL-4 does not act to increase the number of CD23 receptors or prevent 
apoptosis of SMS-SB cells (refer figure 4.14, panel D).
The specificity of liposome binding was demonstrated by pre-incubating the liposomes for 
1 hour at 4^C, with various concentrations of the IgG fraction of Rb55 polyclonal anti- 
CD23 antibody or noimal rabbit IgG, before addition to the cehs. The data of figure 5.11 
hlustrate that anh-CD23 inhibits binding of CD23-containing Liposomes to both SMS-SB 
and RPMI 8226 cehs, but normal rabbit IgG is unable to prevent liposome binding. There 
is no binding of control glycophorin-A containing hposomes to either ceh line and this is 
not affected by either antibody (data not shown). The monoclonal antibodies EBVCS4 
and MAb25, murine IgM and IgGl respectively, are also able to inhibit binding of CD23- 
hposomes to SMS-SB cells and to RPMI 8226 cehs (figure 5.12); control mouse IgGl 
and IgM antibodies have no effect on liposome binding (data represented by hne for CD23 
hposomes + control, top panel). Since both Mab25 and EBVCS4 can inhibit binding of 
CD23-containing hposomes to SMS-SB and to RPMI 8226 cehs, CD23 must bind the 
receptor present on SMS-SB cells via epitopes also used in binding to CD21.
One difference in the CD23 interaction with SMS-SB compared to RPMI 8226 cehs is 
that 25kDa sCD23 rr^ypartially hihibit the CD23-Hposome binding to SMS-SB but not to 
RPMI 8226 cehs (figure 5.13). The addition of 10|4g/ml BSA has no effect on hposome
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Fig,5.8 Quantitation of CD23-containing liposome binding to SMS-SB 
and other B lymphoid cell lines.
Aliquots of 10  ^Raji (panel A), SMS-SB (panel B) and RPMI 8226 cells (panel C), were. 
incubated with either CD23-containing (solid line) or glycophorin-A-containing (broken- 
Hne) fluorescent liposomes, for 2 hours at 4°C. After incubation, the cells were washedJ 
three times in liposome buffer and then analysed by flow cytometry for liposome binding,, 
The x-axis of each panel represents the FITC-fluorescence (due to liposome binding), on a, 
logarithmic scale. The y-axis represents the number of events per channel, on a linear ~ 
scale. The experiment is representative of more than five independent repeats.
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Fig.5.9 Effect of various cytokines on the level of CD23-containing
liposome binding to SMS-SB cells.
SMS-SB cells were incubated in PFHMII supplemented with 5ng/ml of one of the. 
cytokines IL-la to IL- 8  or GM-CSF. After 18 hours, the cells were washed and them 
incubated for 2 hours with 50pl of either glycophorin-A-containing liposomes or CD23- 
containing liposomes. The cells were then washed three times and analysed by flow, 
cytometry. The chart shows the average fluorescence obtained after treatment of the cells< 
with various cytokines, as a percentage of the CD23-liposome binding to untreated SMS- 
SB cells (the positive control for binding is given as 100%). The error bars represent the, 
standard error of the mean, giving the maximum and rninimum difference in fluoresence*  ^
from the control CD23-liposome binding. The data from three experiments was averaged, 
and then the standard error calculated.
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Fig.5.10 IL-4 increases the size of SMS-SB ceUs but does not increase the 
level of CD23-containing liposome binding.
SMS-SB cells were incubated in PFHMII in the presence or absence of 50U/ml IL-4 for 
18 hrs. The cells were then washed and mixed with CD23-containing liposomes for 2. 
hours. After three washes with ice-cold liposome buffer, the cells were analysed ty  
confocal microscopy. Binding of CD23-containing Hposomes to IL-4-treated cells (left 
hand panel, IL-4), demonstrates the increased size of the cells compared to untreated^ 
SMS-SB cells (right hand panel, control). Both photomicrographs were taken at a 
magnification of 160X. The cells were also analysed by flow cytometry and the mean, 
fluorescence observed were the same whether or not the cells had been treated with IL-4 
(see figure 5.9). The experiment is representative of three independent repeats.
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Fig.5.11 Specificity of CD23-containing liposome binding to SMS-SB and -
RPMI 8226 cell lines.
CD23-containing liposomes were pre-incubated for 1 hour with 40pg/ml of either normal 
rabbit IgG or Rb55 anti-CD23 polyclonal IgG fraction. AHquots (10  ^cells) of SMS-SB- 
and RPMI 8226 cells were incubated with the pre-treated liposomes for 2 hours before" 
being washed three times with liposome buffer and analysed by flow cytometry. Panel A, 
illustrates binding to SMS-SB cells; panel B illustrates binding to RPMI 8226 cells. 
both panels:- the broken line represents the autofluorescence of the cell line; the dotted- 
line represents binding of CD23-containing liposomes pre-incubated with normal rabbit. 
IgG; the solid line represents binding of CD23-containing liposomes pre-incubated with 
Rb55 anti-CD23 IgG. The data is illustrated as described in the legend for figure 5.8.? 
'EPC represents 'events per cell'. The experiment is representative of three independent 
repeats.
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Fig.5.12 Differential ability of monoclonal anti-CD23 antibodies to inhibit 
CD23-containing liposome binding to SMS-SB cells.
The experiment was performed as described in the legend of figure 5.11, but using only 
SMS-SB cells, and with addition of CD23- and glycophorin-A-containing liposomes 
which had been pre-incubated for 1 hour with lOpg/ml of EBVCS4 or Mab25 anti-CD23 
MAbs, or control mouse IgG, or mouse IgM. Panel A represents the results obtained on 
addition of control, glycophorin-A-containing liposomes to SMS-SB cells (dotted line) 
the solid line represents control liposomes plus all control and anti-CD23 antibodies 
tested. The evenly broken line represents the autofluorescence of SMS-SB cells
Panel B represents SMS-SB cells incubated with CD23-containing liposomes pretreated 
with either:- EBVCS4 anti-CD23 (dotted line); Mab25 anti-CD23 (broken line); or 
control mouse IgG (solid line). The unevenly broken line represents the autofluorescence 
of SMS-SB cells. The experiment is representative of four independent repeats.
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The liposome binding and inhibition studies are consistent with the hypotliesis that SMS- 
SB cells possess a novel and, as yet, unidentified receptor for CD23.
binding to either cell type, as îc^presented by the line for CD23-Iiposomes alone (figure 
5.13). Binding of sCD23 to CD21 is thought to be a low affinity interaction (Aubry et aL, 
1992) and this result confirms that sCD23 is unable to compete with the binding of the full 
length CD23 contained in the liposomes. However, the CD23 receptor present on SMS- 
SB ceils appears to bind sCD23 with a higher affinity since sCD23 can partially inhibit the 
binding of full length CD23 to SMS-SB cells.
Pre-incubation of SMS-SB cells with a panel of monoclonal anti-CD21 MAbs, including 
BU-33, a strong inhibitor of CD23 binding to RPMI 8226 cells, does not inhibit binding of 
CD23-liposomes to SMS-SB ceUs; and no inhibition is seen on pre-incubation of SMS-SB 
cells with several anti-CD 11 a, -CD 11b and -CD 11c, or anti-CD 18 antibodies (table 5.1). 
The data all support the hypothesis that SMS-SB cells do not bind CD23 via CD21, 
CD 11b or CD 11c, the currently characterised CD23 receptors.
Table 5.1 shows the range of MAbs tested for their ability to bind to SMS-SB ceils and 
the ability to inhibit CD23-liposome binding. The majority of the monoclonals were 
chosen due to the molecular weight of the CD molecule they were raised against; 
preliminary data from affinity-purification columns suggests that the novel receptor may 
have a moleculai* weight of approximately 85kDa (see below). CD5 is a candidate 
receptor because its known ligand, CD72, is a member of the same family as CD23 and 
the two molecules have a very similar structure (Gould et al., 1991). However, none of 
the monoclonals tested, except anti-CD23 Mabs, are able to inhibit binding of CD23- 
containing liposomes to SMS-SB cells (table 5.1). Several of the MAbs against CD 
molecules expressed by SMS-SB cells (such as CD 19, CD54, CD71 and CD 105) gave 
ambiguous results, since addition of the antibodies increased the level of hposome binding. 
This effect was shown to be non-specific, since it also occurred with glycophorin-A- 
containing hposomes. Thus, several CD molecules cannot be excluded as candidate CD23 
receptors, although no decrease in hposome binding was observed even on co-incubation 
with anti-CD23 MAbs, so it appeal's that they are not involved in CD23-binding to SMS- 
SB cells. Fresh liposomes wül be necessary to examine any possible role of these 
molecules in CD23-binding by SMS-SB cells.
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Fig.5.13 Effect of 25kl>a sCD23 on CD23-containing liposome binding.
In this experiment, aliquots (10  ^cells) of SMS-SB and RPMI 8226 cells were pre-treated 
with lOqg/ml of Eco/f-produced 25kDa sCD23 for 30 minutes, on ice. 50pl of CD23- 
containing liposomes were then added and the cells incubated for 2 hours at 4°C before 
they were washed three times with liposome buffer and analysed by flow cytometry. Panel 
A illustrates CD23-Iiposome binding to SMS-SB cells untreated (solid line) or pre-treated 
with sCD23 (dotted line). A control of addition of lOpg/ml BSA was also performed; the 
results are also represented by the solid line. Panel B illustrates the results obtained with 
RPMI 8226 cells, represented as for panel A. The x-axis of each panel represents the 
FITC-fluorescence (due to liposome binding), on a logarithmic scale. The y-axis 
represents the number of events per channel, on a linear scale. The experiment is 
representative of three independent repeats.
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Table 5.1 Antibody inhibition of CD23-containing liposome binding.
SMS-SB cells were harvested, washed and pre-incubated with 10 pg/ml of the antibodies 
listed in the table, for one hour at 4^C. The table shows whether the antigens were 
detectable by FITC-MAbstaining of SMS-SB cells (both FITC conjugated and 
unconjugated MAbs were used; a FITC-conjugated secondary MAb was used where the 
primary MAb was unconjugated).The cells were then stained with CD23-containing 
liposomes as described previously (Fig.5.8), and liposome binding analysed by flow 
cytometry. Binding was scored in relation to cells incubated with CD23-liposomes alone.
represents no binding to SMS-SB cells, or no inhibition of liposome binding (maximal / 
normal CD23-liposome binding), depending on the column heading. represents binding 
to SMS-SB cells or inhibition of CD23-liposome binding equivalent to the inhibition seen 
in figure 5.11. with Rb55 anti-CD23.
* the liposomes were pre-incubated with anti-CD23 antibody rather than SMS-SB 
cells; as described previously, EBVCS4, Mab25 and Rb55 all inhibited liposome 
binding, although to slightly different extents (see figures 5.11 and 5.12)
# the anti-CD21 MAbs tested were: BU33 (The Binding Site), THB5 (GIMB), 
MCA644 (Serotec), CR2 (Becton Dickinson) and lOBIa (Immunotech).
nd this represents a situation where the results were not clearly defined due to non­
specific enhancement of liposome binding.
Each individual experiment was repeated at least three times.
A n t ib o d y  a d d e d B in d in g  t o  s m s -sb In h ib it io n  o f  CD23-
CELLS LIPOSOME b in d in g
control IgG/ IgM M -
MHC class II + nd
CDS + "
CD6 - -
CD9 - -
CDIO ■> -
C D lla -
C D llb - -
C D llc - -
CD16 m
CD18 -
CD19 + -
CD20 - -
CD21# + ”
CD22 + -
CD23 ^ ” + +
CD25 » -
CD32
CD37 “ "
CD38 ” -
CD40 -
CD43 + nd
CD45 + nd
CD49d + nd
CD54 4" nd
CD64 « -
CD71 + nd
CD72 + nd
CD76 " -
CD105 ■ nd
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5.2.3 Characterisation of the CD23"novel receptor interaction
CD23 may be acting as a C~type lectin in its interaction with the novel receptor, as has 
been observed for its interaction with CD21 and CD 1 lb/CD 11c. Figure 5.14, panelA, 
demonstrates that EDTA decreases CD23 binding to SMS-SB cells by chelation of Ca^+ 
in the Hposome buffer. Panel B shows the same result for binding of CD23-liposomes to 
RPMI 8226 ceUs. Ca^+ is, apparently, essential for CD23 binding to SMS-SB ceUs. The 
involvement of sugars in the CD23 / SMS-SB ceU interaction is not clear; technical 
difficulties have prevented a cleai' demonstration of whether fucose- 1 -phosphate or 
glucose-1-phosphate can inhibit Hposome binding to either SMS-SB cells or to RPMI 
8226 ceUs. Fucose-1-phosphate is known to inhibit CD23 / CD21 binding, as does 
tunicamycin treatment of RPMI 8226 ceUs. Tunicamycin treatment of monocytes also 
inhibits CD23 binding, suggesting that sugar stmctures are involved in the binding of 
CD23 to CD 1 lb/CD 11c; unfortunately, tunicamycin treatment of SMS-SB cells was not 
perfoimed. However, it seems likely that a sugar structure will be involved since sCD23 is 
comprised almost exclusively of the lecHn head.
The involvement of siaHc acid stmctures was investigated to examine whether CDw75 or 
CD76 are candidates for the novel receptor. These differentiation antigens have a 
molecular weight of approximately 85kDa, and CDw75 is expressed by germinal centre B 
cells (Bast et al., 1992). Although neither antigen is reported to be expressed by pre-B 
ceUs, the antigens are carbohydrate-rich and neuraminidase-sensitive. SMS-SB cells were 
treated with bacterial neuraminidase for 1 hour at 37°C, before incubation with the 
Hposomes (figure 5.15). Neuraminidase treatment of the cells does not inhibit CD23- 
Hposome binding, demonstrating that siaHc acid is not mvolved in the interaction between 
CD23 and SMS-SB ceUs. This is consistent with CD23 binding to CDllb and CDllc, 
where neuraminidase has no effect on liposome binding (Leconaet-Henchoz et al., 1995).
At present, the binding characteristics of CD23 to the novel receptor are not fuHy 
characterised; numerous experiments require to be performed to understand the 
interaction. Tunicamycin h'eatment of the cells would be useful to identify whether sugars 
are involved in the binding, although tunicamycin can sometimes affect the intracellular 
transport or ceU surface expression of Hgands (Aubry et a i, 1992), so results may not be 
entirely conclusive. Involvement of N-linked oHgosaccharides could be further 
investigated by treatment of the ceUs with plant alkaloids such as castanospermine (CSP) 
and/or swainsonine (SW). These compounds can be used to inhibit N-Hnked 
oligosaccharide processing (Hashim & Cushley, 1988) and would allow determination of 
the role of these sugars in binding of CD23 to the novel receptor. The role of 0-linked 
sugars could also be investigated using the enzyme 0 -glycanase.
Fîg.5.14 Effect of EDTA on CD23-liposome binding to SMS-SB and
RPMI 8226 cells.
SMS-SB and RPMI 8226 cells were stained with CD23-containing or glycophorin-A-  ^
containing liposomes, as described in the legend of figure 5.8. In addition, an aliquot of" 
each cell type was incubated with 5mM EDTA / PBS along with the CD23-containing ^  
liposomes. After 2 hours, the cells were washed three times and liposome binding, 
analysed by flow cytometry. Panel A illustrates liposome binding to SMS-SB cells and* 
panel B shows the results obtained with RPMI 8226 cells. The lines illustrate:-" 
glycophorin-A-liposome binding (wide-spaced dotted line); CD23-Hposome binding 
(dotted line); and the binding observed with CD23-liposomes plus EDTA (solid lines).* 
The x-axis of each panel, ELI, represents the FITC-fluorescence (due to liposome' 
binding), on a logarithmic scale. The y-axis represents the number of events per channel,. 
on a linear scale. The experiment is representative of three independent repeats.
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Fig.5.15. Neuraminidase treatment of SMS-SB cells does not aflPect binding - 
of CD23-containing liposomes.
SMS-SB cells were treated with 50|xl of 0.1 U/ml neuraminidase from Arthrobacter 
ureafaciens, Clostridium perfringens or Vibrio cholerae, for 1 hour at 50pl of-
CD23-containing Hposomes were then added and the cells incubated for 2 hours before ' 
being washed three times (with Hposome buffer) and analysed by flow cytometry. On the 
FACS plot, the black line shows binding of CD23-containing Hposomes and the red line- 
shows binding of CD 23-containing Hposomes in the presence neuraminidase from " 
Arthrobacter ureafaciens (this Hne also represents the results obtained with Clostridium 
perfringens and Vibrio cholerae). The experiment is representative of three independent, 
repeats.
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Identification of the epitopes recognised by anti-CD23 MAbs able to inhibit the interaction 
would give information about the domains of CD23 involved in binding, and once the 
novel receptor is isolated, monoclonal antibodies raised against it can be screened for the 
ability to inhibit liposome binding. After epitope mapping, this would provide information 
about regions on the novel receptor which are involved in binding of CD23.
5.2.4 CD25- affinity purification o f the novel receptor- preliminary results 
Tire method chosen to identify and isolate the novel CD23 receptor on SMS-SB cells was 
a CD23-affmity column. The sCD23 is very strongly bound to the Ajfigel column but, for 
the first few elutions of a new column, some 25kDa sCD23 elutes horn the resin, raising 
the possibility that some of the bound receptor may also be lost; the resin becomes more 
efficient after a few uses.
To examine the efficiency of the CD23 affinity column in the isolation of CD21, from 
RPMI 8226 cells, and to further demonstrate that CD21 is not involved in binding of 
CD23 to SMS-SB cells, cell extracts were made from SMS-SB cells, Raji cells (as a 
negative control) and RPMI 8226 cells. After passing aU the extracts over a BSA pre­
adsorption, and then a CD23-affmity column, the eluted material from the CD23-column, 
and the flow-through of each cell hne was electrophoresed, Western blotted and then 
incubated with a cocktail of anti-CD21 MAbs. A peroxidase-labelled goat-anti-mouse 
antibody was used as a secondary antibody and detected by ECL (figure 5.16). As 
expected, there is a band visible for RPMI 8226 cells (lane C), although, compared to the 
molecular weight markers, it appears to be smaller than expected for CD21. However, 
comparison of this blot with those prepared using an anti-CD21 affinity column, shows 
that the band does represent CD21 (Dr. Piene Graber, personal communication); no band 
is visible for SMS-SB cells (lane B). Raji cells were used as a negative control and, 
indeed, no bands are visible in the eluted material from the CD23-affinity column (lane A). 
However, the flow-through from the Raji column has a very strong band of approximately 
116kDa, thought to represent Raji CD21 (lane D). It is known that only a subtype of 
CD21 molecules binds CD23 (Aubry et al., 1992), and although Raji cells do express high 
levels of CD21 they do not bind CD23.
The results of the CD21 Western suggest that the binding of CD21 to sCD23 may be a 
low affinity interaction. The ECL reaction, used to detect anti-CD21 staining, had to be 
left for 20 minutes before the RPMI 8226 band (lane C) was visible. Lanes D, E & F 
represent the same blot but with the film exposed for only 1 second. Thus, either RPMI 
8226 cells only express a tiny amount of the CD21 isoform or the efficiency of CD21 
capture by sCD23 is very low. The latter explanation appears most likely since results 
using anti-CD21 affinity columns give very strong bands for RPMI 8226, suggesting that
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Fig.5.16 CD23 affinity column - CD21 Western of eluates from SMS-SB, Raji 
and RPMI 8226 cells,
10  ^SMS-SB, Raji and RPMI 8226 cells, produced in large scale cultures, were washed, 
and then 1/10th of the cells were biotinylated. Cell extracts were made from the cells- 
(biotinylated and non-biotinylated cells mixed together) and run through an IgG/BSA pre­
adsorption column and then the flow-through run through a CD23 affinity column (as 
described in materials and methods). After extensive washes, any material bound to the- 
CD23 column was eluted using a NH4SCN elution buffer, and the eluted material dialysed 
extensively. The eluted material and the flow-through samples were diluted 4 parts to one 
part with non-reducing SDS-PAGE sample buffer, boiled for 5 minutes, and 40pl were 
loaded per well of a 7.5% acrylamide gel. After the gel was run, the protein was Western 
blotted onto nitrocellulose and the blot incubated with 10ml of a cocktail of anti-CD21 - 
MAbs (as detailed in the legend of table 5.1) at 10.8mg/ml in PBS/0.05% Tween. 
Antibody binding was detected with 4mg/ml goat anti-mouse-peroxidase in PBS/0,05%  ^
Tween and an ECL detection system with Fuji RX film.
Lanes A, B and C contained the material eluted from the CD23 affinity column for Raji, 
SMS-SB and RPMI 8226 cells respectively. High molecular weight standard markers 
were run in lane D and lanes E, F, and G were the flow-through from the CD23 affinity' 
columns of Raji, SMS-SB and RPMI 8226 cells respectively. The band at approximately. 
120kDa (lane C) is RPMI 8226 cell CD21, and the band seen in the Raji flow-through 
(lane E), although a different molecular weight, also represents CD21, as judged ty  
comparison with Western blots previously performed using anti-CD21 affinity columns 
(courtesy of Dr, Pierre Graber, GIMB), The experiment is representative of three 
independent repeats.
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CD21 is expressed at quite a high level by RPMI 8226 cells (Dr, Pierre Graber, personal 
communication).
The data in figure 5.17 show a strepdavidin-peroxidase, ECL Western blot of biotinylated 
SMS-SB ceU proteins. The surface of the cells was biotinylated and then a cell extract 
prepared using the detergent octyl-p-D-glucopyranoside (OGP), which solubilises 
membrane-bound proteins in their native state. After complete homogenisation, the ceU 
extract was inn through a BSA, pre-adsorption column to remove proteins which bind 
non-specificaUy. The flow-through of the BSA, pre-adsorption column was then passed 
over the CD23-affinity column and the flow-through of this was also collected. Due to the 
small volume of these preliminary affinity columns, it was possible to elute the bound 
material by boiling the resin with non-reducing SDS-sample buffer; thus the material could 
be loaded directly onto an SDS-gel, electrophoresed and then a Western blot performed 
with streptavidin-peroxidase to detect the biotinylated protein. Figme 5.17 shows the 
biotinylated proteins present: in the total ceU extract (lane A); eluted from the BSA 
column (lane B); eluted from the CD23-affinity column (lane C); in the flow-through of 
the CD23 affinity column (lane D). A sample of biotinylated sCD23 was run on the gel as 
a positive control for the biotinylation reaction and strepdavidin-peroxidase binding (lane 
E). The CD23-affinity column reduces the number of bands seen on the gel but there are 
stin numerous bands present. Two particularly strong bands ai'e visible, one of 65-70kDa 
and the other of approximately 85kDa molecular weight. These bands are present in the 
material which has bound to the CD23-affinity column but, unlike most of the other 
bands, aie not present in the flow-through, suggesting that they have bound specifically to 
the CD23 column. To examine if other, non-biotinylated, proteins also bound to the 
affinity column, a silver stain was performed using the Pharmacia, PhastGel system. 
Several other protein bands are visible by silver stain (data not shown) so care must be 
taken if attempts are made to extract bands from the gel for sequencing. It may be 
necessary to perform 2-D gel elecrophoresis to check for contaminating proteins.
In an attempt to reduce the number of proteins bound non-specifically to the column, the 
volume of resin used was increased to 5ml and and sodium thiocyanate was used to elute 
the bound material, as opposed to boiling the resin. To extract sufficient material from the 
blot to attempt sequencing, it was decided to use 2 x1 0  ^cells instead of the 1 0  ^cells used 
previously. After lai'ge scale culture of the cells, only a proportion (1/lOth) of the cells 
were biotinylated since preliminary blots had shown that this was sufficient for detection 
of biotinylated proteins, and the labelling procedure would be very costly for such a large 
number of cells. The results of figui'e 5.18 show a strepdavidin-peroxidase ECL Western 
of biotinylated material eluted from the large scale IgG/BSA pre-adsorption column (after 
the flow-through had been collected to be passed over the CD23 column), and CD23 
affinity column; the flow-through of the CD23-column was collected before the material
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Fig.5.17 CD23 affinity column - attempt to identify the novel CD23
receptor on SMS-SB cells.
A cell extract was prepared from 10 ,^ surface-biotinylated SMS-SB cells, run through an' 
IgG/ BSA pre-adsorption column and then the flow-through from this column was run- 
through a CD23 affinity column. After extensive washes, both the BSA and the CD23 " 
affinity resin were boiled in non-reducing SDS-PAGE sample buffer to elute any bound ^  
material. Samples of the initial cell extract and the flow-through from both columns were 
prepared as described in the legend of figure 5.16. The samples were loaded on a 7.5% ' 
acrylamide gel:- lane A = initial cell extract; lane B = material bound to the BSA column; 
lane C = material eluted from the CD23 affinity column; lane D = the flow-through from  ^
the CD23 affinity column; lane E = a sample of biotinylated 25kDa CD23. High and low' 
molecular weight standard markers were also run, as demonstrated on the figure. After 
electrophoresis and Western blotting, the blot was incubated with streptavidin-peroxidase- 
and then an ECL detection system was used to visualise any biotinylated proteins. The' 
experiment is representative of two independent repeats.
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Fîg.5.18 CD23 affinity column - attempt to isolate the novel CD23 
receptor.
Aliquots of 10 8  SMS-SB (cultured in both PFHMII and 10% FCS/RPMI 1640) and Rajf 
cells were biotinylated, mixed with 1.4x10^ unbiotinylated SMS-SB ceU, before cell- 
extracts prepared, and run through an IgG/BSA pre-adsorption column. The flow-through" 
of this was run through a CD23 affinity column (as described in materials and methods). 
After extensive washes, any material bound to the IgG/BSA or CD23 columns was eluted ., 
using a NH4SCN elution buffer, and the eluted material dialysed extensively. The eluted"' 
material, and the material which passed through the CD23 column, were mixed 4 parts to 
1 part with non-reducing SDS-PAGE sample buffer, boiled for 5 minutes, and 40pl were- 
loaded per well of a 7.5% acrylamide gel. After electrophoresis and Western blotting, the ' 
blot was incubated with streptavidin-peroxidase and an ECL detection system was used to., 
detect the biotinylated proteins.
Lanes 1, 2 and 3 contained the material eluted from the IgG/BSA column:- A, represents 
SMS-SB cells cultured in PFHMII; B, represents SMS-SB cells cultured in 10%'- 
FCS/RPMI 1640; C, represents Raji cells. Lanes 4, 5 and 6  contained the material eluted 
from the CD23-affinity column, and lanes 7, 8  and 9 contained the material which passed, 
through the CD23 affinity column; with A, B and C, as before. High molecular weight' 
standard markers were also run, as represented on the figure. The experiment is_ 
representative of two independent repeats.
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bound to the CD23-column was eluted. This procedwe was performed for SMS-SB cells 
grown in protein-free medium (A), SMS-SB cells grown in serum-containing medium (B) 
and Raji cells (C). Several bands aie visible in the material eluted from the SMS-SB cell 
CD23-affinity columns, and although weaker, most of the bands are also visible in the 
material eluted from the Raji ceU CD23-affinity column. The results suggest that the 65- 
70kDa band visible in figure 5.17 is also present in the Raji ceU extract, and therefore, is 
unlikely to represent the novel CD23 receptor - although it may represent part of a 
receptor complex, the other components of which are missing from Raji ceUs, One band 
which does appear to be specific to SMS-SB cells is approximately 85kDa, which 
corresponds with the initial result (figure 5.17). There is no difference in the banding 
patterns seen with SMS-SB cells cultured in serum-containing or protein-free medium, 
removing the concern that some serum proteins may be biotinylated and detected by this 
method.
Several further attempts were made to isolate the SMS-SB cell receptor by comparing the 
CD23-affinity bound material from large numbers (2x10^ cells) of SMS-SB (test), Raji 
(negative control) and RPMI 8226 (positive conti’ol) ceUs, to allow a complete 
comparison of cell extracts. Unfortunately, the results obtained were disappointing; either 
the gels were overloaded or no bands were visible at all.
However the CD23-affinity-coiumn method does indicate that an 85kDa protein 
represents a candidate for the novel CD23 receptor and, with minor adjustments, this 
large scale procedure should allow enough protein to be isolated for the band to be 
removed and, hopefully, sequenced.
5.3 Discussion
The main findings presented in this chapter are that SMS-SB cells do not express any of 
the known CD23-receptors, namely CD21, CDllb-CD18 or CDllc-CDlS, but bind 
CD23-containing liposomes specifically, demonstrating the existence of a novel CD23- 
receptor on SMS-SB cells. Preliminary results from CD23-affinity columns suggest that 
the novel receptor may have a molecular' weight of approximately 85kDa, although 
attempts to inhibit CD23-containing liposome binding - using MAbs raised against known 
CD antigens of approximately 85kDa - have, so far, failed to identify the novel receptor.
CD21 is not expressed by SMS-SB cells, as shown by several techniques including the 
extremely sensitive technique of RT-PCR, and also by the fact that none of a cocktail of 
anti-CD21 antibodies are able to inhibit the binding of CD23-containing liposomes to 
SMS-SB cells. That SMS-SB ceils do not express CD21 helps to characterise them as 
pre-B cells since CD21 expression usually occurs at the late-pre-B / immature B cell stage 
of development. The expression of CDllb-CD18 and CDllc-CD18 was only examined
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by flow cytometry, which does not exclude the possibility of very low level expression at 
the cell surface. However, none of a panel of anti-CD lib , anti-CD 11c or anti-CD 18 
MAbs are able to inhibit-liposome binding, demonstrating that these molecules are not 
involved in binding of CD23 to SMS-SB ceUs. These P2-integrin molecules are normally 
expressed by cells of the myeloid lineage (Lecoanet-Henchoz et al., 1995) and not by pre- 
B cells, so this result was as expected.
The only available antibodies which ai'e able to inhibit the binding of CD23-liposomes to 
SMS-SB cells are Rb55, a polyclonal anti-CD23, and the MAbs, EBVCS4 and MAb25. 
These monoclonal antibodies are also able to prevent binding of CD23-liposomes to 
RPMI 8226 ceUs, suggesting that binding of CD23 to the novel receptor involves at least 
two epitopes which ai'e involved in binding of CD23 to CD21. Although the results with 
the monoclonal antibodies suggest that the interaction of CD23 with CD21 and with the 
novel receptor involve some common epitopes, binding does appear to differ, at least with 
respect to soluble CD23. The binding of full length CD23 to SMS-SB cells is partially 
inhibited by pre-incubation of the cells with sCD23, however, very little inhibition of 
CD23-liposome binding is observed for RPMI 8226 cells treated m the same way. These 
results demonstrate that the two receptors bind in a similar but substantially different 
fashion, and the novel receptor on SMS-SB cells may bind soluble CD23 with higher 
affinity than does CD21.
None of a range of cytokines tested are able to influence the binding of CD23-Hposomes 
to SMS-SB cells which suggests that the numbers and / or affinity of the novel receptor 
are not affected. This is of particular interest after the report demonstrating that IL -la 
increases the number of IL-2, IL-3 and GM-CSF receptors present on cells (Mossalayi et 
al., 1991). IL -la also appears to affect either the number or affinity of CDllb / CD llc 
molecules present on monocytes, since it increases the level of CD23-liposome binding to 
the cells (Lecoanet-Henchoz et al., 1995). However, IL -la does not affect the binding of 
CD23-liposomes to SMS-SB cells, consistent with the apoptosis studies which also failed 
to demonstrate a role for IL-la.
CD23-binding to SMS-SB cells is Ca^+-dependent and not sensitive to neuraminidase 
treatment, so sialic acid residues are not involved in binding. These results are consistent 
with the interactions involved in binding of CD23 to CD21 and CDl lb/CD 11c (Aubry et 
al., 1992; Lecoanet-Henchoz et al., 1995), although unlike these interactions, inhibition of 
CD23-binding to SMS-SB cells by fucose-1-phosphate has not been clearly demonstrated. 
If fucose-1-phosphate is shown to inhibit the SMS-SB / CD23 interaction then the lectin- 
activity of CD23 is involved in binding; this appears likely since sCD23 consists almost 
entirely of the lectin domain (Delepesse et al., 1991).
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The results of the CD23-affinity columns support the suggestion that the sCD23/CD21 
interaction is of low affinity, since very little CD21 is captured by the 25kDa sCD23 
column. It is also possible that RPMI 8226 cells have only low level expression of CD21 
or that the specific isoform of CD21 which binds CD23 is not continually expressed. 
However, from the results of anti-CD21 affinity columns it appears that RPMI 8226 cells 
do express high levels of CD21, therefore it may be reasonable to suggest that CD21 does
I
not bind to sCD23 with very high affinity (Dr. Pierre Graber, personal communication).
If the SMS-SB cell-specific 85kDa band eluted from the CD23-affinity column does 
represent the novel CD23 receptor, the results suggest that its interaction with CD23 is of 
a higher affinity than that between CD23 and CD21 since much more of the 85 kDa 
protein is captured by the CD23 column, compared with CD21. The main concerns with 
this method of receptor capture and identification are that the biotinylation technique is 
biased towards detection of proteins which are lysine-rich and so some proteins may not 
be labelled and others will be very strongly labelled, giving the impression that they are 
expressed at high levels. There will also be problems in isolation if the receptor consists of 
more than one component.
However, preliminary results suggest that there is a protein of approximately 85kDa 
which can be detected in material eluted from a CD23-affinity column of SMS-SB ceil 
extract but not Raji cell extract, a ceE line which does not bind CD23. Secondly, this 
protein appears to be captured specifically by the CD23 column because no 85kDa band is 
visible in the flow-through of the column, unlike the majority of protein bands seen.
Numerous MAbs specific for CD molecules of between 65 and lOOkDa molecular weight, 
have been tested for the ability to inhibit CD23-liposome binding to SMS-SB cells. 
Several of these antibodies, known to bind to SMS-SB cells, require to be re-tested due to 
non-specific enhancement of liposome binding, although they do not appear to have any 
ability to inhibit liposome binding. At present, the novel CD23 receptor present on SMS- 
SB cells remains to be fully characterised but its function, in prevention of pre-B cell 
apoptosis, makes it an extremely interesting molecule for future investigation.
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Chapter 6 
General Discussion
6.1 Main conclusions
The main findings of this thesis are that the pre-B cell line, SMS-SB, is density-dependent 
for growth, possibly due to the production of an autocrine growth factor. Attempts to 
identify the SB-AF have excluded the interleukins normally associated with normal pre-B 
cell growth and differentiation, namely, IL-3, IL-4, IL-5 and IL-7, since these cytokines 
are not produced by the cells. One candidate component of the SB-AF activity is PDGF- 
a a ; SMS-SB cells express both PDGF receptors, secrete PDGF-a chains, and 
recombinant PDGF-aa promotes the growth of the cells (Tsai et al. , 1994). The presence 
of autocrine PDGF activity in conditioned medium from SMS-SB cells could not be 
proven using anti-PDGF neutralising MAbs, leading to the hypothesis that PDGF might be
acting as an internal autocrine factor. The ability of conditioned medium to promote the V'igrowth of SMS-SB cells cultured at low cell density suggests the existence of another 
component of the SB-AF activity, but at present this factor has not been identified.
During experiments to identify the SB-AF, it was noted that sCD23 can promote the t
growth of SMS-SB cells cultured at low cell density. It has been demonstrated that SMS- 
SB cells do not express CD23 and, therefore, it does not represent the SB-AF. .ÿSubsequent studies have shown that, when cultured at low cell density, SMS-SB cells 
undergo apoptosis; sCD23 can prevent apoptosis of the cells. This effect of sCD23 is 
independent of IL-la, the cytokine which normally synergises with sCD23 during its 
cytokine activities. The mechanism of action of sCD23 appears to be via induction, or i
maintenance, of bcl-2 expression. No role for c-myc expression has, so far, been 
demonstrated in SMS-SB cell apoptosis.
SMS-SB cell do not express any of the known receptors for CD23, namely CD21,
GDI lb-CD 18 or CDllc-CDlB, but the cells do bind CD23-containing liposomes in a
=f;:specific manner and the binding is inhibited by a polyclonal anti-CD23 antibody and at 
least two anti-CD23 MAbs. Thus, SMS-SB cells express a novel receptor for CD23 
receptor. Unlike RPMI 8226 cells, which bind CD23-liposomes via CD21 (Aubry et al. y 
1992), the binding of CD23-Hposomes to SMS-SB cells is partially inhibited by 25kDa 
sCD23, suggesting that the novel receptor has a higher affinity for sCD23 than does 
CD21. CD23-affinity columns were used to identify the novel receptor, and preliminary 
results suggest that the novel receptor has a molecular weight of 85kDa. Of several MAbs 
tested (which have specificity for CD molecules with molecular weights of approximately 
85kDa, and/or expressed by B cells) none have the ability to inhibit binding of CD23-
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liposomes to SMS-SB cells. Therefore, at present, the novel CD23-receptor present on 
SMS-SB cells has not been fuUy characterised.
I
There is very little information available about autocrine factor production during early B 
cell development and so the discovery of the cell line, SMS-SB, a pre-B cell ALL, was of 
great interest. The leukaemia from which the cell line was derived had the unusual 
characteristic that the leukaemic cells were actively dividing in the blood. Most leukaemias 
originate from a proliferating progenitor cell; the progeny may differentiate somewhat but 
they do not continue to divide once they are removed from their source (Salem et al., 
1989; Lowenberg & Touw, 1993). Usually, a differentiation block is involved in 
leukaemia formation which prevents the cell from continued development, leading to an 
accumulation of cells which 'spill' into the blood as undifferentiated B cells. However, in 
the case of SMS-SB cells, the progeny of the stem cell have retained the capacity to 
divide, due to the production of an autocrine growth factor. Consequently, it was a very 
acute and aggressive leukaemia and the patient had a very high white blood ceU count.
Normal, mature B cells, if appropriately activated, produce autocrine growth factors. 
There are also several reports which demonstrate production of negative autocrine growth 
factors; thus, a normal B cell could independently regulate its growth (Gordon & Cairns, 
1991). Autocrine growth stimulation is a potentially dangerous situation, since if a cell can 
continually promote its own growth, and the control mechanisms become deregulated, 
there is a risk that a tumour may occur. It is known that production of an autocrine 
grovdh factor is not usually sufficient for transformation of a cell; multiple mutations 
appear to be required (Young et at., 1991). However, autocrine factor production can 
cause a more aggressive tumour, and is thought to be a contributing factor in tumour 
progression (Overell et al. , 1991). Some investigators believe that autocrine factor 
production may act as a tumour progression factor by increasing the size of the pool of 
potential tumour cells, where another genetic perturbation is required for full 
transformation (Spom & Todaro, 1985). Thus, autocrine factor production could increase 
the chance of a tumour occurring.
There are several mechanisms with the potential to cause constitutive autocrine activity 
and uncontrolled growth of SMS-SB cells. Normal pre-B cells may express receptors for 
SB-AF but the factor is usually produced by the stromal ceU population, to control pre-B 
cell growth. In this case, aberrant expression of the gene for the autocrine factor would 
leave SMS-SB cells independent of stromal cell regulation, leading to development of the 
lymphoma/leukaemia.
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However, SB-AF may well represent a normal pre-B cell autocrine factor, the effects of 
which, in the case of SMS-SB cells, could have become deregulated by:
1) increased production of the SB-AF
2 ) enhanced cellular responsiveness due to an aberrant increase in receptor expression
3) enhanced affinity of the receptor, possibly due to amplification of intracellular signalling 
pathways (in the case of SMS-SB cells, the over-expression of c-fos may be implicated in 
this role)
4) loss of action of a negative autocrine growth factor and/or loss of ability to respond to 
a negative factor produced by stromal cells.
6.2 SMS-SB cell autocrine activity
With respect to SMS-SB cells, the only SB-AF candidate so far identified is PDGF-aa. 
However, it does not appear that PDGF-aa can account for ah of the SB-AF activity, 
consistent with previous accounts of B cell autocrine factors where several cytokines are 
known to synergise to produce the autocrine growth factor activity (Abken et a i , 1992). 
With respect to PDGF, other investigators have demonstrated that, for example, 
transformation of non-neoplastic rat fibroblasts by growth factors, requires the concerted 
action of TGF-a, TGF-p and PDGF (Assoian et al, 1984). PDGF has been described as a 
progression factor (Heldin & Westermark, 1990) and studies using the v-sis product of 
Simian sarcoma virus (SSV), the viral homologue of the PDGF-(3 chain, have 
demonstrated that cells are transformed but not immortalised by the gene product 
(Johnsson et al., 1986). Other factors or genetic alterations appear to be necessary for the 
fuhy malignant phenotype.
It is known that PDGF signalling is important for commitment to DNA synthesis, 
probably via tyrosine phosphorylation of intracellular proteins (Ek & Heldin, 1984), and it 
appears to induce specific genes, including c~myc (Kelly et al„ 1983) and c~fos 
(Greenberg & Ziff, 1984). This is of particular interest in the case of SMS-SB cells since 
they are known to over-express c-fos; this may be due to constitutive activation of PDGF 
receptors via an autocrine loop. It would be interesting, during investigations into the 
possible internal autocrine role of PDGF, by suramin treatment or anti-sense to PDGF, to 
examine the effect that inhibition of PDGF function has on c-fos expression by the cells.
No investigations appear to have been undertaken to examine expression of PDGF by 
normal B ceUs. At present, the only documented role for PDGF, with respect to B cells, is 
the expression of the a-chain by SMS-SB cells and another pre-B ALL cell line Nalm-6  
(Tsai et at., 1994). Although Nalm-6  does not actually secrete the PDGF a-chain, it does 
possess the PDGF-a receptor; SMS-SB cells express the PDGF-(3 receptor. Since PDGF 
is a fibroblast mitogen, it is possible that pre-B cells could also use PDGF to stimulate
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stromal cells to produce other B cell growth or differentiation factors. Thus, the role of 
PDGF in normal B cell development must be investigated more thoroughly since it seems 
intuitively unlikely that two pre-B cell lines would express both PDGF and PDGF 
receptors after random genetic mutations.
'A
If SB-AF has a role in normal B ceU development, then it must have become deregulated 
for the leukaemic SMS-SB cells to continue cycling in the blood; autocrine mechanisms 
are normally tightly regulated to avoid such a devastating scenario. Of the mechanisms 
previously mentioned, there is circumstantial evidence to support several explanations.
1;
The alteration in c-abl expression by SMS-SB cells may have contributed to development 
of malignancy. The cells contain two extra «/^/-related transcripts, and since abl encodes a 
tyrosine kinase activity, it is possible that signals transduced via the autocrine factor 
receptors are amplified by this constitutive activity. The expression of c-abl has also been 
associated with a block in light chain rearrangement, proposed as a reason that mice 
infected with Abelson virus develop pre-B cell leukaemias (reviewed by Rosenberg,
1994). This event appears to act as a differentiation block, with the cells continuing to 
proliferate instead of proceeding along the differentiation pathway. SMS-SB cells are 
known to have non-productively rearranged % and À light chain genes, which may act as a 
differentiation block, allowing deregulated expression of the autocrine growth factor to 
lead to tumour formation. It seems unlikely that the nZ>/-product would have caused this 
differentiation block, since the effect usually prevents any light chain rearrangement from 
occurring, although SMS-SB cells are still CD43-positive (a pre-B cell marker commonly 
found on v-abl transformed cells) and several groups have shown low levels of hght chain 
rearrangement in Abelson-transformed murine B cell lines (Muller & Reth, 1988).
A recent paper demonstrates that, after growth factor withdrawal, v-abl protein tyrosine 
kinase activity prevents apoptosis in a murine mast cell line (Evan et al., 1993). SMS-SB 
cells are known to undergo apoptosis when cultured at low cell density suggesting that c- 
abl cannot 'save' the cells; however, it is possible that during the early stages of tumour 
development, the aberrant abl expression gave the cells a selective growdh advantage over 
normal pre-B cells.
It is possible that Hght chain gene rearrangement occurred at a later stage during 
development of the tumour and the proposed differentiation block was due to some other 
alteration. Due to their continued proliferation, and movement away from bone marrow 
stromal cells, SMS-SB cells may have been deprived of the normal differentiation signals, 
and this, with the concomitant growth promoting signals from the SB-AF, may have 
prevented any further differentiation. This model could be tested by co-culture of early
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SMS-SB cells in contact with various stromal cell lines, to examine whether differentiation 
could occur.
6,3 Hypothetical model fo r  SM S-SB leukaemogenesis and general
lymphopoiesis
SMS-SB cells are known to produce another fibroblast mitogen - TGF-LD- which ÿ
apparently has no autocrine growth-promoting effects. In long-term bone marrow
cultures, TGF-LD inhibits lymphopoiesis, although this effect appears to occur via
macrophage-like cells since when these are removed, lymphopoiesis is stimulated (Dr. B. |
Ozanne, personal communication). A hypothetical model for the role of TGF-LD, SB-AF
and sCD23 in lymphopoiesis and leukaemogenesis is demonstrated in figure 6.1. The
model suggests that in normal bone marrow, TGF-LD is produced by pre-B cells and
activates stromal fibroblasts to produce pre-B cell growth factors. As the cells divide, they |
are pushed away from the fibroblast-containing niche in the bone marrow to interact with
surrounding macrophage-like cells; the TGF-LD acts to induce production of pre-B cell
growth inhibitors by these cells and so allows differentiation to occur.
In the case of leukaemia, tumour cell growth would be enhanced by TGF-LD production 
if the leukaemic cells were somehow resistant to the inhibitory factors; the cells would 
receive the growth promoting signals derived from the fibroblasts but not the subsequent 
growth inhibitory signals from the macrophage-like cells. SB-AF may have been a 
progression factor for the leukaemic pre-B cells if it allowed them to continue dividing 
even after they were removed from the stromal cells, and hence their supply of pre-B cell 
growth factors. It is reasonable to suggest that, at this stage in development, normal pre-B 
cells also produce autocrine factors to allow their continued growth as they differentiate; 
however, they are probably also under the control of inhibitory factors which regulate the 
growth. For SMS-SB transformation, it seems likely that a differentiation block must also 
have occurred, to prevent further development of the cells and promote their continued 
proliferation. Some differentiation of SMS-SB cells did occur, as evidenced by the light 
chain gene rearrangements but for some reason the cells were not eliminated when the 
rearrangement was non-functional and the cells failed to express surface IgM. As 
mentioned previously, v-abl has been implicated in preventing apoptosis of mast cell 
precursors, so it is possible that some alteration in c-abl transcription helped early SMS- 
SB progenitor cells to survive. Eventually, the continued proliferation of resistant I
leukaemic SMS-SB cells, with concomitant inhibition of normal pre-B cell development 
due to production of TGF-LD, would lead to exclusion of normal B cells from the bone 
marrow, and to the release of proliferating leukaemic cells into the blood.
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Once the SB-AF activity has been fully characterised, it will be important to explore its 
role in normal B cell development, and to examine whether normal pre-B cells produce 
the autocrine growth factor or usually respond to SB-AF in an paracrine fashion.
Hopefully, SMS-SB cells will provide a useful model to examine control of the early 
stages of B cell development in the bone marrow, which is, at present, poorly understood.
SB-AF may be able to sustain the growth of immature B cells in long-term bone marrow 
cultures. If other normal or leukaemic cells do possess the capacity to respond to SB-AF, 
it will be interesting to examine the potential negative regulatory cytokines which normally 
control cell growth; these may offer scope for therapeutic intervention in some 
leukaemias.
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6.5 A role fo r  sCD23 in leukaemogenesis ?
There is another explanation for the continued survival of SMS-SB cells after non­
functional rearrangement of the light chain genes. It is now known that sCD23 prevents 
apoptosis of SMS-SB cells and it is possible that the expression of the novel CD23 
receptor allowed survival of the cells even after a differentiation block. If normal pre-B 
cells express the novel CD23 receptor, sCD23 may have a role in normal B cell 
development to keep pre-B cells alive as they differentiate.
CD23 expression by bone marrow stromal cells has already been documented (Fourcade 
et al., 1992), although it occurs at a very low level and is thought to occur mainly on 
activated macrophage-like cells. It is conceivable that TGF-LD produced by SMS-SB 
cells (or another bone marrow-derived cytokine) can induce CD23 expression in addition 
to the production of growth inhibitory factors, by macrophage-like cells (see figure 6 .1); 
however, this has not yet been examined. Assuming that normal pre-B cells express the 
novel CD23 receptor, this would allow tight regulation of pre-B cell development, 
preventing further proliferation of the cells but ensuring their survival as they proceed 
along the differentiation pathway.
If SMS-SB cell growth was not prevented by the inhibitory factors, the cells would 
continue to divide, possibly with some differentiation. However, due to expression of the 
novel CD23 receptor, after the non-functional rearrangement of the light chain genes, 
when normal pre-B cells would undergo apoptosis, SMS-SB cells would survive and 
continue to divide. In this respect, the involvement of sCD23 in maintenance or promotion 
of bcl~2 expression by SMS-SB cells is of great interest. Normal pre-B cells express only 
low levels of bcl-2, leaving them prone to apoptosis as a protection mechanism against 
cells of abnormal phenotype entering the periphery (Merino et al. , 1994). It will be 
important to investigate the expression of other members of the bcl-2 family, such as bcl-x 
and box, since they may regulate bcl-2 function It is possible that negative-regulatory 
transcription factors, possibly members of the Ets family, which are normally functional in
:
ipre-B but not mature B cells, act to down regulate bd-2 expression in pre-B cells by 
binding to Jtl sites in the 5' negative regulatory region of the bcl-2 gene (Chen & Boxer,
1995), sCD23 may act to induce transcription of a protein which can inhibit binding of the 
Ets-like protein to the 3tl  site, or to induce a protein which will bind to enhancer sites m 
the bcl-2 promoter and over-ride any negative regulatory signals.
A comparison of SMS-SB cells with the mature B cell lines Raji and RPMI 8226 showed 
approximately equal levels of bcl-2 expression in all three cell lines. This suggests that |
SMS-SB cells express abnormally high levels of bcl-2\ possibly expression of the negative 
regulatory factors has been lost in SMS-SB cells, or some positive transcription signal, 
induced, for example, by the autocrine factor, over-rides the negative signals, leading to 
high levels of bcl-2 expression. Thus, abnormal regulation of bcl-2 expression may have 
contributed to the ability of SMS-SB cells to survive after a differentiation block, for 
example, non-functional light chain gene rearrangement.
If this hypothesis is correct, the continued action of the autocrine growth factor would 
prevent SMS-SB cells from dying; in vitro, removal of this factor by culture at low cell 
density causes apoptosis of the cells, possibly due to down regulation of bcl-2. Soluble 
CD23 can maintain the bcl-2 levels in SMS-SB cells under these conditions. The in vivo 
significance of the sCD23 action is unclear but it may have aided survival of the cells as 
the tumour developed in the bone marrow. It would have been very interesting to measure 
the levels of sCD23 in the blood of the patient, since it seems likely that after escaping 
into the blood, the cells would have been exposed to much lower concentrations of SB- 
AF than were present in the tumour mass. In several leukamias, e.g. chronic lymphocytic 
leukaemia, the patients have high levels of sCD23 in their blood (Sarfati, 1993). Since 
SMS-SB cells do not express CD23, it seems unlikely that high levels of sCD23 would 
have been present; however, the production of the various stromal cell mitogens may have 
lead to sCD23 production by bone marrow cells. Equally plausible is that the role of 
CD23 was entirely localised to prevention of apoptosis of cells in the tumour mass; the 
levels of SB-AF in the blood may have been sufficiently high for the continued 
proliferation of the leukaemic cells, especially since other plasma proteins would have
been present.
6.5 The novel CD23 receptor
The discovery of a novel CD23-receptor on SMS-SB cells is extremely exciting because it 
suggests that CD23, whether in the membrane bound or soluble form, has a role in early B 
cell development. It is likely that the novel receptor binds CD23 by mechanisms very i
similar to those involved in the interaction of CD23 with CD21, GDI lb and GDI Ic. Since 
fucose-1-phosphate can inhibit GD23 binding to GD21, GDllb and GDllc, the lectin 
domain of GD23 must interact with carbohydrate motifs on these molecules. However,
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..3certain anti-CD23 MAbs, known to have specificity for protein epitopes, can also inhibit
the binding demonstrating that protein-protein interactions are also involved. Several
interactions are likely to occur which all help to stabilise the binding. In this respect, the
ability of CD23 to form oligomers has profound implications for its ability to bind to
receptors since with CD21, GDI lb and GDllc, the low affinity binding appears to be |
enhanced by oligomerisation (Aubry et al., 1992; Beavil et al., 1995). Pochon and
colleagues (1992) failed to demonstrate any binding of natural or recombinant soluble
GD23 to GD21-positive B cells, suggesting that the cells require the multivalency created
by surface expression of the full-length molecule for GD23 binding. This explanation is
somewhat complicated by data which shows that 25kDa form of sGD23 (which is
composed almost entirely of the lectin domain) does form oligomers, even though it lacks
the a-helical coiled stalk region; trimers of 37kDa sGD23 and hexamers of the 25kDa |
form were found after chemical cross-linking (Beavil et aL, 1995). The hexameric form of
25kDa sGD23 is most likely composed of two trimers, possibly due to end-on interactions
of the lectin heads, a situation which could not occur on the cell surface. The low level of %binding of sGD23 to GD21 may be due to steric hindrance of the necessary binding sites.
Several effects of sGD23 are thought to occur via GD21, for example, prevention of 
germinal centre B cell apoptosis (Liu et al, 1991). Also, sGD23 specifically increases IL- 
4-induced IgE production by blood mononuclear cells, the suggestion being that the 
interaction occurs via GD21, since it can be mimicked by anti-GD21 antibodies (Aubry et 
a l, 1992). Thus, it has been assumed that the roles attributed to the soluble form of GD23 
occur via GD21 and GDllb, GDllc. Although no formal demonstration has been made of 
binding of sGD23 to these molecules it does appear likely that a low affinity interaction 
can occur. A molecule with six sites for contact would overcome an inherent low affinity 
interaction of any one site by the high avidity of multiple sites.
1
During isolation of the novel GD23 receptor on SMS-SB cells, a 25kDa sGD23 affinity 
column was used. This method is not very successful for isolation of GD21, as shown by 
the very low levels of protein isolated. The GDllb and GDllc molecules were, however, 
isolated by this method, suggesting that the binding of sGD23 to these molecules is a 
higher affinity interaction, than binding to GD21 (Lecoanet-Henchoz et al., 1995). Indeed, 
recombinant soluble GD23 induces pro-inflammatory cytokine production by activated 
monocytes. It is interesting to note the existence of an 80kDa band in the material eluted 
from the monocyte GD23-affinity column (Lecoanet-Henchoz et al., 1995). GDllb and 
GDllc are 170 and 150kDa, respectively, and the other component of the receptor, 
GDIS, is 95kDa. The nature of this protein was not discussed by the authors but it 
appears to be of a similar size to the protein isolated in preliminary work with SMS-SB 
cells.
J
i
«One hypothesis is that the novel CD23 receptor represents the true soluble CD23 
receptor, responsible for the cytokine effects attributed to sCD23 such as survival of 
germinal centre B cells, and thymocyte and myeloid precursor differentiation (Liu et al. ,
1991 ; Mossalayi et aL, 1990 & 1991). Once characterised, it wiU be interesting to 
examine the expression of the novel receptor on these cell types. It is possible that CD21,
CD l ib  and GDI Ic bind GD23 due to the carbohydrate-lectin interaction but that the 
signals are actually transduced via the novel receptor, which associates with these 
molecules on the cell surface; such a situation occurs with receptors for both basic 
fibroblast growth factor and IL-6  (Taga et al. , 1986). The existence of the SOkDa band 
eluted from the GD23-affinity column of the monocyte cell extract would support such a 
theory, if the approximately 85kDa band isolated from SMS-SB cells turns out to be the 
novel GD23 receptor.
6.6 A soluble CD23 receptor?
The receptor present on SMS-SB cells is known to bind full length GD23 and the three 
soluble forms - 37, 29 and 25kDa sGD23. There is no real difference in effect of the 
different sized sGD23 fragments in proliferation assays. Unfortunately, problems were 
encountered during comparison of the ability of the sGD23 fragments to prevent apoptosis |
of SMS-SB cells, due to the inherent instability of sGD23; conclusive results were only 
obtained for the 25kDa form. If the 25kDa form does exist as a hexamer then the effective 
concentration of sGD23 used in the assays would have been much lower than that of the 
other sGD23 fragments yet it gave a similar response. The novel receptor appears to have 
an increased affinity for soluble, as opposed to full length GD23, when compared with 
GD21. Evidence which supports this hypothesis is that 25kDa sGD23 partially inhibits 
binding of GD23-containing liposomes to SMS-SB cells, but not to RPMI 8226 cells. It 
will be interesting to examine whether sGD23 could inhibit GD23-liposome binding to 
monocytes.
It is likely that the main role of GD21, and possibly GDllb & GDllc, are as adhesion 
molecules binding to membrane-bound GD23, for example, on follicular dendritic cells in 
germinal centres (Liu et aL, 1991), and in B/T cell interactions, to regulate IgE 
production, since GD23 and GD21 are expressed by both T and B cells (Flores-Romo et 
aL, 1993). If GD21 and GDllb/GDllc are really receptors for the full-length, stable ?trimer form of GD23 (binding may be enhanced by a high concentration of these trimers 
on the cell surface), this may explain why the responder cells require pre-activation before 
the effects of soluble GD23 are seen in these systems. Usually, sGD23 functions are only 
seen after pre-treatment of the responder cells with IL-la (Mossalayi et aL, 1990; Liu et 
rz/., 1991) or, in the case of monocytes, after activation of the cells (Lecoanet-Henchoz et 
aL, 1995). Several explanations may be advanced for this. Firstly, it is possible that cells 
such as centrocytes require two distinct signals, from IL-la and sGD23 before survival
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and differentiation can occur; i.e. the signal via CD21 is not sufficient to prevent 
apoptosis. Although anti-CD21 antibodies can 'save' germinal centre cells from apoptosis, 
this affect may have been enhanced by cross-linking of CD21 molecules by the antibodies.
It appears that binding of soluble CD23 to CD21 is not of sufficient affinity to transduce 
the anti-apoptotic signal.
The second hypothesis is supported by reports that IL-la can increase the number and /or 
affinity of cytokine receptors on cells (Mossalayi 1991); it is possible that IL -la 
acts to pre-activate the cells, ready for the signal from sCD23. Monocytes must be pre­
activated before an effect of sCD23 is seen in the absence of IL-la (Lecoanet-Henchoz et 
aL, 1995) and treatment of resting monocytes with IL-la increases the binding of CD23- 
containing liposomes to the cells, suggesting that IL-la may increase the number and /or 
affinity of cytokine receptors on cells. Therefore, for the low affinity interaction of CD21 
and CDllb/CDllc with soluble CD23 to exert its effect, the cells probably require pre 
activation. The hypothesis is that, in vivo, these molecules act as receptors for full length, 
membrane-bound CD23, which can either bind with sufficient affinity for signalling to ....
occur, or the cells will be activated by co-stimulation from other receptor/hgand 
interactions which occur on the surface of the cells.
i;i
With respect to SMS-SB cells, sCD23 alone is sufficient for the biological effects to be 
seen; however, as a leukaemic cell line, SMS-SB may already be in an activated state and 
possibly constitutively expresses the novel CD23 receptor. A good working hypothesis is 
that the novel receptor is the soluble CD23 receptor and interaction of the novel receptor 
with sCD23 is of high enough affinity to negate the requirement for IL-la; until the novel 
receptor has been identified and its function on normal pre-B cells investigated, this 
remains to be tested.
6.7 Identity o f  the novel receptor?
Attempts to identify the novel CD23 receptor by antibody inhibition of CD23-liposome 
binding were not successful; however, several candidate molecules exist. It is striking that 
the three known CD23 receptors, CD21, GDI lb and GDllc are all receptors for 
complement proteins. SMS-SB cells should be examined for expression of the fourth 
complement receptor, GD35, and if it is present, the ability of anti-GD35 to inhibit 
liposome binding must be tested. However, GD35, or complement receptor 1, although 
found on most haematopoietic cells, is a large protein of 190-280kDa (depending on the 
isoform) ; no band of this size was visible on the Western blots from the affinity columns. 
Gomplement is known to be essential for germinal centre formation and is involved in 
activation of monocytes in sites of inflammation. Thus, a low affinity interaction of 
complement receptors with the 'sticky' sGD23 molecule may just mimic the normal cellular 
responses to complement. Bonnefoy and colleagues (199$ showed that anti-GD21
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antibodies can prevent apoptosis of centrocytes, and suggest that this mimics the in vivo 
effects of CD23 in germinal centres. Unfortunately, the fact that germinal centres are full 
of complement proteins and that IFN-a, another ligand for CD21, is also essential for 
germinal centre formation, mean that the role of CD23/CD21 interaction, at least in
germinal centres, is far from clear. i
The novel CD23 receptor could also represent another IFN-a receptor, since CD21 binds 
IFN-a. Although IFN-a has no apparent role in B cell development, it must remain a 
candidate for the novel CD23 receptor.
The final candidate to be discussed is CD5 because it is the ligand for CD72, a member of 
the C-type lectin family which has significant homology with the structure of CD23.
Antibodies against CD5 fail to inhibit CD23-Hposome binding to SMS-SB cells, 
suggesting that CD5 is not the novel receptor for CD23, but it is possible that the epitopes 
blocked by the MAbs are not critical for CD23 binding or that, as with CD21, only a 
specific glycosylated form of the molecule actually binds CD23, It is of interest that 
CD23-liposomes do not bind to Raji cells even though these cells are strongly CD21 
positive. Raji cells are also strongly positive for CD5 expression, suggesting that it is not 
involved in the interaction with CD23, but Raji cells may lack a specific enzyme required 
for the appropriate glycosylation of these molecules.
It seems likely that, due to the similarities in CD23 and CD72 structure, that the novel 
receptor, if not CD5, may be a CD5-like molecule. It would be useful to design 
oligonucleotides against CDS homology domains to see whether SMS-SB cells express 
any related molecules. Western blots, using anti-CD5 antibodies, of material eluted from 
the CD23-affinity columns would also be interesting since CD5 is a 67kDa protein - 
approximately the same size as the lower band detected in the SMS-SB cell extract.
Vi;
It might also be useful, for future experiments to re-design the CD23-affinity column. The 
use of chemically-cross-linked sCD23 hexamers, bound to an affinity column, may allow 
higher affinity binding of the novel receptor and, thus, aid isolation and identification of 
the protein.
6.8 Role o f  the novel CD23 receptor in haematopoiesis
The results demonstrate that sCD23 prevents apoptosis of a pre-B cell line; in parallel to 
studies where a combination of IL-la and sCD23 promote proliferation and maturation of 
both thymocytes and myeloid precursors (Mossalayi et aL, 1990a & 1990b). This suggests 
that CD23, whether in the membrane-bound or soluble form, has a role in haematopoiesis; 
supported by the demonstration of CD23 expression by stromal cells in the bone marrow 
(Fourcade et aL, 1992), and by human thymic epithelium in the outer cortex (Mossalayi et
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a/., 1991). Once the novel receptor has been fully characterised, it will be interesting to 
examine its expression on other ceU lines and primary cells from all stages of B cell, and 
other haematopoietic lineage, development. At present, all the demonstrated in vitro 
effects attributed to sCD23 are assumed to occur through CD21 or CDllb/CDllc. 
However, pro-thymocytes do not express CD21 or CDllb/CDllc, suggesting that the 
novel receptor may also be involved in early T cell development.
As mentioned previously, IL-la is necessary for these sCD23 effects to occur, suggesting 
that cells require to be pre-activated. It was suggested earlier that the novel receptor on 
SMS-SB cells may bind sCD23 with sufficient affinity to negate the requirement for IL- 
la . However, in light of the requirement for IL-la by pro-thymocytes, and assuming that 
the novel CD23-receptor is actually present on pro-thymocytes, it appears likely that, in 
vivo, an element of pre-activation is required for the effects of sCD23 to be seen. As a
leukaemic cell Hne, SMS-SB cells exist in a constitutively activated state by virtue of SB- 
AF, which could explain their ability to respond to sCD23 alone. The requirement that 
cells are pre-activated would protect against CD23 having non-specific effects, especially 
in areas such as the bone marrow, thymus and germinal centres where massive cell 
proliferation and negative selection occur.
The role of CD23 during haematopoiesis was recently disputed after the development of a 
CD23 knockout mouse which has apparently normal haematopoietic development; the 
only phenotype noted is a severe impairment of antigen-specific IgE-enhancement of the 
antibody response - a process entirely attributable to membrane-bound CD23 (Fujiwara et 
aL, 1994). It is possible that the apparently normal phenotype occurred due to redundancy |
in in vivo immunoregulatory systems. However, murine and human CD23 differ in several 
ways, including the apparent lack of the CD23b isoform in mice, and this could also 
explain the differences. It can be hypothesised that, since the CD23a isoform is only 
expressed by B cells, human bone marrow and thymic stromal cells will only express the 
CD23b isoform. The soluble forms of both isoforms are identical, due to the inverted 
membrane orientation, but early B cells do not express CD23 and so the only source of 
CD23 in the bone marrow is stromal cells; thus, the CD23b isoform is the molecule to 
which the roles in haematopoiesis are attributed. As such, it is no surprise that CD23 has 
no role in murine haematopoiesis, since they lack this isoform.
Another factor which may help to explain the contradictory results is the state of 
oligomerisation of murine soluble CD23 - 'A molecule in search of a function' according 
to Bartlett and Conrad, 1992. Murine sCD23 can only interact with IgE in a univalent 
manner, suggesting that it exists as a monomer (Dierks et aL, 1993). A recent paper 
supports this idea with studies where recombinant 28kDa CD23 (equivalent to the human 
25kDa form) interacts with IgE in a monomeric fashion but a soluble form of full-length
168
CD23 has increased capacity for IgE binding, suggesting a multivalent interaction 
(Bartlett et aL, 1995). These data contrast with the discovery of hexameric sCD23 in the 
human (Beavü et a l , 1995); if murine sCD23 is unable to form oligomers then the absence 
of biological activity may be explained by lack of avidity required for binding to receptors.
6.9 Coda
The SMS-SB cell line provides a very useful model for the study of several aspects of 
early B cell development. The identity of the pre-B cell autocrine growth factor, SB-AF, 
and its role in normal and leukaemic B cells should be investigated further; the role of 
negative regulatory cytokines should also examined. This may shed some hght onto how 
pre-B cell growth is regulated, and the processes involved in early B cell leukaemogenesis 
- possibly leading to targets for therapeutic intervention.
The novel CD23 receptor present on the pre-B cell line, and the ability of sCD23 to 
prevent apoptosis of these cells, suggests a role for soluble and/or full-length CD23 in 
haematopoiesis; roles in T cell and myeloid development have already been demonstrated. 
Examination of expression of the novel receptor on cells from all stages of haematopoietic 
development will help to clarify:- the role of CD23; the CD23-receptors which are 
involved at different developmental stages; and whether the novel CD23-receptor is, 
indeed, a functional receptor îot soluble CD23.
SMS-SB cells wül be extremely useful in these investigations because they do not express 
any of the known CD23 receptors and so the mechanisms of CD23 action can be 
examined in the absence of interference from other receptor types. The role of CD23 in 
regulation of bcl-2 expression should also be examined - aided by fact that SMS-SB cells 
have no autocrine production of CD23, but possibly hindered if the ceUs aberrantly 
express bcl-2 as a consequence of their leukaemic phenotype.
Ultimately, the precise expression and importance of SB-AF and the novel CD23 receptor 
in B cell development, wiU have to be examined in long term bone marrow cultures with 
’normal' pre-B cells. However, SMS-SB cells will hopefully provide answers to several of 
the intriguing questions which have been raised.
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